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Abstract 
The effects of Mirazie (MZD), an extract of myrrh, on Schistosoma mansoni were 
investigated and compared to those of praziquantel (PZQ). The effects of both drugs on 
the soluble proteome and the immune responses to schistosome infections were also 
investigated. In vitro studies showed that MZD was more effective than PZQ against the 
schistosomula stage. However, its effects against adult worms were less than those of 
PZQ. Lengthy exposures to high concentrations of MZD were required for the drug to 
be effective. In vivo studies showed that MZD had no anti-schistosomal activity against 
S. mansoni in mice. 
In vitro exposure of adult worms to either PZQ or MZD caused significant changes in 
the expression of some proteins. Interestingly, some vaccine candidates including 
paramyosin and actin were among the proteins that showed differential expression. 
Treament of human S. haematobium infection with PZQ favoured the development of 
protective immune responses that render the individuals resistant to reinfection. Sera 
from putatively resistant individuals showed distinct recognition patterens of soluble 
worm antigen, after exposure to reinfection, compared to sera from susceptible 
individuals. Interestingly, many putative vaccine candidate antigens were recognised by 
antibody isotypes that are found in individuals with some degree of resistance to 
infection. 
In conclusion, although the in vitro studies revealed some promising effects of MZD, 
the results of the in vivo studies do not support the use of this drug in the treatment of 
schistosome infections. 
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Chapter one 
General Introduction 
1.1 Introduction 
Schistosomiasis is a chronic parasitic disease caused by a blood dwelling trematode 
(fluke) of the genus Schistosoma It is a major parasitic disease in the tropics and 
subtropics, with more than 200 million people in 76 countries estimated to be infected 
and about 600 million people at risk of infection (Savioli et aL, 1997). 
Schistosomiasis is strongly linked with human behaviour, as humans are both the 
victims of the disease and in most epidemiological settings the major source for the 
spread of the infection. Infection occurs on human contact with infected water 
containing the cercariae. Within minutes to hours of contact of the cercariae with the 
skin of a susceptible host, they penetrate the skin, shed their tails and complete their 
transformation into highly motile schistosomula. The schistosomula migrate into the 
micro-circulation and are carried to the heart, then to the lungs and after another 10 days 
or so, they reach the small veins of the portal circulation in the liver. There, they mature 
and the mature male and female worms pair. The female worms start to lay eggs 4-6 
weeks after the initial penetration of the cercariae through the skin (Strickland and 
Abdel-Wahab, 1991). There is strong evidence that coupling with male worms is 
essential for the development, sexual maturation and subsequent egg production by 
female worms. However, the stimulus for their development and maturation is not yet 
determined (Ribeiro-Paes and Rodrigues, 1997). 
The pathology and clinical symptoms of schistosomiasis are mainly related to the 
immunological reactions stimulated by the deposition of eggs which pass from the 
blood into the tissues of the host. Soluble egg antigens originating from the developing 
miracidium in the egg diffuse out through ultra-microscopic pores in the egg shell and 
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initiate the granulomatous reaction, a manifestation of a delayed hypersensitivity 
response mediated by T-cells (Warren, 1972). 
The control of human schistosomiasis is principally dependent upon the use of 
chemotherapy. The major objectives of chemotherapy are to eradicate or control human 
infection thus alleviating the symptoms of the disease by preventing finther deposition 
of eggs and reducing the number of eggs passed by patients into the environment. The 
reduction of contamination of the environment with eggs could result in reduced 
miracidium-snail contact and thus lead to lower levels of transmission (El Garem, 
1998). However, few clear examples of such reductions can be found in the literature 
(Ouma et aL, 1985). Fortunately, non-toxic, oral, schistosomicidal drugs are available to 
treat the infection. The drug of choice is praziquantel (Fallon et al., 1992). Reinfection 
after treatment and the possible appearance of resistant strains ensures schistosomiasis 
remains a major public health problem (Ismail et al., 1996). In the last few years two 
enew' drugs including artemesinin derivatives and Mirazido, reported to have the 
potential for treating human schistosomiasis have been investigated. 
1.2 Parasite 
1.2.1 Historical notes 
The ancient Egyptians recorded human infection with schistosomes in the papyrus of 
Kuhn with symbolic depiction of endemic haernaturia around 1900 years BC. In 1910, 
Ruffer described ova in the kidneys of Egyptian mummies who lived around 1250-1090 
years BC (El Garem, 1998). 
In Egypt, Theodore Bilharz described the worm that caused Egyptian endemic 
haematuria in 1851. He named the parasite Dislomum haematobium. In 1858, Weinland 
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proposed the name Schistosoma. At that time it was thought that one species was 
responsible for both the intestinal and vesicular forms of schistosomiasis. In 1905 Sir 
Patrick Manson postulated that intestinal and vesicular schistosomiasis are distinct 
diseases, caused by distinct species of worms. The complete life cycle of the parasite 
and the role of the snail intermediate host were defined in 1913 by Miyairi and 
confirmed experimentally by Leiper (a graduate of the University of Glasgow) in 1915 
(Smith and Roberts, 1989; Strickland and Ramirez, 2000). 
1.2.2 Details of the life cycle of schistosomes 
Adult worms mate in the small vasculature, of the liver and migrate against the venous 
blood flow to the venous plexus. The female progresses further alone to the narrowest 
parts of the veins and lays her eggs. The favoured eventual location of the adult worm 
and consequently of egg deposition varies according to species; S. haemalobium is 
concentrated in the blood vessels around the bladder and S. mansoni in the inferior 
mesenteric vessels of the large intestine (Strickland and Ramirez, 2000). 
In order for the parasites' life cycle to be completed, eggs must pass from their site of 
deposition in the vasculature through the tissues and into the lumen of the intestine or 
the bladder. This is achieved in part by virtue of their spines and the secretion of 
histiolytic enzymes. In mice, about 50% of the deposited ova succeed in reaching the 
external environment via urine and stools of the host while the remaining eggs are 
retained in the tissues. If eggs reach fresh water, they hatch and motile, relatively short- 
lived miracidia emerge and swim ceaselessly in water where they may encounter their 
next and intermediate snail host (El Garem, 1998). 
In the vicinity of a snail host, miracidia are stimulated to swim more rapidly and change 
direction much more frequently, thus increasing their chances of encountering the snail. 
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During penetration of the snail, the miracidium sheds its epithelium and begins 
development into a mother sporocyst, normally near the point of entrance. After about 2 
weeks, the mother sporocyst produces daughter sporocysts, which migrate to other 
organs within the snail. The mother sporocyst continues producing daughter sporocysts 
for up to 6 to 7 weeks (Smith and Roberts, 1989). 
Cercariae metamorphose from sporocysts and start to emerge from the snail into the 
water about 4 weeks after snail infection with miracidia. The cercariae can survive up to 
3 days under controlled laboratory conditions although their infectivity begins to 
diminish by 8-12 hours. Once cercariae come in contact with the skin of a suitable host, 
they penetrate the skin and trmsform into schistosomula. Schistosomula enter the 
vascular system directly (less commonly, indirectly through the lymphatics). They 
migrate through the right heart to the lungs, and then via the left heart and the systemic 
circulation to the splanchnic vasculature of the hepatic portal system, eventually 
reaching the sinuses of the liver to mature in about 4 to 6 weeks to complete the cycle 
(Sturrock, 2001). 
1.23 Morphology 
Morphology of cercariae and schistosomula 
Schistosome cercariae are furcocercus with a head (the immature body of the adult 
worm) 175 to 240pm long by 55 to 100pm wide and a locomotory organ or tail 175 to 
250tim long by 35 to 50Am wide. The head has an anterior organ, often called the oral 
sucker, and a prominent, muscular ventral sucker or acetabulum. (see figure 1.1d) The 
body is bounded by a syncytial tegument with an external lipid bilayers which, in 
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electron micrographs, appears trilaminate and covered with an external amorphous and 
carbohydrate rich "glycocalyx" (Smith and Roberts, 1989; Sturrock, 2001). 
During cercarial penetration the tail is shed and the body, now called a schistosomulum, 
enters the skin of the definitive host (see figure IA e). The conversion from the cercariae 
to schistosomula is a crucial and potentially vulnerable point of the life cycle. This 
transformation process involves many structural and physiological changes, the most 
important of which is the loss of the outer water-proof glycocalyx and its replacement 
with an outer lipid bilayer, providing the organism with a heptalaminate membrane. 
Furthermore, acquisition of host antigens and other manifestations of immunological 
survival mechanisms become evident at this point (Basch, 1991). 
Morphology of adult worms 
Adult worms are from 12 to 26mm. in length and from 0.3 to 0.6mm in width. 'Me adult 
male worm is shorter and thicker than the longer, slender female. The male has a 
longitudinal body cleft, the gynaccophoric canal or schist (hence their names), in which 
the female lies during most of her life. Both sexes have weakly developed oral suckers 
perforated by the mouth. The ventral sucker, situated antero-ventrally, is more strongly 
developed in male worms than female worms (see figure 1.1g). The entire body is 
covered with a tegument which is a continous syncytium bounded with an external 
heptalaminate membrane. 
Beneath the tegument, there are circular and longitudinal muscles coordinated by a 
network of neural fibres to permit contractions and other movements. Ile alimentary 
canal passes from the oral cavity into an oesophagus, dividing immediately anterior to 
the ventral sucker into two lateral gut caeca that reunite behind the gonads to form a 
single, blind posterior gut caecum. There is no anus and the contents of the gut are 
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periodically regurgitated through the mouth. The vomitus contains both parasite 
digestive enzymes and the products of digestion, largely breakdown products of 
erythrocytes. 
The reproductive organs of schistosomes are unremarkable in that male reproductive 
system consist of several testes (6 to 9 in S. mansoni), a number of vasa deferentia 
joining to form a vesiculd seminalis, an ejaculatory duct, and a genital pore situated 
posterior to the vetral sucker. The female reproductive system is composed of an 
elongated ovary, an oviduct, vitelline glands, shell glands, and an ootype in the central 
canal that passes forward to the uterus. The straight or slightly tortuous tubule-shaped 
uterus leads to the genital pore just behind the ventral sucker. 
The excretory system is composed of fine tubules which link the protonephridial flame 
cells embedded in the mesenchymatous cells to the posterior excretory bladder, 
allowing excretion of excess water and soluble metabolic waste products (Strickland 
and Ramirez, 2000; Sturrock, 2001). 
Morphology of the eggs 
The eggs of all schistosome that have so far been described are non-operculate. They 
are either ovoid or spherical and range in size from 60 to 400pm in length. They are 
immature when laid but mature rapidly during their 6-10 days' passage to the exterior 
(see figure 1.1a). The mature egg contains a single miracidium, a ciliated larval stage. 
The shell, which is either clear or yellow in colour, is composed of sclerotin-tanned 
protein and is perforated by numerous micropores through which can pass enzymes 
produced by the enclosed miracidium. The egg of & mansoni is oval in shape with 
prominent lateral spine. It measures 115 to 175pm in length and 45 to 70[im in width 
(Strickland and Ramirez, 2000; Sturrock, 2001). 
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Figure 1.1 Life cycle of S. mansoni. 
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(a) Eggs of S mansoni, (b) miracidium, (c) Intra-molluscan stages, (d) Cercaria, (e) 
schistosomulum, (f) maturing worms in the mesenteric blood vessels, (g) Adult worm 
pairs and (h) eggs surrounded by granuloma. 
(Courtesy of The Wellcome Trust. International Health Image Collection. ) 
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1.3 Clinical picture of schistosomiasis mansoni 
The first evidence of infection may be a transient itching and a mild skin rash that 
develops immediately after water contact. This occurs at the sites of cercarial 
penetration. Depending on several factors, acute or chronic schistosomiasis may 
develop. 
1.3.1 Acute schistosomiasis 
Acute schistosomiasis, often called Katayama fever, occurs 4 to 6 weeks following 
initial exposure to infection. It is a feature of infection in travellers and visitors to 
endemic areas and is less commonly found in the indigenous peoples of endemic areas. 
Katayama fever usually starts at the time adult worms begin to mature and with the 
onset of egg deposition. It is presented as a systemic allergic illness characterised by 
fever, chills, weakness, weight loss, cough, arthralgias, marked eosinophilia and often, 
abdominal pain and bloody diarrhoea (Neva and Brown, 1994). 
1.3.2 Chronic schistosomiasis 
The pathogenesis of chronic schistosoniiasis is almost exclusively explained by the 
hosts' granulornatous response to schistosome eggs deposited in tissues. Deposition of 
eggs in the intestinal wall results in granulomatous lesions which may result in intestinal 
polyposes, haemorrhages, enteropathies, fibrosis and strictures. The liver is another 
favoured site for the trapping of S. manson! eggs during infection. The chronic 
granulomatous response produces a peri-sinusoidal inflammation and fibrosis called 
SYMMers' clay pipe-stem fibrosis. The pathogenesis of severe schistosomiasis results 
from the slow, cumulative blockage of portal flow that results in portal hypertension, 
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porto-systernic collateral circulation, oesophageal varices and upper gastrointestinal 
bleeding which is the most common morbid consequence of hepatic schistosomiasis and 
is responsible for the ma ority of deaths due to schistosomiasis. Interestingly, the liver i 
functions remain normal until the very late stages of the disease. Eggs can embolise in 
other places including the central nervous system resulting in granuloma formations at 
such sites (Neva and Brown, 1994; Strickland and Ramirez, 2000; King, 2001). 
1.4 Diagnosis of S. munsoni 
In order to diagnose schistosome infection, to determine the strain of schistosomes and 
to determine the severity of infection, several methods have been developed and 
exploited. 
1.4.1 Parasitological diagnosis 
Detection of ova and their morphological identification is the traditional method of 
diagnosis. It is a cheap, direct and specific means of diagnosis but there is a possibility 
of missing light infections that are characterised by low egg output. The most widely 
used protocols are those based on the Kato-Katz thick faecal smear (Kato and Miura, 
1954; Katz et al., 1972). Other methods including stool concentration techniques and 
rectal snip examination are also used. For instance, a separation technique based upon 
the greater density of viable schistosome eggs relative to faecal material has been 
described and has been found to be more sensitive in detecting light infections than the 
Kato-Katz thick smear method (Eberl et aL, 2002). 
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1.4.2 Detection of parasite antigens 
The presence of detectable quantities of parasite-derived antigens in the circulation and 
excreta of infected hosts has prompted considerable research on their potential for 
immunodiagnosis of schistosomiasis. Several circulating antigens have been employed 
including circulating anodic antigen (CAA) and circulating cathodic antigen (CCA), 
named according to their migratory behaviour in immuno-electrophoresis. A variety of 
assay methods have been used to detect these antigens. Parasite antigen detection 
methods have the advantage of being schistosome specific. However, they can miss 
light infections and, because of the shared carbohydrate epitopes between schistosome 
species, they cannot be used for differentiation between schistosome species (Doenhoff 
et aL, 2004). 
1.43 Detection of antibodies 
This method is based on the detection of anti-schistosomal antibodies produced by the 
host in response to exposure to infection. Both humans and animals normally respond to 
a range of different parasite antigens. Several crude and purified antigens from different 
life cycle stages have been used in antibody detection assays. The most widely used 
assay method is the enzyme-linked immunosorbent assay (ELISA). This method is 
normally less specific than the antigen detection method, it is of limited value in 
monitoring the curative effects of chemotherapy and it is not correlated with the 
intensity of infection. However, the use of purified antigens in such assays has greatly 
improved these factors (Hamilton et aL, 1998; Doenhoff et al., 2004). For instance, the 
use of the CEF6 fraction of soluble egg antigens, which consists of two antigens (a 
30kDa (o-I and a 36-41kDa cc-1), has been tested for the diagnosis of schistosomiasis 
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with sensitivity and specificity values of 91% and 90%, respectively (Mott and Dixon, 
1982). 
1.4.4 Detection of parasite DNA 
In the last few years, a polymerase chain reaction has been developed for the diagnosis 
of human S. mansoni infections. It exploits a highly repeated schistosome DNA 
sequence that can be detected in the sera and faeces of infected individuals. The method 
is very specific and very sensitive. It is normally used effectively in situations when 
there is good laboratory infi-astructure (Pontes et aL, 2002). 
1.5 Liver granuloma in S. mansoni infection 
After egg deposition, soluble egg antigens (SEA) are released from the developing 
miracidium. These antigens induce host sensitisation and recruitment of lymphocytes, 
eosinophils, macrophages, giant cells and fibroblasts which constitute the host 
granulomatous response (Boros and Warren, 1970). The granulomatous response serves 
to wall-off the eggs and prevent the release of potentially toxic molecules and help to 
destroy the ova (Doenhoff et aL, 1986). Iffie mechanism of granuloma formation is T 
lymphocyte-dependent (Harrison and Doenhoff, 1983) and the CD4' T helper subset is 
key (Mathew and Boros, 1986). 
While the schistosome granuloma formation and development is largely dependent on 
Th2-immune response, the role of Thl-immune response cannot be neglected especially 
in the early phases of granuloma formation. With the beginning of egg deposition and 
early phases of granuloma formation in murine schistosomiasis, at weeks 5 to 6, high 
levels of IFN-y and low levels of IL-4 and IL-5 have been reported implicating a role of 
Th I -immune response. As deposition of eggs in tissues continues, the immune response 
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is shifted toward a Th2-type immune response and by 8 weeks after infection, when 
granuloma attain their maximal sizes, high levels of IL-4, IL-5 and minimal levels of 
IFN-y are detected. These results indicate that the egg-induced granuloma is mainly a 
Th2-type immune response (Pearce et al., 1991; Lukacs and Boros, 1992). The role of 
the Th2 response in granuloma formation was confirmed with the work carried out by 
Kaplan and colleagues (1998). They used (signal transducer and activator of 
transcription 4) STAT74- and STAT6-deficient mice, which lack Tbl and Th2 type 
responses, respectively. Lymphocytes from both naive and infected STAT6-deficient 
mice produced minimal levels of 7112 cell cytokines but showed enhanced production of 
IFN-y following schistosome egg injection. This shift away from a Th2 cell-mediated 
immune response was coupled with the development of pulmonary and hepatic 
granulomas that were greatly decreased in size compared with those in control 
littermates. Hepatic granulomas in STAT6-deficient mice were composed 
predominantly of mononuclear cells with only a sparse appearance of eosinophils. The 
smaller size of the hepatic granulomas was accompanied by decreased amounts of liver 
hydroxyproline indicating reduced collagen deposition. In contrast, lymphocytes from 
infected STAT4-deficient mice produced Th2 cell cytokines in amounts comparable to 
those produced by control littermates, but low levels of IFN-y. The granuloma size and 
amount of collagen deposition in the liver were equivalent to those seen in control 
littermates. These studies demonstrate that M cells are required for the full 
development of the granulomas and fibrosis (Kaplan et al., 1998). 
While much is known about the roles of cytokines in granuloma formation, new 
information is being generated. For instance, repeated injections of rIL-2 or rIL4 in 
chronically infected mice restored the down-regulated liver granulomas to their peak 
size (Mathew et al., 1990; Yamashita and Boros, 1992). Injections of anti-IL-2 
(Cheever et al., 1992) and anti-IL4 monoclonal antibodies (Yamashita and Boros, 
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1992) suppressed the granulomas in acute murine infection. These results together 
confirm the inflammatory role of IL-2 and IL-4 in schistosomiasis. 
Using IL-4, IL-13 and IL-VIL-13-deficient mice infected with S. mansoni, Fallon and 
colleagues demonstrated that IL-13-deficient mice showed significantly enhanced 
survival following infection, which correlated with reduced hepatic fibrosis. In contrast, 
increased mortality was manifest in IL4-deficient and IL4/13-deficient mice, and this 
correlated with hepatocyte damage and intestinal pathology. Ibis hepatic damage was 
caused as a result of a skewed Thl type response. They concluded that IL-13 is 
detrimental to survival following infection, whereas IL-4 is beneficial (Fallon et al., 
2000a; Fallon et al., 2000b). Furthermore, IL-13 stimulated collagen production in 
fibroblasts, and procollagen I and procollagen III mRNA expressions were decreased in 
mice treated with an IL-13 inhibitor, soluble IL-13 R alpha 2-17c fusion protein. The 
reduction in fibrosis observed in IL-4-deficient mice was much less pronounced than 
that in soluble IL-13 R alpha 2-Fc treated mice. Ilese results confirm that IL-13 is the 
dominant Th2-type cytokine regulating fibrosis (Chiaramonte et al., 1999). 
Furthermore, administration of recombinant tumour necrosis factor-alpha (rTNF-oc) to 
chronically infected mice enhanced liver granuloma size and injection of anti- TNF-a to 
acutely infected animals suppressed their granulomas (Joseph and Boros, 1993). In 
human S mansoni infection, TNF-cc was associated with aggravation of hepatic 
periportal fibrosis while IFN-y and IL- 10 was associated with protection against fibrosis 
(Henri et al., 2002; Booth et al., 2004). 
Recombinant interleukin (IL)-12 administered together with schistosome eggs partly 
prevented pulmonary granuloma formation on subsequent intravenous challenge with 
eggs, partly inhibited hepatic granuloma formation and dramatically reduced the tissue 
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fibrosis in murine S. mansoni infection. The effect of IL-12 was attributed to increased 
production of IFN-y. These results revitalised the concept of the development of a 
vaccine preventing pathology rather than infection (Wynn et al., 1994; Wynn et al., 
1995; Sher et al., 1996; Qadir et al., 2001). 
Interleukin-10 seems to be the most important down-regulatory cytokine for granuloma 
formation and fibrosis. Repeated injections of anti-IL-10 mAb and studies of IL-4, IL- 
10, IL-12 in single and double knockout mice showed that IL-10 is an important 
endogenous down-regulator of Tb2-type as well as Thl-type cytokine synthesis, 
preventing over expression of either of these immune response types. It was also shown 
that IL- 10 regulates not only the intensity of hepatic inflammation, but also granuloma 
organization and cohesiveness (Wynn et al., 1997; Boros and )NUtfield, 1998; Sadler et 
al., 2003). In vitro, IL- 10 was shown to be an important cytokine regulating the in vitro 
granulornatous reactivity of PBMC from intestinal S. manson! patients (Falcao et al., 
1998). In murine S mansoni infection, IL-10 is generated by both the innate and 
adaptive immune response, with both sources regulating the development of type-2 
immunity, immune-mediated pathology, and survival of the infected host. Most of the 
I CD4 +T cell-produced IL-10 was confined to a subset of T cells expressing CD25 
(Hesse et al., 2004). 
The role of transforming growth factor-beta (TGF-P) in S. mansoni granuloma 
formation and fibrosis is controversial. On the one hand, treatment of cultured hepatic 
cells with TGF-p I increased the level of type I procol lagen mRNA and increased levels 
of TGF-P I gene expression that precedes the increase in collagen synthesis was 
demonstrated (Czaja et aL, 1989). On the other hand, SEA-induced TGF-P correlated 
with diminished hepatic granuloma size during S mansoni infection in the baboons, 
implying its participation in down-modulation of granuloma (Mola et aL, 1999). 
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Furthermore, diminished immuno-pathology in S. mansoni infection following 
k 
intra- 
nasal administration of cholera toxin B subunit conjugated to an immunodominant 
peptide (amino acid 234-246) of Sm-P40 of S. niansoni eggs correlated with enhanced 
TGF-P production (Hernandez et al., 2002). A similar immuno-modulating effect of 
TGF-P in S. japonicum hepatic fibrosis was reported (Zhu et aL, 2000). 
Other molecules and chemokines may play a role in formation or modulation of hepatic 
granulomas. The co-stimulatory B7 molecule, on the surface of antigen-presenting cells, 
may bind to CD28 receptor on T cells and enhance their proliferation (Greenfield et al., 
1998). Intercellular adhesion molecule I (ICAM-1), lymphocyte function-associated 
antigen I (LFA-1), very late antigen 4 (VLA-4) and VLA-6 may play a role in initiation 
and maintenance of hepatic granulomas (Jacob et al., 1997). Furthermore, mice infected 
with S. mansoni and deficient in the IgE gene developed smaller granulomas than the 
wild animals implicating a role for IgE in granuloma formation (King et al., 1997). On 
the other hand, gene knock out experiments indicated a role for B lymphocytes and Fcc- 
R-bearing cells in down regulation of granulomas and fibrosis (Jankovic et al., 1997; 
Jankovic et al., 1998). 
Of course the effects of single or combination of cytokines on the formation of the 
granulomas are relatively easy to investigate but it must be remembered that during 
granuloma formation in humans and animals, an array of different cytokines operate at 
different levels and at different times. 
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1.6 Immunity to schistosomiasis 
1.6.1 Evidence of acquired immunity in humans to schistosomiasis 
The strongest circumstantial evidence for immunity to schistosomiasis in humans is the 
pattern of infection intensity in human populations in relation to their age. The age- 
intensity curve assumes a convex shape with older individuals being less heavily 
infected than young children. This pattern has been described in areas endemic with S. 
haematobium (Wilkins et al., 1984; King et al., 198 8) and & mansoni (Gryseels, 199 1). 
The peak intensity of infection was shifted from approximately 15 years of age, for 
areas of low transmission, to 10 years of age for areas of high transmission of & 
haematobium infection in Zimbabwe suggesting a role for acquired immunity that is 
dependent on a cumulative experience of infection (Woolhouse et aL, 1991). Similarly, 
a negative correlation between the mean intensity of infection and the age of the peak of 
intensity has been described in S. manson! infection in Kenya (Fulford et aL, 1992) and 
in Senegal (Marguerite et al., 1999). In this context, chemotherapy accelerated the 
development of the acquired immune responses to S. haematobium infection (Mutapi et 
al., 1998) and this has been speculated to be a result of increasing the exposure and 
release of previously concealed antigens of the damaged or dead parasites (Woolhouse 
and Hagan, 1999). 
In order to dissect the age-related immunity to schistosomiasis and to overcome the 
problems encountered with human population studies, Butterworth and colleagues 
established the treatment-reinfection approach to studying S. mansoni in humans. They 
treated children with praziquantel to remove the existing worms and re-examined the 
children for infection 12 months after chemotherapy. The mean age of the resistant 
group, with no or few eggs in their stools, was two years greater than the susceptible 
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group, with high egg output in the stools. These results were interpreted as evidence that 
the resistance was acquired and age-dependent (Butterworth et al., 1984; Butterworth et 
al., 1985). 
A similar approach was used for the study of human S. haematobium infection in the 
Gambia. Reinfection was found to depend on exposure and other factors (Hagan et al., 
1985). In a second study by the same group, the trend for reinfection to decrease with 
increasing age, after an allowance for variation in exposure, was highly significant. 
These observations suggested that subjects in this area slowly acquired an increasing 
degree of immunity to the acquisition of S. haematobium infection (Hagan et al., 1987; 
Wilkins et al., 1987). Recently, more detailed experiments have confirmed the role of 
acquired immunity in human schistosomiasis haematobium (Hagan et al., 1991; Mutapi 
et al., 2003) and schistosomiasis mansoni (Demeure et al., 1993; Abebe et al., 2001). 
1.6.2 Evidence of humoral immunity: 
Due to ethical considerations it is impossible to Conduct exposure experiments to 
examine the immune responses against schistosomes infection in humans. As an 
alternative, several experimental animals as well as animal reservoir hosts have been 
exploited to study the immune response to schistosome infection. In mice, while S. 
mansoni irradiated cercariae protected B-cell deficient mice against re-infection with S. 
mansoni, the protection achieved was not as great as that achieved in the wild-type mice 
vaccinated with the same regime, implicating a role for B-cells in immunity to S 
mansoni infection. The level of protection was restored when B-cell deficient mice 
received sera from singly vaccinated wild-type mice. Furthermore, multiple 
vaccinations of mice deficient in IFN-y increased the levels of protection compared to 
those obtained with a single vaccination. The increased protection was attributed to an 
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increase in the antibody levels (Jankovic et al., 1999b). Multiple vaccination of wild- 
type mice was associated with Th2 reactivity in the form of an increase in IL-4, IL-5 
and IgGl antibodies (Caulada-Benedetti et al., 1991). Moreover, sera from multiply 
vaccinated mice conferred protection when transferred to naYve mice confirming the 
role of humoral immunity in protection against schistosomiasis in mice (Wynn et al., 
1996). 
In rats, that are essentially non-permissive hosts, primary infection with S manson! 
induced a strong, immunologically mediated resistance to re-infection, with IgE directly 
implicated in this phenomenon (Capron and Capron, 1994). Treatment of rats with anti- 
IgE antibodies partially inhibited the expression of this protective immunity, supporting 
the role of IgE in protection against schistosomiasis in rats (Cetre et aL, 2000). In 
relation to this, serum from rats multiply immunised. with radiation-attenuated cercariae 
conferred passive protection to naive animals when it was given at time the challenge 
parasites were migrating through the lungs (Ford et aL, 1987). 
In baboons, a single infection with 1000 S. manson! cercariae and multiple infections 
with 100 cercariae per week for 10 weeks induced 59% and 80% protection to challenge 
infection, respectively. The animals in this experiment were cured with praziquantel 
prior to challenge with 1000 cercariae. The only immune correlate of protection was the 
levels of soluble adult worm antigen (SWAP)-specific IgE in senim at the time of 
challenge infection and/or 6 weeks later (Nyindo et aL, 1999). Furthermore, three and 
five vaccinations of vervet monkeys with radiation-attenuated S mansoni cercariae 
resulted in 48% and 39% protection, respectively. The specific IgG levels peaked after 
three vaccinations and there was a clear correlation between the antibody levels at the 
time of challenge and the protection observed in individual vervcts (Yole et aL, 1996). 
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In human populations, the first trial to correlate the reinfection levels after treatment 
with humoral responses was carried out by Butterworth and colleagues. They treated 
129 Kenyan school children infected with S mansoni and measured the reinfection 
levels and the parasite specific IgG and IgM. They found a negative correlation between 
reinfection intensities and both IgM anti-schistosomulurn antibodies and IgM and IgG 
anti-egg antibodies. They concluded that these antibodies act as blocking antibodies that 
interfere with an effective immune response (Butterworth et al., 1987). 
The first clear correlation between antibodies and resistance came from the work of 
Hagan and colleagues on S haematobium in endemic areas in the Gambia. A 40% 
sample of the age spectrum of the study village were included in this study and the 
prevalence of re-infection after treatment was found to be higher in children than in 
adults although some had the same level of exposure. IgG subclasses and IgE specific to 
adult worm and egg antigens were measured. It was found that IgE was highly 
correlated with resistance to re-infection and IgG4 was correlated with susceptibility to 
re-infection (Hagan et aL, 1991). Similarly, correlation between anti-adult worm IgE 
(Dunne et al., 1992) and anti-larval IgE (Rihet et aL, 1991) and resistance to re- 
infection after treatment was reported in human S. mansoni infection. 
In another treatment re-infection study of S. mansoni, IgE showed positive and IgG4, 
and IgG2 showed negative association with resistance to re-infection after 
chemotherapy. The opposite effects of IgE and IgG4 were undissociable in the analysis, 
indicating that these isotypes probably antagonise each other in protection (Demeure et 
al., 1993). This antagonism was further supported by the work of Caldas and colleagues 
(2000). They reported an increase in IgE anti-SWAP and anti-schistosomular tegument 
(STEG) responses and a decrease in IgG4 anti-SEA and anti-STEG responses after 
treatment in the resistant group (Caldas et al, 2000). 
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In a Zimbabwean study, anti-SEA IgE and anti-SWAP IgA negatively correlated with 
levels and intensity of S. haematobium infection. On the other hand, intensity of 
infection correlated positively with total IgG, IgG4 and IgM responses to SEA and with 
IgG4 and IgM responses to SWAP. These findings supported the concept of IgG4 and 
IgM as blocking antibodies. Interestingly, similar recognition patterns by IgE and IgG4 
of the schistosomulum antigens was detected in immunoblotting suggesting a sort of 
competition between these antibodies for the same antigens (Ndhlovu et al., 1996). A 
similar positive correlation between IgE and IgA and protective immunity against S. 
haematobium was reported in Egyptian individuals (Khalil et al., 1999). 
In S. japonicum, a positive correlation between anti-SWAP and anti-SEA IgG4 
antibodies and susceptibility to reinfection and a negative correlation between anti- 
SWAP and anti-SEA IgE antibodies and intensity of reinfection were reported in a 
Chinese population (Li et al., 2001). 
In summary, the immunoepidemiological studies of human populations showed 
significant correlation between resistance to re-infection with schistosomes and some 
antibodies. Of particular interest are IgE, which correlated positively with resistance and 
IgG4, which correlated negatively with resistance to re-infection. 
1.7 Treatment of human schistosomiasis 
At present, praziquantel, oxamniquine and metrifonate appear on the World Health 
Organisation's list of essential drugs: metrifonate is employed for the treatment and 
control of infection with S. haematobium, oxamniquine for S. mansoni and praziquantel 
for all schistosome species infecting humans, including 9 japonicum (Cioli et at, 
1995). 
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1.7.1 Metrifonate 
Metrifonate is an organophosphorous compound. It is unstable in aqueous solutions and 
it spontaneously and non-enzymatically transforms into various compounds, of which 
the most interesting is dichlorvos which is the active molecule (Nordgen et aL, 1980). 
By inhibition of schistosome acetylcholinesterase, metrifonate (or its breakdown 
product, dichlorvos) causes accumulation of acetylcholine and flaccid paralysis of 
worms. The paralyzed schistosomes lose their hold on the inner wall of blood vessels 
and are swept away in the bloodstream. As S. haematobium are located mostly in the 
veins of the vesical plexus, they are shifted to the lungs via the vena cava where they 
remain trapped and eventually die (Cioli et aL, 1995). 
The generally accepted therapeutic regimen in h an S. haematobium i ections UM nfi 
consists of 3 oral administrations of 7.5-10mg kg" at intervals of 14 days (Davis and 
Bailey, 1969). Cure rates have been reported to average between 40-60% after one dose, 
50-80% after two doses, and over 90% after three doses (Snellen, 198 1). 
Metrifonate is a well-tolemted drug with low incidence of mild and tmnsient side effects 
thought to be a consequence of cholinergic stimulation. Ilese side effects include; 
fatigue, muscular weakness, tremor, sweating, salivation, fainting, abdominal colic, 
diarrhoea, nausea, vomiting and bronchospasm (Davis, 1993). 
1.7.2 Oxamniquine 
Oxamniquine is considered as an oxidative metabolite of the parent compounds; 
lucanthone and UK-3883. It is effective against S. mansoni and ineffective against S. 
haematobium and S. japonicum. It shows more activity against male worms than female 
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worms and little activity against the immature stages. Oxamniquine exerts its action 
most likely through the irreversible inhibition of nucleic acid synthesis in sensitive 
schistosomes (Cioli et aL, 1995). Furthermore, hycanthone and oxamniquine have anti- 
cholinergic effects that by blocking the acetylcholine receptors, will remove the 
inhibiting effect of acetylcholine. The resulting disturbance of motility disrupts 
peristalsis and feeding mechanisms to the point of causing a delayed death by starvation 
(Hillman et aL, 1978). 
The usual therapeutic dose is a single oral dose of 15-20mg kg-1, although a higher dose 
of up to 60mg kg" divided over 2-3 days may be needed in Egypt, South Africa and 
Zimbabwe (World Health Organisation, 1990). With the appropriate therapeutic dose, 
cure rates of over 80% and often over 90% have been reported. The drug has been used 
safely in all stages of the disease. Some late-stage and complicated forms have shown 
clinical improvement. Oxamniquine is well tolerated with side effects limited to a mild 
and transient dizziness, headache and occasional drowsiness. Transient neuropsychiatric 
disturbances have been recorded in a very small number of patients (Foster, 1987; 
Davis, 1993). 
1.73 Praziquantel 
Praziquantel, a pyrazino-isoquinoline derivative, is the drug of choice for the treatment 
of schistosomiasis because it has a high efficacy against all schistosome species and 
against cestodes; lacks serious short-term and long-term side effects; is administered as 
a single oral dose and is cheap (Cioli et al., 1995; Kabatereine et al., 2003). 
The most important effects of praziquantel on schistosomes are tegumental damage in 
the fonn of vacuolisation at the base of tegumental syncytium and blebbings at the 
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surface (Becker et aL, 1980), muscular contraction and spastic paralysis (Pax et aL, 
1978) and metabolic changes (Andrews, 1985). 
Damage to the surface of the parasite could prime hosts immune responses by exposing 
antigens previously concealed from the hosts immune system (Harnett and Kusel, 1986; 
Brindley et al., 1989; Woolhouse and Hagan, 1999). This is indirectly supported by the 
previous finding that the effects of praziquantel are dependent upon the hosts immune 
responses (Sabah et al., 1985; Brindley and Sher, 1987). In this context, treatment with 
praziquantel has been shown to change the antibody isotype profile of treated children. 
The effect was dramatic, a single treatment with praziquantel had the capacity to 
transform the response of susceptible children to that of adults considered to be immune 
against infection (Mutapi et aL, 1998; Mutapi et al., 2003). 
Ile exact mode of action of praziquantel is not known, however, its effects can be 
interpreted as a direct or indirect consequence of Ca2+ redistribution among various 
worm tissues and the environment (Day et al., 1992). In support of this, calcium 
channels have been described in schistosomes and they have been shown to be crucial 
for praziquantel action (Kohn et al., 200 1 b; Kohn et al., 2003). 
The standard recommended dose of praziquantel is a single oral dose of 40mg kg" body 
weight for S. mansoni, S. haemalobium, and S. intercalatum. In S japonicum infections, 
a total dose of 60mg kg" is recommended, split in two or three doses in a single day. S 
mekongi may require two treatments at 60mg kg" (Davis, 1993). Praziquantel is a safe 
drug with minimal side effects related to the gastrointestinal tract in the form of 
abdominal pain, nausea, vomiting, anorexia and diarrhoea. Other side effects including 
headache, dizziness, drowsiness, pruritus and fatigue may occur (Davis, 1993). 
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The cure rates recorded with these doses were 75-85% for S. haematobium, 63-85% for 
S. mansoni, 80-90% for S. japonicum, 89% for S. intercalatum and 60-80% for double 
infections with S. mansoni and S haematobium (Wegner, 1984). However, a lower cure 
rate of 36-38% has been reported in S. mansoni infection in Senegal and strains of lower 
susceptibility to praziquantel have been isolated (Gryseels et al., 1994). Other resistant 
strains have been isolated from Egypt (Ismail et al., 1996). In vitro tests on these 
isolates and laboratory-selected isolates support the conclusion that a degree of 
resistance to PZQ can occur in S mansoni, but the levels of drug resistance found so far 
are low (Doenhoff et aL, 2002). Furthermore, although praziquantel is very effective 
against cercaria, invasive stages and adult schistosomes, it has been shown to have a 
significantly lower efficacy against the immature stages of schistosomes, between I to 4 
weeks after infection (Xiao et al., 1985; Sabah et al., 1986). 
1.7.4 Roll-3128 and Rol5-5458 
Roll-3128 and Ro15-5458 are benzodiazepine derivatives which showed 
antischistosomal effects. A single oral dose of 80mg kg-1 of Rol 1-3128 showed 90% 
cure rates of mice or hamsters infected with either S mamoni or S haematobium. 
Rol 1-3128 was active against all stages of schistosomes (Bickle and Andrews, 1985). 
However, in a pilot clinical study in humans, a subcurative dose caused severe and 
long-lasting sedation, ataxia and muscle relaxation (OBoyle et al., 1985). ROIS-5458 
was administered at two dose levels (25mg and 15mg kg" body-weight) to S. mansoni 
infected vervet monkeys. It dramatically reduced the faecal egg-output, worm burden 
and tissue egg load (Suliaman et al., 1989). In S. haematobium infection, R015-5458 
was used, in comparison with PZQ, for treatment of hamsters at different stages of 
infection. R015-5458 was more effective against 4-week infection than PZQ. After 8 
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and 12 weeks of infection both drugs showed remarkable anti-schistosome effects 
(Guirguis, 2003). 
1.7.5 Artemisinin derivatives 
Arternisinin is the active principle derived from the leaves of Artemisia annua. The 
main anti-schistosomal derivatives of arternesinin are artemether and artesunate 
(Utzinger et al., 2003). Artemisinin derivatives are characteristically active against the 
immature stages, I to 3 weeks after infection, of S. mansoni, S. japonicum and S. 
haematobium with less effect on the very early invasive and the adult worms (Utzinger 
et al., 200 1 b; Utzinger et aL, 2001 c). Hence, artemether has been used as a prophylactic 
agent against S. mansoni, S. japonicum and S. haemalobium with significant reduction 
in prevalence (Xiao et aL, 2002; N'Goran et al., 2003). 
Furthermore, artesunate has been tried with praziquantel as a combination 
chemotherapy for the control of S mansoni and S. haemalobium resulting in higher cure 
rates as compared to placebo, praziquantel alone or artesunate alone (De Clercq et al., 
2000; Borrmann et al., 2001). The usual dose of artemether for human prophylaxis 
against schistosomiasis is 6mg kg-1 every 2 to 4 weeks for periods of up to 6 months. 
This regimen has reduced the neurotoxicity which is the main adverse effect of the drug 
(Utzinger et al., 2003). 
1.7.6 Myrrh (Mirazid) 
in the last few years, myrrh which is an oleo-gum resin, derived from the stem of 
Commiphora molmol is said to be effective against S haematoblum and S. mansoni with 
cure rates of up to 91.7% after single course of 10mg kg-1 every day orally for 3 days. 
The cure rate increased to 98% after a second course. The drug was well tolerated with 
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minimal side effects (Sheir et al., 200 1). As a consequence of that, Mirazie, myrrh, has 
been licensed and released for the treatment of human schistosomiasis in Egypt. 
Nothing is known about its mode of action, however, the product data sheet indicates 
that it causes separation of adult worm pairs with a consequent shift of female worms to 
the liver where they are destroyed. It also indicated that Mirazido improves the clinical 
picture of the treated individuals one week of the treatment. However, there has been 
significant debate in the scientific community about the true efficacy of Mirazido with 
very low cure rates being reported (Fenwick et al., 2003). 
In summary, there is a consensus that praziquantel is central to the treatment of human 
schistosomiasis and it has been used on a large scale for a long duration. 'Me limited 
emergence of schistosome strains with lower susceptibility to praziquantel and the fear 
of the spread of praziquantel-resistant strains have made it very important to find 
alternatives and to investigate any drug with potential activity against schistosomes. 
The work in this thesis has been designed to: 
Investigate the in vitro anti-schistosomal activities of Mirazido, compared to the 
standard drug praziquantel, against adult worms and schistosomula, stages of S. 
mansoni. 
* Investigate the in vivo anti-schistosomal activities of Mirazido, compared to 
praziquantel, against S. mansoni in mice. 
* Try to elucidate the mode of action of Mirazido in terms of the effects on 
viability and the damage it causes. 
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* Investigate the effects of Mirazieand praziquantel on the expression of 
different proteins of adult S. mansoni. 
Investigate the impact of Mirazido and praziquantel on the immune response of 
mice in response to S. mansoni infection. 
Investigate the different recognition patterns of S. haemalobium antigens in 
human infections before treatment, after treatment and aller re-infection. 
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Chapter Two 
comparative study of the effects of Mirazido 
and praziquantel on schistosomula and adult 
worms of Schistosoma mansoni and on murine 
immune responses to infection, 
2.1 Introduction 
2.1.1 Schistosoma mansoni: the tegument 
Schistosomes infect their mammalian hosts by direct penetration of the skin. As 
cercariae penetrate the skin of a suitable host, they begin to undergo substantial 
changes. These changes include the loss of the outer glycocalyx and substitution of their 
outer trilaminate membrane with a heptalaminate membrane. These structural changes 
start to be evident 30 minutes after penetration and manifest as loss of the glycocalyx, 
decrease in the number of cercarial spherical bodies and appearance of vacuoles with 
membranous contents in tegumental. matrix. However, the outer membrane of the 30- 
min schistosomula is trilaminate. In the 3-h schistosomula the outer membrane is almost 
heptalaminate and the tegument contains small membranous bodies and few discoid 
bodies (Hockley, 1973; Hockley and McLaren, 1973). In this context it has been 
suggested that the gross changes that occur during schistosomula transformation are 
accompanied with modification of the surface membrane lipid from a gel phase with 
restricted mobility to a liquid crystalline phase with increased motility (Foley et al., 
1988). 
The changes in the parasite tegument continue as the parasites develop. When S. 
mansoni has fully matured the tegument of the adult male is approximately 4ýLrn thick 
and is bound externally by a surface membrane. While the surface membrane is 
normally heptalaminate, some areas of membrane showing a trilaminate or even a 
multilaminate appearance can be identified using transmission electron microscopy. The 
surface membrane serves as an interface between the parasite and the surrounding 
environment. The tegument is bounded internally by a trilaminate basal membrane 
which separates the tegument from the underlying muscle layer. 'IIiis I Onni thick basal 
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lamina is highly folded and penetrates deep into the cytoplasm of the tegument. The 
tegumental cytoplasm consists of an electron-dense granular matrix in which 
membranous bodies, discoid bodies and mitochondria, may be recognised. 'Me inclusion 
bodies are formed in sub-tegumental cells (cytons) located beneath the muscle layers 
and are transferred to the tegumental cytoplasm through tortuous cytoplasmic 
connections connecting the cells with the tegument (Hockley, 1973; Hockley and 
McLaren, 1973; McLaren, 1980). The role of the inclusion bodies is not clear, however, 
the membranous bodies fuse with the outer membrane and may contribute to its 
formation during penetration, while the discoid bodies may contribute to membrane 
maintenance and turnover (McLaren, 1980; Skelly and Shoemaker, 2001). 
In the area posterior to the ventral sucker, the dorsal surface of the male worm is 
covered with large tubercles covered with spines. The tubercles are few in number in 
the lateral and posterior parts of the dorsal surface. In these regions and between the 
tubercles, the surface of the worm is ridged and in the depressions between the ridges 
there are numerous distinct pits. Small numbers of individual spines and sensory 
papillae are present between the ridges. A characteristic feature of male schistosomes 
and one from which their name derives is the cleft (schist) in the body (soma). This 
groove is the normal location for the female worm during pairing and is designated the 
gynaecophoric canal. The surface of the gynaecophoric canal lacks tubercles and is 
ridged and covered with many small, irregularly arranged spines. The surface 
topography of female worms is less dramatic than that of male worms. The surface of 
the female worm lacks tubercles and only a few spines are present mainly at the 
posterior end (Race et al., 1971; Hockley, 1973). 
The tegument of schistosomes, particularly the surface membrane, is of fundamental 
importance for parasite survival in the blood stream of its hosts. It plays a role in 
nutrient uptake and in evasion of the hosts' immune responses (Chappell, 1974; Levy 
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and Read, 1975; MacGregor and Kusel, 1989). The tegument is metabolically highly 
active and undergoes continuous turnover and replacement. The in vitro rate ofturnover 
of the outer bilayer of adult S. mansoni has been studied and estimated to have a half- 
life of 2-3 hours (Wilson and Barnes, 1977). 
The tegument of the schistosome contains inclusion bodies including discoid (DII) and 
membranous (MB) bodies. Beneath the tegument are the circular (CM) and the 
longitudinal muscles. The subtegumental cells (SC) are located beneath the muscle 
layers and they have cytoplasmic connections (C) with the tegument. 
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Figure 2.1 Ultrastructure of the male worm ofS. mansoni. 
The surface of adult male ofS. mansoni has many tubercles J) which are covered with 
spines (S). Between the tubercles the surface is ridged with a few scattered spines and 
sensory organs (SO). 
The composition of the two bilayers of the outer tegumental membrane has been shown 
to be very different. The first clear evidence of differences between the layers was the 
selective requirement of the outer layer for uranyl acetate fixation while the inner layer 
could be fixed with ordinary fixatives (I lockley and McLaren, 1973). Freeze Fracture 
studies of the tegument ofS. mansoni have shown that the intra-membranous particles 
are more numerous in the outermost monolayer than the inner-most 111onolaycr adjacent 
to the cytoplasm (McLaren el al., 1978). Furthermore, Foley and colleagues (1986) 
have shown that lipid probes diffuse freely in the external monolayer of the outer 
tegument membrane of S. mansoni whereas in the inner layers they have a restricted 
diffusion (Foley et al., 1986). This may be a consequence ofthe outer membrane being 
composed of micron-scale liquid crystalline-phase lipid domains that lack significant 
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Figure 2.2 Surface topography of adult maleV. mansoni worm. 
amounts of trans-membrane proteins (Caulfield et aL, 1991) while the lateral diffusion 
of the inner bilayer is limited by the insertion of glycosylphosphatidylinositol-anchored 
glycoprotein antigens (Camacho et aL, 1995). 
In addition to its critical role in the survival of the parasite, the tegument of 
schistosomes is also potentially important as a target for the action of many anti- 
schistosomal. drugs, most importantly praziquantel (Andrews et al., 1983; Cioli et al., 
1995). The effects of the anti-schistosomal agents, praziquantel (PZQ) and Mirazido, on 
the tegument of S mansoni are a major focus of this thesis. 
2.1.2 Mirazido as an anti-schistosomal drug 
Mirazido (MZD) is the trade name of myrrh which is an oleo-gum resin derived from 
the plant, CommiPhOra MIMI- In ancient Egypt, myrrh was one of the constituents 
exploited to preserve mummies (Buckley and Evershed, 2001). In the recent years, there 
have been a number of studies on the biological activity of myrrh and as a result, many 
medicinal uses have been proposed for it. The anti-schistosomal activities of myrrh 
were first reported by Sheir and colleagues. They treated 204 Egyptian schistosomiasis 
patients, 171 infected with S. mansoni, 4 with S. haematoblum and 29 with mixed S 
mansoni and S. haematobium. Iley reported an average parasitologic cure rate of 
91.7% after a single course of treatment and 98% after a second course of the drug. The 
drug was effective against both S. mansoni and S. haematobium. They also reported 
complete relief of symptoms in 90.7% of patients (Sheir el al., 2001). In another study 
on human schistosomiasis, treatment with MZD at a dose of 600mg per day for six days 
was reported to have 97.4 and 96.2% cure rates against& haematobium and S. mansoni, 
respectively (Abo-Madyan et aL, 2004). They also reported "a marvellous clinical cure 
without any side effects" after this treatment regime. Furthermore, MZD has been 
shown to have strong anti-schistosomal properties, in vitro, against S. mansoni adult 
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worms as determined by its ability to induce somatic muscle contractions and to cause 
tegumental damage of the parasite in the form of tegumental disruption, oedema and 
loss of the spines covering the tubercles (Hassan et aL, 2003). 
In addition to its activity against schistosomes, MZD has been also reported to be 
effective against human fascioliasis at a dose of 12mg kg-1 of body weight daily for 6 
consecutive days. All treated patients showed a pronounced improvement of their 
general conditions and symptoms and stopped passing eggs in their stools (Massoud et 
al., 2001a). A similar fasciolicidal effect of MZD has been reported in sheep. A total 
dose of 600mg gave a cure rate of 83.3 %, while a dose of 900 to 1200mg gave a 100% 
cure rate (Haridy et al, 2003). MZD was also reported to be cffective against human 
and sheep dicrocoeliasis dendriticum with a cure rate of 100% (Al-Mathal and Fouad, 
2004). 
Other reported properties of myrrh include; molluscicidal activities against 
Biomphalarla alexandrina, Bulinus truncatus and Lymnaea cailliaudi (Allam et al., 
2001; Massoud and Habib, 2003), larvicidal activity against Culex pipiens larvae 
(Massoud et al., 2001b), anti-inflammatory effect (Kimura et al., 2001), local 
anaesthetic, anti-bacterial and anti-fungal properties (Dolara et aL, 2000) and smooth 
muscle relaxing properties (Andersson et al., 1997). 
In Egypt, MZD has been licensed for use for the treatment of human schistosomiasis 
and fascioliasis and it has been said to be safe and well tolerated with few side effects 
(Sheir et al., 2001; Massoud et al., 2004). However, in other trials of treatment of 
human schistosomiasis, low cure rates have been reported and the previously reported 
high cure rate seems to be difficult to reproduce (Fcnwick et al., 2003). Furthermore, in 
a multicentre study for treatment of S. mansoni in mice indicated that MZD is not 
effective against adult schistosomes (Botros et al., 2004). To clarify this situation, the 
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present study was designed to investigate the efficacy of MZD, compared to the 
standard drug PZQ, against S. mansoni both in vitro and in vivo. 
2.2 Materials and methods 
2.2.1 Drugs and reagents 
Drugs 
The extract of Commiphora molmol (myrrh) used in the experiments is produced by 
Pharco Pharmaceuticals (Egypt). It is sold as a "purified" extract in capsules of 300mg 
although details of the extraction process and subsequent processing are not available. It 
licensed and marketed as Mirazide for the treatment of human schistosomiasis and 
fascioliasis in Egypt. Praziquantel was obtained as a powder from Bayer (Germany). 
Both MZD and PZQ were dissolved in dimethyl, sulfoxide (DMSO) to make stock 
solutions of I 00mg ml". 
Reagents 
Unless otherwise stated, all reagents used in the experiments were purchased from 
Sigma-Aldrich Company Ltd, Dorset, England. Details of the solutions are provided in 
the appendix. 
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In vitro experiments 
2.2.2 Parasites 
Recovery of adult S. mansoni worms 
The Puerto Rican strain of S mansoni is maintained in Professor John Kusel's 
laboratory (University of Glasgow) by routine infection of female TO mice. Adult 
worms were recovered by perfusion of 6-8 week-infected mice according to the method 
of Smithers and Terry (1965). Six to eight weeks after infection, mice were killed by an 
intra-peritoneal injection of 0.2ml (60mg ml") of Sagatal. The abdominal and thoracic 
cavities of the mice were exposed by dissection and the mice were suspended against a 
vertical perspex sheet. An incision was made in the portal vein and heparinised RPMI- 
1640 medium was pumped into the heart using a 50ml disposable syringe. The worms 
passed through an incision in the portal vein and were collected on a sheet of muslin 
gauze and washed in RPMI- 1640 before use in the experiments. 
Mechanical transformation of schistosomula 
The method used for mechanical transformation of schistosomula is a modification of 
that of Colley and Wikel (1974). Schistosoma mansoni cercariae freshly shed from 
Biomphalaria galabrata snails were transferred to a plastic universal. By chilling the 
cercariae on ice for 15 minutes, their motility is reduced and they rapidly sank to the 
bottom of the container. This facilitated their concentration in smaller volumes. Water 
was then removed until approximately Iml remained and 9ml of pre-warmed (370C) 
RPMI-1640 was added. The cercariae were then aspirated 10 times using a 10ml 
syringe and 21 -gauge needle to shear off their tails. The schistosomula were washed 
twice in RPMI- 1640 and left for 2 hours at 3 7*C to complete their transformation before 
use. 
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2.2.3 In vitro treatment and observations of adult worms of S. mansoni 
Adult S. mansoni worms were incubated in complete RPMl- 1640 medium (RPMI- 1640 
+ 10% Foetal calf serum (FCS) + 2% penicillin/streptomycin + 2% Fungizone, all from 
Gibco Limited, Paisley, Scotland) with various concentrations (3,6,12,25,50,100 and 
200pg ml-1) of either PZQ or MZD. Ten worm pairs, consisting of one male and one 
female, were incubated in a volume of I ml in each well of a 24-well tissue culture plate 
(Microplate, IWAKI, Japan). As controls, worms were incubated in media containing 
1% DMSO. The plates were incubated at 37'C in a humid atmosphere with 5% C02. 
Damage, changes in shape, changes in motility and unpairing of adult worms were 
assessed using an inverted light microscope (Leitz DIAVERT"). 
2.2.4 Assessment of the viability of schistosomula of S. mansoni after in 
vitro exposure to pranquantel or Mirazidlý 
Toluidine blue exclusion test 
Schistosomula were incubated in 96-well tissue culture plates (Microplate, IWAKI, 
Japan). Two hundred schistosomula were incubated in I ml of medium containing either 
MZD or PZQ at concentrations of 3,6,12,25,50,100 and 20OAgml". As controls, 
schistosomula were incubated in media containing 1% DMSO. The viability and 
integrity of schistosomula were assessed by their ability to exclude the toluidine blue 
dye 1,2,4 and 8 hours after exposure. One percent of a methanolic solution of toluidine 
blue (Fisher Scientific UK LTD, Leics, UK) was spread over glass slides and allowed to 
dry. Schistosomula were then placed onto these slides and examined using a Leitz 
(DIALUX model 22EB) light microscope. Normal schistosomula remained unstained 
whereas damaged ones became stained with the dye (Dessein et al., 1983). 
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Confinnatory evidence of drug effects on the viability of schistosomula of S. manson! 
was obtained by using the Hoechst test. 
Hoechst test 
The effect of both drugs on the viability of schistosomula was further investigated using 
the Hoechst 33258 dye. Hoechst 33258 dye is relatively membrane impermeable and 
can access the cells through damaged membranes. It specifically binds to the DNA 
where it fluoresces (Modha et aL, 1997). Two hundred schistosomula were incubated 
for 4h in Iml of medium containing either MZD or PZQ at concentrations of 50,100 
and 200lig ml-1. As controls, schistosomula were incubated in media containing 1% 
DMSO. Hoechst 33258 was added (2pg ml") during the last 20 minutes of incubation. 
Schistosomula were then mounted on slides and examined using a fluorescent 
microscope (Leitz Laborlux S with 3-1 PLEOMOPAK fluorescence illuminator). Tle 
damaged areas of the parasites gave a blue fluorescence. 
2.2.5 Fluorescent Recovery After Photobleaching (FRAP) 
Another method that has been used to investigate the effect of the drugs on the surface 
membrane of the schistosomes is FRAP. FRAP allows the assessment of membrane 
fluidity as an indirect indication of membrane function. For FRAP, the sample to be 
examined is probed with a fluorescent substance and then an attenuated laser beam is 
focused to a small spot on the sample. The initial fluorescence level inside the spot is 
measured and the laser is momentarily de-attenuated to bleach irreversibly the 
molecules within the spot. The recovery of fluorescence inside the spot is a 
consequence of the difflusion of unbleached molecules from outside the spot. FRAP thus 
provides two measures of diffusibility; the fmction (percentage recovery) of molecules 
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that are able to move and the diffusion coefficient (DL) of that fraction (Modha et aL, 
1997). 
Incorporation of the fluorescent lipid analogue 
Lipid motility on the surfaces of worms was examined by probing adult worms and 
schistosomula with a fluorescent lipid analogue, 5-N-octadecanoyl aminofluorescein 
(AF18) (Molecular Probes Europe BV, PoortGebouw, The Netherlands). Schistosoma 
mansoni adult males and schistosomula were incubated, as before, with either MZD or 
PZQ at concentrations of 200ýtg ml-1 (as a high drug concentration) and 20pg ml-1 (as a 
low drug concentration). As controls, parasites were incubated in media containing 1% 
DMSO. Twenty adult males or 200 schistosomula were incubated in Iml of complete 
RPMI-1640 medium at 370C and 5% C02. After 4 and 24 hours of incubation, 5PI of an 
ethanolic solution containing I Opg of the AF-18 probe were added to each well and the 
parasites were incubated for another 15 minutes. Then, parasites were washed 3 times 
with RPMI-1640 to remove any unbound probe. Worms were re-suspended in I OOgI of 
RPMI, placed on a glass slide and immobilised by addition of I OPI of carbachol (I Omg 
ml-1). When myrrh was used, 100pl of carbachol (10mg ml") was required to 
immobilise worms (see discussion). 
Lipid mobility assessment 
Measurement of the diffusion of lipid molecules in adult worm and schistosomula 
membranes was carried out according to the method outlined by Foley et al. (1986). 
Fluorescence was measured over a small and defined spot of 1.2[Lm diameter on the 
surface of the labelled parasite using an attenuated argon laser (LEXEL model 85) 
attached to a microscope (Ortho 11). The power of the laser was increased for 70ms to 
irreversibly bleach a proportion of the fluorescent molecules in the spot, and the 
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recovery of fluorescence recorded using a Tektronix Digital real-time oscilloscope. 'Me 
mobile fraction (percentage recovery), and the lateral diffusion coefficient of lipid 
molecules were measured in 5 spots on the tubercles of the dorsal tegument of each 
adult worm, just behind the head region. For measurements on schistosomula, a spot 
was selected in the central portion of the body. 
2.2.6 Scanning Electron Microscopy (SEM) 
Adult worms and schistosomula of S mansoni were incubated with either MZD or PZQ 
at concentrations of 200pg ml-1 and 20pg ml-1 for MZD and 200,20 and 5pg ml-I for 
PZQ. As controls, parasites were incubated in media containing 1% DMSO (the drug 
solvent). Either twenty adult worms or 200 schistosomula were incubated in Iml of 
complete RPMI-1640 medium at 37'C and 5% C02. After 4,24 and 72h of incubation, 
treated and control parasites were fixed in 2.5% glutaraldehyde buffered with O. IM 
phosphate for lh and then washed 3 times for 5min each time with O. IM phosphate 
buffer rinse (containing 2% sucrose). The samples were secondarily fixed in 1% 
osmiurn tetroxide for I h, washed 3 times for 10 minutes each time with distilled water, 
fixed in 0.5% aqueous uranyl acetate, in the dark, for I hour and then washed again with 
distilled water. Then samples were dehydrated in ascending grades of alcohol, 30,50, 
70,90 and 100% and finally in dried absolute alcohol, for 10 minutes each time. After 
critical point drying with liquid C02, the specimens were mounted on metal stubs with 
double-sided copper tape. They were coated with gold using a Polaron SC515 SEM 
coating system and examined using a Phillips SEM 500 electron microscope. The 
procedures were carried out as recommended by Hayat (1989). 
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2.2.7 Transmission electron microscopy (TEM) of adult S. mansoni 
worms after exposure to praziquantel or Mirazid2' 
Adult S. manson! were incubated with either MZD or PZQ at concentrations of 200 and 
20pg ml-1. As controls, parasites were incubated in media containing 1% DMSO (the 
drug solvent). Twenty adult worms were incubated in Iml of complete RPMI-1640 
medium at 37'C and 5%CO2. Four and 24h after incubations, treated and control 
parasites were fixed in 2.5% glutaraldehyde buffered with O. IM phosphate for lh and 
then washed 3 times for 5min each time with O. IM phosphate buffer rinse (with 2% 
sucrose). The samples were secondarily fixed in 1% osmium tetroxide for 1h, washed 3 
times for 10min each time with distilled water, fixed in 0.5% aqueous uranyl acetate, in 
the dark, for lh and then washed again with distilled water. Then samples were 
dehydrated in ascending grades of alcohol, 3 0,50,70,90 and 100% and finally in dried 
absolute alcohol, for 10min each time. The specimens were washed with propylene 
oxide 3 times for 5min each time and further dehydrated by incubation in a 1: 1 volume 
to volume mix of propylene and araldite. Specimens were left overnight on a rotator 
until the propylene oxide was evaporated leaving pure araldite, which was replaced by 
fresh araldite and left overnight. Samples were then embedded in moulds and left to 
polymerise at 60'C for 48h. Sections, 60-80nm thick, were cut using an ultramicrotome 
(Reichert Ultracut) and stained with 2% methanolic uranyl acetate for Smin followed by 
Reynold's lead citrate for another 5 minutes. Specimens were viewed using a TEM 
(Zeiss 902). 
2.2.8 Calcium labelling with Fluo 3 AM 
Fluo-3 AM cell permeant (Molecular Probes Europe BV, PoortGebouw, The 
I 
Netherlands) is a fluorescent probe which fluoresces intensely when it binds calcium. Its 
57 
acetoxymethyl (AM) ester allows it to permeate the cell membrane. Once inside the 
cell, it is metabolised to an impermeable compound that leaks out only slowly. Fluo-3 
AM is purchased as a powder in 50pg-vials. The contents of each vial were dissolved in 
50ptl of DMSO. Either twenty S. mansoni adult worms or 200 schistosomula were 
incubated in Iml of complete RPMI-1640 medium to which 5[d containing 5pg of Fluo- 
3 AM was added. They were incubated for 2 hours at 37*C in 5% C02. MZD or PZQ 
was then added to the parasites to achieve a concentration of 200pg ml" for either drugs 
and incubation continued. As controls, parasites were incubated with 1% DMSO. After 
15min, 30min, 1,2 and 4h of exposure to the drugs, parasites were washed 34 times 
with RPMI- 1640 to remove excess probe and drugs. The parasites were re-suspended in 
approximately 100ptl of fresh RPMl medium and deposited within silicon grease 
squares on glass slips and covered with cover slides for quantitative measurements. All 
measurements were carried out using a fluorescent microscope (Leitz Laborlux S with 
3-1 PLEOMOPAK fluorescence illuminator). Fluorescence was quantified using a Leitz 
MPV compact photometer with MPV-COMBI control electronics attached to a PC 
(Silicon Valley) installed with MPV-STAT software for data and statistical analysis 
(Leica). 
The experiment was repeated but with the adult worms being exposed to the drugs prior 
to fluo-3 AM labelling. One and 4 hours after exposure to MZD or PZQ at 200pg ml", 
parasites were washed with RPMI medium 3-4 times, to remove the drugs. They were 
then labelled with fluo-3 AM for 2h as before. The parasites were washed again with 
medium and quantitative fluorescent measurements were calculated as mentioned 
previously. 
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In vivo experiments 
2.2.9 Design of the experiment 
Thirty female TO mice were infected by subcutaneous injection of 150 cercariae (per 
mouse) of the Puerto Rican strain of S. mansoni. Six weeks after infection, they were 
divided into 3 groups; a control infected group (10 mice) left without any treatment, a 
MZD group (10 mice) treated with 400mg: kg-1 of body weight daily dose of MZD given 
orally for 3 consecutive days and a PZQ group (10 mice) treated with a single dose of 
400mg kg-1 of body weight of praziquantel given orally. A fourth group of control non- 
infected mice (5 mice) were included as control for cytokine assays (see figure 2.3). 
Two weeks after treatment, mice were perfused for recovery of adult worms. The whole 
liver of each mouse was dissected, weighed, a piece was dissolved in KOH to assess 
egg numbers in liver tissue and the rest of the liver was fixed for histopathology 
sectioning. Spleen and mesenteric lymph nodes (LNs) were dissected, washed with 
RPMI and processed for lymphoblastogenesis and cytokine assays. Further technical 
details of the methodologies are given below. 
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Figure 23 Design of the In vivo experiments. 
Sub-cutaneous injection (SQ, post infection (PI) and lymph nodes (LNs). 
2.2.10 Recovery of adult S. mansoni worms 
The process of liver perfusion and recovery of adult worms was carried out as 
mentioned previously (see section 2.2.2). The worms recovered from each mouse were 
collected in a universal container containing RPMI-1640 medium supplemented with 
10% FCS. The worms were placed into a Petri dish and they were counted using a 
dissecting microscope. The worms of each group were then pooled (for the proteomic 
analysis) and washed in 40mM Tris solution and stored at -20'C until used. 
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2.2.11 Counting of eggs per gram of liver tissue 
A piece from each liver was excised, weighed and placed in a labelled universal tube 
containing 10ml of 5% KOH solution. The tubes were incubated for 24h at 37T. The 
content of each tube was mixed thoroughly with an equal volume of 10% formol saline 
solution and then centrifuged at 60g for I min. The residues were re-suspended in 6ml of 
phosphate buffered saline (PBS) and mixed thoroughly. A 200ptl was then placed on a 
glass slide and the eggs were counted. Duplicate counts were made and the mean 
number of eggs per gram of liver tissue was calculated. 
2.2.12 Liver histology 
Tle liver samples were fixed in neutral buffered formol saline over night at room 
temperature. They were washed under gently running tap water and then passed in 
ascending grades of alcohol (2 x 30min in 70%, 4x 30min in 90% and 4x 30min in 
100% alcohol). The samples were incubated in tissue-clear solution (2 x 15min) and 
then in paraffm wax (2 x 2h). Samples were then embedded in cassettes using fresh 
paraffin wax. The specimens were trimmed, cooled on ice and then sectioned at 5[tm 
using a microtome (Leica RM2035). 'Me sections were floated on distilled water at 
36'C, mounted on poly-l-lysine coated microscope slides and dried over night at 36*C. 
For general tissue structure sections were stained by haematoxylin and eosin (H&E). 
The sections were de-waxed in tissue clear solution and then hydrated in decreasing 
concentrations of alcohol (100,90 and 70%). The sections were washed in gently 
running tap water and then stained with Mayer's haernatoxylin for 5min. They were 
washed in gently running tap water and then stained with eosin stain for 2min. The 
excess stain was washed in gently running tap water and then the sections were 
dehydrated in increasing concentrations of alcohol (70,90 and 100%). The sections 
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were cleared again in tissue clear and then mounted in synthetic mounting media. The 
nuclei stain blue and all other structures stain pink/red. 
The collagen fibres were stained with picro-sirius red F3B dye according to the method 
of Junqueira et aL (1979). Briefly, the sections were hydrated in water and stained with 
picro-sirius red for lh. They were then washed in two changes of acidified water and 
dehydrated in 3 changes of absolute alcohol. The sections were cleared in tissue clear 
solution and mounted. In ordinary brightfield microscopy, collagen fibres stain red on a 
yellow backgound. 
Eosinophils were localised using the picro-sirius red technique according to the method 
of Llewellyn (1970). The sections were hydrated in water and stained using Mayer's 
haematoxylin for Imin. They were washed gently under running water until the stain 
became blue. They were rinsed in alcohol and then transferred to picro-sirius red for I- 
2h. The sections were washed thoroughly under gently running water. They were then 
dehydrated in absolute alcohol, cleared in tissue clear and mounted. Eosinophil granules 
stain bright red, nuclei stain blue and the background colourless. Ile eosinophils in the 
high power field (HPF) surrounding the egg of each granuloma was counted. Only 
granulomas surrounding a single egg were included. 
2.2.13 Extraction of lymphocytes 
The spleens and mesenteric lymph nodes (LNs) were dissected and collected in labelled, 
sterile universal tubes containing RPMI-1640. The spleens of each group of mice were 
pooled in a single tube. Similarly the LNs were pooled in another tube. The spleens and 
LNs were pressed with a sterile syringe plunger through a fine sieve in a Petri dish 
containing 15ml of RPMI-1640- The Petri dishes were tilted to allow cell clumps to 
settle and the supernatants were collected in 50ml-sterile tubes, supplemented to 30ml 
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with RPMI- 1640 and centrifuged for 7min at 180g and 4'C. Residues from spleens were 
re-suspended in 6ml of RPMl and added gently to a universal tube containing 4ml of 
Lymphoprep (1.077 ± 0.001g/ml) (Nycomed Pharma AS, Oslo, Norway). Then they 
were centrifuged at 40C for 40min at 220g. The lymphocytes were collected using a 
glass pipette and placed in a universal tube. The cells from the spleens and LNs were 
then washed twice for 7min each time at 180g at 18-25'C. After the last wash, cells 
were re-suspended in Iml of RPMI-1640. A 10pl sample from each tube was diluted 
with 190AI of 2.5% solution of trypan blue. The cells were counted using an improved 
Neubauer haemocytometer. After calculating the total number of cells in each tube, they 
were diluted with RPMI- 1640 to achieve a working concentration of Ix 107 cellshnl. 
2.2.14 Lymphocyte proll ration assay 
Lymphocytes from spleens and LNs of each group were cultured in 96-well tissue 
culture plates. Blastogenesis was assessed by incubation of lymphocytes with 5ýtg ml-1 
of Concanavalin A (ConA) or 25pg ml-1 of either S. mansoni soluble worm antigens 
(SWAP) or soluble egg antigens (SEA) (150ýtl of complete RPMI-1640 + 25PI of cell 
suspension containing 2.5 x 105 cells + 25ýd of antigen) with unstimulated cells as 
control (175ýd of complete RPMI-1640 + 251d of cell suspension). Assays were run in 
triplicate. The plates were incubated at 37'C, 5% C02 and humidity. After 5 days, 
0.2ýtCi of radioactive-thymidine (Amersharn Biosciences UK Ltd, Buckinghamshire, 
UK) was added to each well and further incubated for 18 hours. At the end of 
incubations, the plates were harvested and isotype incorporation by the cells measured 
using a liquid scintillation counter (Wallac 1450 Microbetaý Trilux). 
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2.2.15 Cytokine assays 
Culture of lyniphocytes and splenocytes with different antigens 
Lymphocytes were cultured as described previously and the supernatants were collected 
after 5 days of incubation. Aliquots of 150[d of supernatant were collected from each 
well and stored in sterile tubes at -800C until they were used. 
Cytokine detection and estimation by Duoset(& enzyme linked immuno-sorbent 
assay (ELISA) 
DuoSet'9 kits for detection of IL-4, IL-10, IL-13 and INF-y cytokines were purchased 
from R&D Systems Europe Ltd, Abingdon, UK. The protocol used was that defined by 
the supplier. The plates were coated with 1001il of capture antibodies, 41Lg ml-1 for IL-4, 
IL-13 and IFN-y and 2jig ml" for IL-10, at room temperature overnight. They were 
washed three times with wash buffer, 0.05% Tween 20 in PBS, pH 7.2. They were 
blocked with 200[d of block buffer (1% BSA, 5% sucrose in PBS with 0.05% Na N3) 
sealed at room temperature for two hours and washed as before. I 00gl of each sample 
and standard dilution were loaded per well. Samples were run in duplicate. Seven two- 
fold dilutions of the standard were used starting with 10OOpg ml"' for IL4,20OOpg ml" 
for IL-10 and IFN-y and 2500pg ml" for IL-13. They were sealed and incubated for 2 
hours at room temperature. The plates were washed and 100tLI of detection antibodies, 
0.2ýtg ml-1 for IL-4 and IL-13 and 0.4pg ml-1 for IL-10 and IFNy were loaded and 
incubated for 2 hours at room temperature. Excess antibodies were washed away with 
wash buffer and a 100til of streptavidin-HRP was loaded per well. Plates were then 
incubated for 20 minutes at room temperature, away from direct light. The plates were 
washed as before and a 1001A of substrate solution (1: 1 mixture Of 11202 and 
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tetramethylbenzidine) was added to each well and were further incubated for another 20 
minutes at room temperature, away from direct light. The reactions were then stopped 
with 50ýtl of 2N H2SO4. Optical densities were determined immediately using a 
microplate reader (DYNEX MRX Revelationo) set to 450rim with wavelength 
correction set to 540run. 
2.2.16 Statistical analysis 
All statistical tests were carried out on the means using the analysis of variance 
(ANOVA) test with P<0.05 as the criterion of significance. When there was a 
significant difference it was followed by the student Wests for pair wise comparisons 
between different groups. The MINITAB software (version 12) were utilised for this 
purpose. 
2.3 Results 
Results of the in vitro experiments 
2.3.1 Effects of Mirazid"' and praziquantel on the viability of 
schistosomula of S. mansoni 
Toluidine blue dye exclusion test 
The effects of MZD on schistosomula were assessed using toluidine blue dye exclusion. 
Schistosomula were incubated with either MZD or PZQ at concentrations of 3,6,12, 
25,50,100 and 200pg ml" and their ability to exclude toluidine blue dye were observed 
microscopically 1,2,4 and 8 hours of exposure to the drugs. Control schistosomula 
were incubated in medium with the solvent only (1% DMSO). 
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At all times, most of the control schistosomula retained their ability to exclude the dye 
and remained unstained. In the drug exposed groups, although most of the 
schistosomula exposed to either MZD or PZQ showed increased granularity and 
decreased motility, only stained parasites were regarded as damaged or dead. The 
characteristic feature of schistosomula exposed to PZQ was blebbing in the area around 
the mouth of the parasites. At lower concentrations, 3,6,12,25pg ml", neither drug had 
any visible effects on the ability of parasites to exclude the dye. Even after 8 hours of 
exposure, the numbers of stained parasites were not significantly different from that 
found in the controls. After 2h of exposure, only MZD at a concentration of 200pg ml" 
caused a significant decrease in the viability of schistosomula (P=0.037). After 4h of 
exposure, MZD at concentrations of 200,100 and 50pg ml-1 had highly significant 
(P<0.01) effect on parasites viability (63,25 and 10% of schistosomula were stained, 
respectively). This effect progressed with time and after 8h of exposure 91,37 and 18% 
of schistosomula were stained, respectively (see figure 2.4). 
After 4h of exposure to PZQ, only PZQ at a concentration of 20OAg ml" caused a 
significant impainnent (P=0.013) of the ability of schistosomula to exclude toluidine 
blue (11% of schistosomula were stained). After 8h of exposure to praziquantel at 
concentrations of 200pg ml-1 and 100pg in]" there was significant impairment (P<0.01 
and P=0.032) of the ability of the parasites to exclude the dye (16% and 7% of 
schistosomula were stained). 
These results indicate that MZD has a strong damaging effect presumably on the 
membranes of schistosomula, resulting in their inability to exclude toluidine blue dye. 
PZQ has a modest effect. With both drugs the effects are dose and time dependent with 
the highest effect evident after 8 hours of exposure to a concentration of 200pg ml". 
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Hoechst test 
The effect of MZD or PZQ on the viability of schistosomula of S. mansoni was further 
confirmed using the Hoechst 33258 dye. Schistosomula were incubated with either drug 
for 4h with the dye added during the last 20 minutes of incubation and then they were 
examined under the fluorescent microscope. The percentage of damaged parasites of 
each group was calculated. 
Control schistosomula were unstained. After exposure to MZD at concentrations of 
200pg ml-1 and I OOpg ml-1,65% and 25% of schistosomula were fluorescent (P<0.01). 
After exposure to MZD at a concentration of 50pg ml", 15% of schistosomula were 
fluorescent (P=0.012). After exposure to PZQ at concentrations of 200pg ml-1 and 
I Oopg ml-1,19% (P<0.0 1) and 9% (P=0.02) of schistosomula were fluorescent. 
These results (not shown) confinned the results of the toluidine blue test that MZD is 
more effective than PZQ against the schistosomula stage of S. mansoni. 
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Figure 2.4 Effect of Mirazide and praziquantel on the viability of schistosomula of S. mansoni 
assessed by the toluidine blue exclusion test. 
Schistosomula of S. mansoni were incubated with either PZQ or MZD at concentrations 
of 100pg ml-1 and 200pg ml-1. One, 2,4 and 8 hours after exposure, their ability to 
exclude toluidine blue dye was determined. The columns represent the mean 
percentages of damaged (stained) schistosomula ± 95% confidence interval. MZD 
200pg ml-1 (M 200), MZD 100pg ml-' (M 100), PZQ 200pg ml-1 (PZQ 200), PZQ 
100pg ml-1 (PZQ 100) and control schistosomula incubated with 1% DMSO (Control). 
All groups consisted of 500 schistosomula and these results represent the mean of five 
experiments. 
2.3.2 Effects of Mirazido and praziquantel on adult worms of S. 
mansoni 
Adult wonns of S. mansoni were cultured with either MZD or PZQ at concentrations of 
3,6,12,25,50,100 and 200pg ml-1. Worms were observed under an inverted light 
microscope immediately after exposure and at 15min, 30min and at 1,2,4,8,24 and 
48h after exposure. Control worms were incubated in medium with 1% DMSO. Control 
worms remained alive and moved normally. The female worms started to lay eggs 
between 18 and 24h of incubation. 
The earliest changes, caused within seconds of exposure to PZQ, were muscular 
contractions and rapid coiling of worms, at all PZQ concentrations used. The worms 
contracted becoming shorter and thicker than the control parasites. The coiled worms 
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began to uncoil 30-60 minutes later although they remained shorter and thicker than the 
control parasites at all times. Worm motility started to diminish within 15-30 minutes of 
exposure. Motility decreased progressively with time. Surface blebbing became evident 
between 1-2h of exposure to concentrations of 200,100 and 50pg ml-1 and became 
evident at all PZQ concentrations after 4h of exposure (see table 2.1). 
The earliest effect of MZD was separation of adult S. mansoni worms. This started as 
early as 15 minutes after exposure to concentrations of 200pg ml-1 and 100pg ml-1. 
With time the number of worm separations increased. At 200Pg ml" and 100Pg ml", 
MZD caused an initial increase of motility and an increase in length of the parasites 
compared to the control group. This increase in motility was accompanied by increased 
regurgitation of intestinal contents of the worms, especially by the female worms, 
causing increased turbidity of the media. Worm motility returned to control levels after 
3 to 4 hours of exposure. At a MZD concentration of 200pg ml-1, worm motility began 
to decrease after 8 hours of exposure. This decrease in motility progressed with time. 
MZD at concentrations of I OOpg ml-1 and 50pg ml-1 caused a decrease in worm motility 
18 and 48h after exposure, respectively. At concentrations of 200Pg ml-1 and 100Pg ml' 
1. surface blebbing became evident between 18-24h after exposure. At concentrations 
ranging between 3 and 25pg ml-1, MZD seemed to have little effect on adult worms. 
They showed no obvious evidence of damage and the female worms started to lay eggs 
after 24h of incubation. 
These results indicate that while PZQ is very effective against adult S mansoni worms, 
MZD seems to be effective only at high concentrations and has obvious effects only 
after a considerable duration of exposure. However, at high concentrations MZD caused 
rapid separation of wonn pairs but it is impossible from these data to determine whether 
the effect of MZD on pairing was due to a differential effect of the drug on male or 
female worms. Other evidence from SEM studies indicates that both male and female 
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worms are likely to be affected though specific changes in the gynaecophoric canal of 
male worms may be significant (see section 2.3.7). 
Table 2.1 Observations of the effect of MirazidO and praziquantel on adult worms of S. mansonL 
Adult worms were exposed to either MZD or PZQ at concentrations of 3,6,12,25,50, 
100 and 200pg ml". Worms were observed at 15min, 30min and at 1,2,4,8,24 and 48 
hours. 
TIME PRAZIQUANTEL MIRAZID CONTROL 
Coiling of worms at all Increased motility at 200pg Control worms 
concentrations. This was ml-1 and I 00jig ml-1 with an were alive 
in 15 apparent 
immediately after increase in worms' length. At 
" 1 
throughout the 
m worm exposure although 200gg mI- and I OOgg ml experiment. 
worms remained coiled at separation of paired worms. Worms showed 
15min. 
- - - - 
no abnormal 
Uncoiling of worms. ae-nd, 100tigml-' m r r At 200tig movements and 
Decreased worm motility. finther separation of paired began to lay 30min Worms thick and short. worms. eggs after 18-24 
hours of 
Further decrease in worm. At 200pg ml-' and I OOgg ml-' incubation. 
1h motility, separation of paired worms 
Surface blebbing at At 200pg ml-' and I OOgg mi" 
concentrations of 200,100 worm separation. Worms' 
2h and 50pg ml-1. motility returns back to 
normal. 
Worms non-motile. At 200gg ml-' all worm pairs 
- Surface blebbing at all separated. At I OOpg ml 4h 
concentrations. worm separation increased. 
Worm paralysed. More At 200pg ml-' decreased 
8h surface blebbing. motility. 
Extensive surface blebbing At 200gg ml-' and I OOpg ml-' 
24h 
and paralysis. sluýgish motility. At 200pg 
ml and I OOgg ml" surface 
blebbing. 
Complete paralysis of At 200jig mV worm 
worms. Severe surface paralysis. At 100pg ml" and 
48h blebbing. 50pg ml-1 slupgish motility. 
At 200gg m1' and I OOgg ml" 
surface blebbing increased. 
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2.3.3 Unpairing effect of Mirazid"' on adult S. mansoni worms 
Based on the previous observations, the unpairing effect of MZD was fixther 
investigated. Paired adult S. mansoni worms were incubated with MZD at 
concentrations of 50,100 and 200pg ml-1 and were observed using an inverted light 
microscope at 15min, 30min and at 1,2,3,6 and 12h after exposure. Control worm 
pairs were incubated in mediurn with 1% DMSO. 
Control worms remained paired and after 12 hours of incubation only 15% of them 
were separated. With MZD at 200pg ml-1 and I OOpg ml" worm separation was evident 
as early as 15 minutes after exposure (28.9 and 13%, respectively). The separation of 
worm pairs was highly significant for both groups compared to the control group 
(P<0.01). After 30 minutes of exposure to MZD at 200pg ml" and 100pg ml-1 40.2% 
and 17.6% of worm pairs were separated, respectively. One hour after exposure, MZD 
at 200pg ml-1 and 100pg ml" caused separation of 52 and 23.7% of worm pairs, 
respectively. Additional worm separation occurred gradually and 6h after exposure, all 
worms (100%) were separated at 200pg mI-1 and 47.9% were separated at 100Pg ml-1. 
After 12h of exposure to MZD at 100pg ml-1,59% of worm pairs were separated (see 
figure 2.5). With MZD at 50pg ml-1 worm separations were not significantly different 
from those of the control group throughout the duration of the experiment. 
A similar experiment (data not shown) was conducted using PZQ. However, the 
rapidity with which PZQ acts on the parasites precludes observations of an effect on 
worm pairing over time. The worm unpairing effect of MZD appears to be at least in 
part dependent upon continued worm motility. 
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Figure 2.5 Unpairing effect of Mirazid* on S. mansoni adult worms. 
Adult worm pairs were incubated with MZD at 100pg ml-1 or 200pg ml-1 and were 
observed for separation at 15min, 30min, 1,2,3,6 and 12h after exposure. Figures 
represent the mean percentage of adult worm separation ± 95% confidence interval. 
MZD 200pg ml-1 (M 200), MZD 100)ig ml-1 (M 100) and control worms incubated with 
1% DMSO (Control). (Note; x-axis scale intervals are not proportional). All groups 
consisted of 30 worm pairs and these results represent the mean of five experiments. 
2.3.4 Effects of Mirazide and praziquantel on the membrane fluidity of 
schistosomula of S. mansoni as determined by fluorescent 
recovery after photobleaching (FRAP) 
The outcome of a S. mansoni infection is dependent upon the host parasite relationship 
and the parasite surface is the primary interface for this interaction. It has been 
suggested that the outer layer of the membrane consists of a sheet of phospholipids and 
sterols that is shed continuously releasing potentially antigenic material and bound 
antibodies (Wilson and Barnes, 1977). The effect of MZD or PZQ on the fluidity of the 
outer membrane of schistosomula was investigated using the FRAP technique. Only 
two concentrations of the drugs were used, 200pg ml-1 as a high concentration which 
appeared to have such dramatic effects in the previous experiments and 20Pg ml-' as a 
low concentration which appeared to have no significant effect in the previous 
experiments. The membranes of schistosomula were labelled with a fluorescent lipid 
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analogue AF- 18. They were then treated with MZD or PZQ at 200ýtg ml-1 and 20 Vg ml-1 
for both drugs. As controls, schistosomula were incubated with 1% DMSO. Four hours 
after exposure, the membrane was bleached with a 1.21im diameter laser beam and the 
recovery after photobleaching (the mobile fraction) and the lateral diffusion coefficients 
were calculated using MPV-COMBI software program. All treated groups showed a 
highly significant reduction (P<0.01) in the percentage recovery of fluorescence after 
photobleaching compared to the control group. The average percentage recoveries were 
49% for the control group, 25.5% for MZD 200pg ml-1,29% for MZD 20Pg ml"', 28% 
for PZQ 200pg ml" and 31.5% for PZQ 20gg ml-1. There were no significant 
differences among the treated groups (see figure 2.6). The average lateral diffusion 
coefficients were 6.9 ± 4.1 x 10-8 for the control, 3±1.7 x 10-8 for MZD 200Pg ml*', 3.3 
± 2.1 x 10-8 for MZD 20pg ml", 3.2 ± 3.1 x 10-8 for PZQ 200jig ml" and 3.5 ± 2.1 x 10" 
gcniý sec-1 for PZQ 20pg ml-1. These results indicate that MZD and PZQ caused a 
decrease in the fluidity of the surface membrane of schistosomula of S. mansoni and 
these effects could interfere with the survival mechanisms of the parasites. 
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Figure 2.6 Effect of Mirazid4o and praziquantel on the membrane fluidity of schistosomula of S. 
mansoni. 
Four hours after exposure of the AF- 18 labelled schistosomula to MZD or PZQ at 
200pg ml-1 and 20pg ml-1, their membranes were bleached with a laser beam and the 
percentage recovery was assessed. The columns represent the percentage recovery of 
fluorescence after laser photobleaching ± 95% confidence intervals. Control 
schistosomula incubated with 1% DMSO only (Control), MZD 200pp ml-1 (M200), 
MZD 20pg ml-1 (M20), PZQ 200pg ml-1 (PZQ200), PZQ 20pg ml- (PZQ20). All 
groups consisted of 100 schistosomula and these results represent the mean of 3 
experiments. 
2.3.5 Effects of Mirazido and praziquantel on the membrane fluidity of 
adult S. mansoni male worms as determined by FRAP 
The membranes of adult male worrns were labelled with a fluorescent lipid analogue 
AF-18. Then they were treated with MZD or PZQ at 200pg ml-1 and 20pg ml-1. Four 
and twenty four hours after exposure, the membrane was bleached with a 1.2gm 
diameter laser beam and the percentage fluorescence recovery after photobleaching was 
calculated using MPV-COMBI software program. Control worms were incubated in 
medium supplemented with the 1% DMSO (drug solvent). 
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After 4 hours of exposure, all drug exposed groups showed highly significant reductions 
in the percentage of fluorescence recovery after photobleaching compared to the control 
group (p<0.01). The average percentage recovery was 72% for the control, 33% for 
MZD at 200pg ml", 38% for MZD 20pg ml", 32% for PZQ at 200pg ml" and 41% for 
PZQ 20pg ml-1. The average lateral diff-usion coefficients were 1.8 ± 8.8 x 10-7 for the 
control, 6.1 ± 5.9 x 10-8 for MZD 200pg ml", 7.3 ± 7.7 x 10-8 for MZD 20Pg ml-1,8.4 ± 
7.5 x 10-8 for PZQ 200[ig n-d" and 1.07 ± 8.2 x 10-7 cm2 sec" for PZQ 20pg ml"' (see 
table 2.2). 
After 24 hours of exposure, all drug exposed groups showed highly significant 
reductions in the percentage of fluorescence recovery after photobleaching compared to 
the control group (p<0.01). The average percentage recovery was 56.5% for the control, 
28% for MZD 200jig ml", 34% for MZD 20pg ml-1,22% for PZQ 200pg ml-1 and 
26.5% for PZQ 20pg ml-1 (see figure 2.7). There were highly significant differences 
between PZQ 200pg ml-1 and MZD 200jig ml-1 (P<0.01) and between PZQ 20pg ml-1 
and MZD 20[tg ml-1 (P< 0.01). The average lateral diffusion coefficients were 1.74 ± 
8.6 x 10-7 for the control, 5.9 ±7x 10-8 for MZD 200pg in]", 9.4 ± 7.7 x 10-8 for MZD 
20pg ml-1,3.4 ± 2.1 x 10-8 PZQ 200[ig mI-1 and 7.1 ± 7.2 x 10-8cmý sed" for PZQ 20pg 
ml-1 (see table 2.2). These results indicate that both MZD and PZQ caused reductions in 
the membrane fluidity of adult male S. mansoni and that after 24h of exposure PZQ had 
a greater effect than MZD. 
75 
4h 24h 
Control parasites 1.8 ± 8.8 x 10-7 CM2 sec-' 1.7 ± 8.6 x 1()-7 CM2 sec- 1 
MZD 200pg ml-' 6.1 ± 5.9 x 10-8 CM2 sec-' 5.9 ±7x 1()-8 CM2 sec- 1 
MZD 20pg ml-' 7.3 ± 7.7 x 1()-8 CM2 sec-' 9.4 ± 7.7 x 10-8 CM2 sec-' 
PZQ 200pg ml-' 8.4 ± 7.5 x 10-8 CM2 sec-' 3.4 ± 2.1 x 10-8 CM2 sec-' 
PZQ 20pg ml-' 1.1 ± 8.2 x 10-7 
1 
CM2 sec-' 7.1 ± 7.2 x 1()-8 CM2 
1 
sec-' 
Table 2.2 Effect of Mirazide and praziquantel on the lateral diffusion co-efficient of the fluorescent 
membrane of adult S. mansoni worms. 
Four and twenty four hours after exposure of the AF- 18 labelled schistosomula to MZD 
or PZQ at 200pg ml-1 and 20pg ml-1, their membranes were bleached with a laser beam 
and the lateral diffusion co-efficient was assessed. This table represents the mean lateral 
diffusion co-efficient for each group ± 95% confidence intervals. 
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Figure 2.7 Effect of Mirazide and praziquantel on the membrane fluidity of adult males of S. 
mansoni. 
Adult worms were labelled with AF-18 and then exposed to either MZD or PZQ at 
concentrations of 200pg ml-1 and 20pg ml-1. After 24h of exposure, the membrane of 
the parasite was bleached with a laser beam and the percentages recovery were 
calculated. The columns represent the percentage recovery of fluorescence after laser 
photobleaching ± 95% confidence intervals. Control worms incubated with 1% DMSO 
only (Control), MZD 200)lg ml- I (M200), MZD 20pg ml-1 (M20), PZQ 200pg ml-1 
(PZQ200) and PZQ 20pg ml-1 (PZQ20). All groups consisted of 50 adult male worms 
and these results represent the mean of 3 experiments. 
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23.6 Scanning electron microscopy (SEM) of schistosomula of S. 
mansoni after exposure to Mirazid 0 or praziquantel 
Schistosomula of S. mansoni were incubated with MZD or PZQ at 200pg ml" and 20pg 
ml". Control schistosomula were incubated in medium supplemented with 1% DMSO. 
After 4 and 8 hours of exposure, schistosomula were fixed and processed for SEM (see 
section 2.2.6). 
Control schistosomula retained their normal structure and showed no obvious changes. 
Four hours after exposure, MZD at 200pg ml" caused tegumental damage and 
protrusion of hair-like extensions from the outer surfaces of schistosomula in a high 
proportion but not all of the parasites. Eight hours after exposure, the damage was 
severe with sloughing of the tegument of the schistosomula leaving exposed areas 
(possibly basal membrane or muscle) behind. With MZD at 20pg ml-1, the surfaces of 
schistosomula were similar to those of controls. 
With PZQ at 200pg ml-1 the surface of schistosomula showed evidence of blebbing, 
particularly near the oral sucker, with schistosomula adopting irregular contracted 
shapes after 4 and 8h of exposure. At 20pg ml-1 of MZD or PZQ, the surfaces of treated 
schistosomula were apparently unaffected exhibiting morphologies similar to those of 
control schistosomula (see figure 2.8). 
These results showed that MZD at 200pg ml-1 caused a substantial damage to the 
surface of schistosomula of S. mansoni, this damage increased with time supporting the 
results of the previous experiments that MZD is more effective than PZQ against the 
schistosomula stage of S. mansoni. 
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Figure 2.8 Scanning electron microscopy of schistosomula oLV. mansoni after exposure to Mirazid" 
or praziquantel. 
Schistosomula of S mansoni were exposed to MZD and PZQ at concentrations of' 
200pgml-1 and 20ýLg ml-1. After 4 and 8 hours ofcxposure, schistosomula were fixed, 
processed for SEM and examined using an electron microscope (Phillips SIN 500). (A) 
Control schistosomula incubated with 1% DIVISO for 4h, (11) MZD 200[tg inl-1 4h after 
exposure, (C) PZQ 200pg ml-1 4h after exposure, (D) control schistosomula incubated 
with the drug solvent for 8h, (E) MZD 200pg ml-1 8h aftcr exposure and (F) PZQ 200fig 
ml-1 8h after exposure. The scale bars measure 10ýtm fior (A), (11), (C), (F) and (F) and 
20tim for (D). 
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2.3.7 Scanning electron microscopy (SEM) of adult worms of S. 
mansoni after exposure to Mirazido or praziquantel 
Adult worms of S. mansoni were incubated with MZD at 200gg ml-1 or 20Ag ml-1 or 
PZQ at 200,20 and 5pg ml-1. Control worms were incubated in medium supplemented 
with 1% DMSO. After 4,24 and 72 hours of incubation, adult worms were fixed and 
processed for SEM (see section 2.2.6). 
Four hours after exposure to MZD at 200pg ml-1 male worms demonstrated surface 
blebbing (small diameter) and a partial loss of the spines from the tubercles. At this 
concentration, female worms showed considerable swelling of the tegument such that 
the spines appeared to be deeply embedded within it. Damage appeared to be 
progressive and by 24 hours of exposure, MZD at 200gg ml-1 caused loss of the surface 
ridges between the tubercles, loss of some tubercular spines and more surface blebbing 
in both adult male and female worms. After 72 hours, MZD at 200pg ml" caused severe 
damage to the surfaces of the parasites with complete sloughing of the surfaces across 
much of the length of the adult worms. After 4 hours, MZD at 20jig ml-1 had no evident 
effects on the surface of adult worms, however it caused surface blebbing of the surface 
of the gynaecophoric canals of male worms. After 24 hours of exposure, MZD at 20pg 
ml-' caused some loss of the surface ridges between the tubercles and loss of some 
tubercular spines of male worms and induced surface blebbing of female worms. At this 
concentration, the damage was more evident after 72 hours after exposure (see figure 
2.9-12). 
The most striking effect of PZQ was surface blebbing shown by both male and female 
worms. On female worms blebbing was mainly confined to the anterior region of the 
parasite, behind the ventral sucker whereas the effect on male worms was widespread. 
Blebbing was evident within 4 hours of exposure even to PZQ at Spg rnl" and increased 
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progressively with time. After 72 hours, blebbing was evident across all surfaces of the 
male worms but there was little evidence of any sloughing. 
Given concerns about the potential development of drug resistance among parasites 
(and other microbial pathogens), combination therapies are often employed to reduce 
the likelihood of its emergence. This consideration led us to examine the effect on 
worms of simultaneous exposure to both PZQ and MZD- Surprisingly, the surface 
damage observed when using both drugs was less than that observed when either drug 
was used in isolation. 
In conclusion, both MZD and PZQ cause dose and time-dependent damage to the 
surfaces of adult wonns of S. mansoni though higher doses of MZD than PZQ are 
required to cause damage to the worms. 
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Figure 2.9 Scanning electron microscopy of adult male worms of 'V. mansoni after 4 hours of 
exposure to Mirazid() or praziquantel. 
Adult male worms of S. mansoni were exposed to diff'crent concentrations of' MZD or 
PZQ. Four hours after exposure, worms were fixed. processed and Ior SIN and 
examined using an electron microscope (Phillips SFM 500). (A) Control adult male 
incubated with 1% DMSO, (B) MZD 20jig mi-1, (C) MZD 200pg ml-' and (D) PZQ 
20pg m1_1 - 
Scale bar I Opm. 
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Figure 2.10 Scanning electron microscopy of adult male worms of V. mansoni after 24 hours of 
exposure to Mirazid"or praziquantel. 
Adult male worms of ý;. mansoni were exposed to different concentration of' MZD or 
PZQ. After 24 hours of exposure, worms were fixed, processed fi cxamincd )r SIN and 
using an electron microscope (Phillips SEM 500). (A) Control adult male incubatcd 
with 1% DMSO, (13) MZD 20[tg ml-1 (C) MZD 200ltg ml-1 and (D) PZQ 5Vg ml-'. 
Scale bar I Opm. 
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Figure 2.11 Scanning electron microscopy of adult male worms of V. mansoni after 72 hours of 
exposureto Mirazid"' or praziquantel. 
Adult male worms of S. mansoni were exposed to difilerent concentration of MZD or 
PZQ. After 72 hours of exposure, worrns were fixed, processed Ior SIN and examined 
using an electron microscope (Phillips SEM 500). (A) Control adult male incubated 
with 1% DMSO, (B) MZD 20pg ml-1, (C) MZD 200[ig ml-1 and (D) PZQ 5fig inl-1. 
Scale bar I Opm. 
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Figure 2.12 Scanning electron microscopy of adult female worms of S. mansoni after exposure to 
Mirazid"' or praziquantel. 
Adult female worms were exposed to different concentrations ofMZD or PZQ. AI`tcr 4 
and 24 hours of exposure, worms were fixed, processed lor SIN and examined using 
an electron microscope (Phillips SEM 500). (A) Control lernale exposed to I%o DMSO 
for 4h, (B) MZD 200pg ml-1 4h after exposure, (C) PZQ 5pg ml-' 4h after exposure and 
(D) MZD 20[ig ml-' 24h after exposure. Scale bar I Opm. 
2.3.8 Transmission electron microscopy of adult worms of S ,. mansoni 
after exposure to Mirazid'. ) or praziquantel 
Having investigated the surface eflIects ofMZD and PZQ through S11'. M, a more dctalled 
investigation of damage was launched in a series of' experiments designed to permit 
examination of worm ultrastructure using transmission electron microscopy ('11', M). 
Adult worms ofS. mansoni were incubated with dill'erent concentrations ofMZI) and 
" 
. '- 
- 
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PZQ (200ýtg ml-1 and 20[ig ml-'). Control worms were incubated in medium 
supplemented with 1% DMSO. After 4 and 24h, adult worms were fixed and processed 
for TEM. Control worms retained their normal structure and showed no signs of 
damage throughout the experiment. 
Four hours after exposure to MZD at 200pg ml", both adult male and female worms 
showed sub-tegumental vactiolisation. The vacuoles were of variable sizes and 
originated from beneath the basal lamina of the tegument and extended into the 
tegumental cytoplasm. The tegumental cytoplasm showed increased numbers of discoid 
bodies. There was no or little evidence of damage to the parasites' musculature and 
parenchyma. Parasites exposed to MZD at 20pg ml-1 showed little damage and their 
structure was similar to that of control parasites (see figure 2.13). Twenty-four hours 
after exposure, worms exposed to MZD at 200pg ml-1 showed an increase in the number 
of the sub-tegumental vactioles and an increase in the number of discoid bodies and 
membranous vesicles in the tegument cytoplasm. Worms exposed to WD at 20Ag ml', 
showed a small increase in the number of discoid bodies and membranous vesicles in 
the tegument cytoplasm. There was no or very little evidence of damage to the 
parasites' musculature and parenchyma at either drug concentration (see figure 2.14). 
On the other hand, PZQ caused sub-tegumental vacuolisation and substantial damage 
and loss of integrity of the musculature and parenchyma of both adult male and female 
worms. The effects were evident after 4h of exposure to both drug concentrations and 
greatest after 24h of exposure to PZQ at 200pg mi-I. The male worms showed more 
extensive damage than the adult females at all the concentrations used. 
These observations showed that there is an apparent overlap in the type of damage 
caused by the drugs. Both drugs cause sub-tegumenW vacuolisation of both male and 
female worms of S. mansoni. However, though the damage caused by MZD was mainly 
as 
confined to the tegument of the parasites in the form of multiple sub-tegumental 
vacuoles and small increase in the number of the discoid and membranous bodies. In 
contrast, the damage caused by PZQ affects the musculature and parenchyma as well as 
the tegument. 
C I) 
Figure 2.13 Transmission electron microscopy of adult male worms ofV. man. %oni after 4 hours of 
exposure to Mirazid") or praziquantel. 
Adult male wonns of . S. mansoni were exposed to 
M/D or PZQ a( concentrations of 
200pg ml-1 and 20pg ml-1. Four hours after exposure, wornis were fixed, processed l'or 
TEM and examined using a TEN (Zeiss 902). (A) Control male wornis exposed to I IVo 
DMSO only, (B) MZD 20[tg ml-1, (C) MZD 200pg ml-' and (D) P/Q 200pg nil-'. Scale 
bars measure 5[tm for (A), (B) and (C) and 10[tin for (D). '['he arrows poln( to Sub- 
tegumental vacuolisation. The stars point to muscle and parenchymal damage. 
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Figure 2.14 Transmission electron microscopy of adult male worms of S. maitsoni after 2411 after 
exposure to Mirazid. ) or praziquantel. 
Adult male worms of S. mansoni were exposed to M/D or PZQ at concentrations of' 
200pg nil-' and 20[tg ml-'. After 24 hours of exposure, won-ns were fixed, processed for 
TEM and examined using a TEM (Zeiss 902). (A) Control male worms exposed to I 'Yo 
DMSO only, (B) MZD 20[tg nil-', (C) MZD 200pg nil-' and (D) PZQ 200[tg nil-1. Scale 
bars measure 10ýtm flor (A), (C) and (D) and 5fim for (11). The arrows point to sub- 
tegumental vacuolisation. The stars point to muscle and parenchymal damage. 
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Figure 2.15 Transmission electron microscopy of adult female worms after 24 hours of exposure to 
Mirazid(') or praziquantel. 
Adult female worms of ý'. mansoni were exposed to either MZD or PZQ at a 
concentration of 200pg ml-1. After 24 hours ofcxposurc, worms were fixed, processed 
for TEM and examined using a TEM (Zeiss 902). (A) Control Icinalc worms exposed to 
1% DMSO only, (B) MZD 200pg ml-1, (C) MZD 200pg ml-' and (D) P/Q 200pg nil-1. 
Scale bar 5ýtm- The arrows point to sub-tegumental vacuolisation. The stars point to 
muscle and parenchymal damage. 
2.3.9 Effect of Mirazid"' and praziquantel on intra-parasite calcium 
While the precise modes ol'action of' M/D and PZQ havc yet to be determined, it has 
been suggested that the eflects of' PZQ are in part a result of' changes in calcium flux 
(Cioli el al., 1995). To investigate the effects of' PZQ and M/D on calcium balance 
within the parasites, we exploited fluo-3 AM which is a specific fluorescent dyc that 
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increases its fluorescence when it binds calcium. Schistosomula and adult worms of S. 
mansoni were labelled with fluo-3 AM and then treated with either MZD or PZQ at a 
concentration of 200pg ml-1. Control parasites were incubated with media containing 
1% DMSO. Thirty minutes, 1,2 and 4h after exposure, the amount of fluorescence 
(indicating the level of intracellular calcium) was measured using the fluorescent 
microscope. 
Schistosomula exposed to PZQ or MZD for 30 minutes showed no significant 
difference in the fluorescence compared to the control parasites. One and two hours 
after exposure, MZD caused highly significant increases in the fluorescence (P<0.01) 
compared to the control group while PZQ caused no significant effect (see figure 2.16). 
Adult worms exposed to PZQ for 30 minutes showed a highly significant increase in the 
fluorescence in both male and female worms compared to both the control and MZD 
groups (P<0.01). MZD on the other hand caused a non significant increase in the 
fluorescence of male worms (P=0.27) and a significant increase in the fluorescence of 
female worms (P--0.036). 
One, 2 and 4 hours after exposure, both MZD and PZQ caused highly significant 
increases in the fluorescence in both male and female worms compared to the control 
group (P<0.01). However, the increases of fluorescence observed in worms treated with 
pZQ were always highly significant compared to MZD in both male and female worms 
(P<0.01) (see figure 2.17). 
When adult worms were treated with either MZD or PZQ first, washed and then 
labelled with the fluorescent dye, the results were significantly different. Adult worms 
exposed to MZD or PZQ for I and 4 hours showed highly significant increases in the 
fluorescence of both male and female worms compared to the control group (P<0.01). 
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However, in this case worms exposed to MZD showed a highly significant increase in 
the fluorescence of both male and female worms compared to worms exposed to PZQ 
(P<0.01) (see figure 2.18). 
These results indicate that both PZQ and MZD cause an increase of the intra-parasite 
calcium levels. Some aspects of similarities of the effect of both drugs on the tegument 
of schistosomes taken together with these results might indicate that both drugs could 
exhibit their effects at least partially through changes in calcium fluxes. 
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Figure 2.16 Effect of I hour of exposure to Mirazidqo or praziquantel on the intra-parasite calcium 
of schistosomula of S. mansoni. 
Schistosomula were labelled with fluo-3 AM and then treated with either MZD or PZQ 
at 200pg ml-' for lh before their fluorescence was quantified using a fluorescent 
microscope. The columns represent the quantities of fluorescence ± 95% confidence 
intervals. Control schistosomula exposed to 1% DMSO only (Control), MZD 200pg ml- 
1 (M 200) and PZQ 200pg ml-1 (PZQ 200). All groups consisted of 100 schistosomula 
and these results represent the mean of 3 experiments. 
90 
500 
- 450 
400 
350 
300 
250 
200 
150 
0 100 
Figure 2.17 Effect of 2 hours of exposure to Mirazid* or praziquantel on the intra-parasite calcium 
of adult worms of S. mansoni. 
Adult male and female worins were labelled with fluo-3 AM and then treated with 
either MZD or PZQ at 200pg ml-' for 2h. The fluorescence was quantified using a 
fluorescent microscope. The columns represent the quantities of fluorescence ± 95% 
confidence intervals. Control male worins exposed to 1% DMSO (in Control), male 
worms exýosed to MZD at 200pg ml-1 (m MZD), male worms exposed to PZQ at 
200pg ml- (in PZQ), control female worms exposed to 1% DMSO (f Control), female 
worms exposed to MZD at 200pg ml-1 (f MZD) and female worms exposed to PZQ at 
200pg MI-1 (f PZQ). All groups consisted of 30 males and 30 females and these results 
represent the mean of 4 experiments. 
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Figure 2.18 Effect of 1 hour of exposure of adult worms of S. mansoni to Mirazide or praziquantel 
prior to labelling with fluo-3 AM. 
Adult male and female worms were treated with either MZD or PZQ at 200pg ml-I for 
lh, washed and labelled with fluo-3 AM. The fluorescence was quantified by 
fluorescent microscope. The columns represent the quantities of fluorescence ± 95% 
confidence intervals. Control male worms exposed to 1% DMSO only (m Control), 
male worms exposed to MZD at 200pg ml-1 (m MZD), male worrns exposed to PZQ at 
200pg ml-I (m PZQ), control female worms exposed to 1% DMSO only (f Control), 
female worrns exposed to MZD at 200pg ml-1 (f MZD) and female worms exposed to 
PZQ at 200pg ml-1 (f PZQ). All groups consisted of 30 males and 20 females and these 
results represent the mean of 3 experiments. 
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2.3.10 Effect of calcium chelation with EDTA on calcium labelling of 
adult S. mansom after exposure to Mirazid @ 
The effect of calcium chelation. with EDTA on calcium labelling after exposure of adult 
male S. mansoni to mirazid has been examined to test the possibility that MZD can 
cause an increase of calcium uptake by schistosomes. One group of adult worms was 
incubated for 15minutes with ImM solution of EDTA prior to their treatment with 
MZD at 200pg ml" for I and 2h. The second group was treated with MZD without 
EDTA and the third, the control group, was incubated in medium supplemented with 
1% DMSO. Parasites were washed and labelled with fluo-3 AM. Fluorescence 
quantification was carried out as before (see section 2.2.8). 
After I and 2 hours of exposure to MZD at 200pg ml-1, adult worms showed a highly 
significant increase of fluorescence compared to the control group (P<0.01). Parasites 
incubated with EDTA prior to exposure to MZD for I and 2 hours, showed a highly 
significant reduction in fluorescence (P<0.01) compared to parasites treated with MZD 
alone, however, they showed a highly significant increase in fluorescence compared to 
the control group (P<0.01) (see figure 2.19). 
These results indicate that MZD causes an increase of intra-parasite calcium as 
indicated by the increase of fluorescence and that EDTA at least partially interfere vvith 
MZD-induced calcium re-distribution. 
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Figure 2.19 Effect of calcium chelation with EDTA on calcium labelling after exposure of adult 
worms of S. mansoni to Mirazid4o 
Worms were exposed to MZD at 200pg ml-1 for lh with or without prior incubation 
with ImM solution of EDTA. They were washed, labelled with fluo-3 AM and 
fluorescence was quantified using fluorescent microscope. The columns represent the 
quantities of fluorescent (in arbitrary units) ± 95% confidence intervals. Control worms 
incubated with the solvent only (Control), adult worms exposed to MZD 200pg ml-1 
without EDTA (MZD) and adult worms treated with ImM of EDTA prior to exposure 
to MZD 200pg ml-1 (MZD+EDTA). All groups consisted of 35 males and these results 
represent the mean of 3 experiments. 
Results of the in vivo experiments 
2.3.11 Effect of praziquantel and Mirazide on worm burden 
Mice infected with S. mansoni were treated with either MZD or PZQ 6 weeks after 
infection. One group, control infected, was left without treatment. Two weeks after 
treatment (8-weeks after infection), mice were killed and perfused (see section 2.2.2) for 
worm recovery. 
The number of worms recovered from mice treated with MZD at 3 doses each of 400mg 
kg-1 was not significantly different from that of the non-treated mice (see table 2.3). On 
the other hand, mice treated with PZQ at a single dose of 400mgkg-' showed a highly 
significant reduction in the numbers of both male and female worms (P<0.01). The 
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worms recovered from mice treated with PZQ were smaller in size while those 
recovered from MZD treated mice were not different from controls. 
These results showed that although PZQ was an effective anti-schistosomal drug against 
adult worms of S. mansoni, MZD did not seem to have significant effects in vivo. 
Group Mean male worm burden 
Mean female worm 
burden 
Control non-teated group 36 ± 3.1 7.6 ± 0.9 
Mirazide treated group 35.8 ± 3.6 5.8 ± 0.3 
Praziquantel treated group 16.5 ± 4.8 1.4 ±I 
Table 2-3 Number ot worms recoverea aiter periusion oi mice. 
Control mice and mice treated with either MZD or PZQ were perfused 2 weeks after 
treatment and the worms recovered were counted. The table presents the mean number 
of male and female worms for each group ± standard error. All groups consisted of 10 
mice. 
2.3.12 Effect of treatment of infected mice with either Mirazidlo or 
praziquantel on the egg burden in liver tissue 
After perfusion of mice a piece of each liver was weighed and digested with KOII. The 
digested tissue was centrifuged and the eggs were re-suspended in PBS. Egg counting 
was carried out using a light microscope. 
The number of eggs per gram of liver tissue of the MZD-treated mice showed a slight 
reduction (16% reduction) and this reduction was not significantly different from that of 
the control non-treated mice (P=0.39). In contrast the number of eggs per gram of liver 
tissue of the PZQ-treated mice showed a highly significant decrease compared to that in 
the infected non-treated mice (P<0.01) (see figure 2.20). 
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Most of the eggs in the livers of PZQ treated mice appeared to be granular and dark in 
colour while that of both MZD treated mice or infected non-treated mice were bright 
and showed normal morphology. 
These results showed that PZQ caused a decrease in the number of eggs deposited per 
gram of liver tissues of infected mice. This reduction can be as a result of anti-fecundity 
effects of the drug or secondary to the decrease in the number of female worms after 
treatment. On the other hand, treatment with MZD did not cause any significant 
reduction in the number of eggs per gram of liver. 
18000 
16000 
E 14000 
12000 
10000 
0 8000 
6000 
4000 
2000 
0 
E Control N MZD 13 PZQ 
Figure 2.20 Egg burden per gram of liver tissue of mice infected with S. mansoni and treated with 
either Mirazid" or praziquantel 
After killing of mice, a piece of each liver was weighed and digested in KOH. The eggs 
were counted using a dissecting microscope. The columns represent the number of eggs 
per gram of liver tissue ± 95% confidence interval. Control non-treated mice (Control), 
Mirazido treated mice (MZD) and praziquantel treated mice (PZQ). All groups 
consisted of 10 mice. 
2.3.13 Effect of treatment of infected mice with either Mirazid"' or 
praziquantel on the total tissue egg load 
After killing the infected mice, a piece of the liver and the whole gut of each mouse 
were digested with KOH. They were then processed exactly as mentioned previously. 
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The number of eggs in the whole liver was added to the number of eggs in the gut to 
represent the total tissue egg load. 
Mice treated with PZQ showed a highly significant decrease in the total tissue egg load 
compared to the infected non-treated mice and to MZD-treated group (P<0.01). In 
contrast, the total tissue egg load in mice treated with MZD was not significantly 
different from that of the infected non-treated mice (P=0.6 I) (see figure 2.2 1 ). 
These results showed that while treatment of S. mansoni infected mice with PZQ caused 
a reduction in the number of eggs deposited in the tissues of infected mice which will be 
reflected as a reduction of the pathology, treatment with MZD caused no significant 
change in the total tissue egg burden. 
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Figure 2.21 Total tissue egg burden of mice infected with S. mansoni after treatment with either 
Mirazid4o or praziquantel. 
After killing of the mice, the gut and a piece Of liver were digested in KOH and their 
total egg count was calculated. The columns represent the mean of total number of eggs 
in mice tissues ± 95% confidence interval. Control non-treated mice (Control), Mlrazidlý 
treated mice (MZD) and praziquantel treated mice (PZQ). All groups consisted of 10 
mice. 
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2.3.14 Effect of treatment of infected mice with either Mirazido or 
praziquantel on the diameter, content and structure of liver 
granulomas 
Mice were killed 2 weeks after treatment. A piece of the liver of each mouse were fixed, 
processed for histology and stained with H&E. Ile diameter of granulomas was 
measured using a light microscope with graduated eye-pieces. The mean of the 
diameters of granulomas of each mouse were used for the statistical analyses. 
There was no significant difference in the diameter of liver granulomas of treated or 
non-treated mice. The average diameter of liver granulomas were 362 ± 23prn for 
control non-treated mice, 381 ± 15pm for mice treated with PZQ and 355.5 ± 28pm for 
mice treated with MZD. Granulomas surrounding adult worms were observed in the 
livers of mice treated with PZQ (see figure 2.22). 
The fibrous tissue of the granulomas was arranged into three layers; an interlacing 
fibrous tissue layer with a cellular infiltrate, a concentric layer of fibrous tissue and an 
outer layer of inflammatory cells with a less organised fibrous tissue network. The 
arrangement of collagen fibres in the liver granulomas of mice treated with MZD tended 
to be less organised and not fully arranged in concentric layers surrounding the 
granulomas compared to that in the control and PZQ-treated mice. While the number of 
eosinophils in liver granulomas of mice MZD treated mice (78 ± 9/11PF) was slightly 
less than the control mice (84 ±I I/HPF) or mice treated with PZQ (91 ± 14/liPF), this 
difference was not significant. 
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Figure 2.22 Effect of treatment of mice infected with S. mansoni with either Mirazido or 
praziquantel on the diameter of liver granulomas. 
After killing of mice, a piece of liver was processed for histology and stained with 
H&E. The diameter of the granulomas was measured using a light microscope. The 
columns represent the average of the diameter liver granulomas of each group ± 95% 
confidence intervals. Infected non-treated mice (Control), PZQ treated group (PZQ) and 
MZD treated group (MZD). All groups consisted of 10 mice. 
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Figure 2.23 Sections of S. mansoni egg granuloma in the livers of infected treated or un-treated 
mice (Haematoxylin and Picro Sirius red stain). 
Liver sections were processed and stained Picro Sirius red to localise collagen fibres. 
Egg granuloma in liver section from infected un-treated mouse (A), egg granuloma in 
liver section from PZQ treated mouse (B), egg granuloma in liver section from MZD 
treated mouse (C) and worm granuloma in liver section from PZQ treated mouse (D). 
2.3.15 Effect of treatment of infected mice with either Mirazide or 
praziquantel on lymphoblastogenesis and cytokine production 
After killing of the mice, lymphocytes from mesenteric LNs and spleen from each 
group were stimulated in vitro with ConA, SWAP and SEA. Control cells were cultured 
without stimulation. After 5 days of culturing, the supernatants were collected for 
cytokine assays for IL-4, IL-10, IL-13 and IFN-y. A blastogenesis assay was carried out 
using radioactive thymidine and the rate of cell multiplication was assessed by 
measuring the cellular radioactivity. All cells were stimulated to multiply with ConA 
indicating their viability. Although lymphocytes from LNs and spleen of Infected 
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treated and infected un-treated mice were reactive to both SWAP and SEA, the level of 
reactivity was less in mice treated with either PZQ or MZD. 
Levels of IL-4 and IL-13 were lower in LNs and spleen cells from MZD or PZQ treated 
mice than infected un-treated mice in response to stimulation with SEA and SWAP. The 
difference was greatest in spleen cells stimulated with SEA. V; Mle spleen cells from 
infected un-treated mice produced high levels of IFN-y, levels of IFN-y from spleen 
cells of MZD or PZQ treated mice were below the cut off level for the assay. 
Furthermore, LNs from MZD treated and un-treated mice produced lower levels of IFN- 
y in response to stimulation with SEA compared to the levels produced after stimulation 
with SWAP. In both cases the level of IFN-y from LNs of PZQ treated mice were below 
the cut off level for the assay. 
Levels of IL- 10 from spleen cells of PZQ treated mice were similar to those of untreated 
animals in responsc to stimulation with eithcr SWAP or SEA. Howcvcr, LNs from PZQ 
treated mice produced higher levels of IL-10 than un-treated animals after stimulation 
with either SWAP or SEA. Spleen cells and LNs from MZD treated mice produced 
lower levels of IL-10 in response to stimulation with either SWAP or SEA compared to 
the un-treated animals. 
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Table 2.4 Levels of different cytokines produced by spleen and LNs cells from infected mice. 
Cells from spleen and LNs were culture in vitro and stimulated with different antigens. 
Five days after culture, levels of different cy-tokines were measured using ELISA. The 
levels were measured in pgml". Un-infected mice (Control), infected un-treated mice 
(infected), MZD treated mice (MZD), PZQ treated mice (PZQ). 
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2.4 Discussion 
Despite all efforts that have been made to control schistosomiasis this disease remains a 
major health problem in the tropics and subtropics. Chemotherapy is considered to be 
the keystone of any control programme against schistosomiasis, with praziquantel being 
the drug of choice because it is effective against all schistosome species, it is easy to 
administer, it is safe with few and transient side effects and most importantly is now 
cheap (Hagan et al., 2004). However, the appearance of schistosome strains with lower 
susceptibility to praziquantel has highlighted the need for other anti-schistosomal drugs 
(Kusel and Hagan, 1999; Doenhoff et al., 2002). Furthermore, praziquantel has modest 
effects against the immature stages of schistosomes (Andrews, 1981; Sabah el al., 
1986). In the last few years, Mirazido has been licensed and released for the treatment 
of human schistosomiasis in Egypt. Since then, there has been much debate about its 
anti-schistosomal effects. In this study, the anti-schistosomal activities of Mirazie, 
compared to those of praziquantel, were investigated both in vitro and in vivo against 
early schistosomula and adult stages of S. mansoni. 
The effects of MZD and praziquantel on the viability of schistosomula of S. mansoni 
were assessed using the toluidine blue exclusion test. This test is appropriate for 
assessment of viability of schistosomula since results are not different from those 
obtained using the morphology and mobility parameters. It has the advantage of being 
quick and easy to perform (Gold, 1997). In this study, the viability of schistosomula 
exposed to MZD at concentrations of 200,100 and 50pg ml-' was significantly reduced 
after 4 and 8 hours after exposure. PZQ caused less, but significant, impairment in the 
viability of schistosomula at concentrations of 200pg ml" and 100pg nil". Ile effects 
of both drugs were time and dose dependent. However, the most striking feature of 
schistosomula exposed to PZQ was the blebbing around or within the oral sucker of the 
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parasites that was evident, under light microscope, within lh of exposure to PZQ at 
concentrations of 200,100 and 50gg ml-1. The results of the toluidine blue exclusion 
test were confirmed with the results of the Hoechst test. The number of worms stained 
with Hoechst dye, indicating damage, was significantly increased after exposure to the 
high doses of either MZD or PZQ. Based on the results of the toluidine blue exclusion 
test, two concentrations were used in the rest of experiments on schistosomula. The 
200ýtg ml-1 was used as a high and effective concentration and the 20tig ml-1 was used 
as a low concentration that did not show any significant effects in the toluidine blue test 
but may have other effects not detectable with this method. SEM revealed that in 
schistosomula exposed to MZD there was surface damage within 4h of in vitro exposure 
to the high concentrations of the drug. The changes were progressive with time. After 
8h of exposure, parts of the surface of schistosomula were sloughed leaving bare areas. 
PZQ on the other hand caused limited surface blebs and irregular contractions of the 
parasites after 4 and 8h of exposure. These results are in agreement with the results of 
(Xiao et al., 1985). They reported that the immature stages were less susceptible to PZQ 
in vitro and that in early schistosomula stages about 2 to 4h of exposure is required to 
cause limited small blebs around the oral sucker and on the surface of the parasites. 
Similarly, in vivo studies showed that artemether (Utzinger et al., 2001a) and Rol5- 
5458 (Guirguis, 2003) were more effective against the immature stages of schistosomes 
compared to PZQ. However, Andrews reported that all stages of S. mansoni are equally 
affected after in vitro exposure to PZQ (Andrews, 1981). However, higher 
concentrations of PZQ were used in this study than reported in the previous studies 
because the current study was designed to investigate the efficacy of MZD and to 
compare it to that of PZQ. 
The earliest observed in vitro effect of MZD on adult wonns of S. mansoni was 
enhanced worm motility with an increase in their length and subsequent separation of 
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worm pairs. The increased worm activity observed in this study accords well with the 
observations of Hassan and colleagues. They reported that MZD induced contractions 
of the somatic muscles of adult S. mansoni worms (Hassan et al., 2003). Increased 
worm activity has been reported after in vitro exposure to other drugs, for instance, 
hycanthone (Senft and Hillman, 1973), oxamniquine (Chavasse et al., 1978) and low 
doses of PZQ (Chavasse et al., 1979; Xiao et al., 1985). The increase in motility after 
exposure to hycanthone and oxamniquine was attributed to the blockade of 
acetylcholine receptors caused by the drugs, With subsequent suppression of the 
inhibitory effects of acetylcholine (Hillman and Senft, 1975). A similar effect may be 
produced by MZD. In support of this idea is the observation that a higher concentration 
of carbachol (a cholinergic compound) was needed to stop worm motility during the 
FRAP experiments in the worms treated with MZD. 
Worm separation was evident as early as 15 minutes after exposure to the high doses of 
MZD (200pg ml-1 and I OOpg ml-1). 'Me separation progressed with time to the extent 
that all worm pairs were separated after 6h of exposure to MZD at a concentration of 
200pg MI-1. The exact mechanism of worm separation is not known. A possible 
explanation is that it could be a result of the increased and irregular worm motility. 
However, separation of worm pairs continued to progress with time even though worm 
motility had returned to normal after 3-4h of exposure. Another possible cause of worm 
separation is the preferential tegumental. damage observed in scanning electron 
microscopy. Surface blebs were observed only on the surface of gynaecophoric canals 
of male worms after 4h of in vitro exposure to MZD at a concentration of 20pg ml*'. 
This damage could interfere with the interaction between male and female worms and 
promote their separation. These results accord with the in vivo results observed by 
Badria and colleagues (2001) who reported that MZD induces separation of S mansoni 
worm pairs (Badria et al., 2001). 
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After lengthy in vitro exposure of adult worms of S. mansoni to MZD at high doses, 
there was a marked damage to the surface of the parasites manifested by the loss of 
tubercular spines, loss of the surface ridges between the tubercles and surface blebbing. 
Both male and female worms appeared to be equally affected. Ile damage became 
extensive in the form of sloughing of parts of the surface of the parasites after 3 days of 
exposure. These observations agree with the observation of Hassan and colleagues. 
They showed that MZD causes tegumental damage of the parasite in the form of 
tegumental disruption, oedema and loss of the spines covering the tubercles (Hassan et 
aL, 2003). 
The earliest observed effects after in vitro exposure of adult worms to PZQ were 
contractions and coiling of worms that became evident within seconds of exposure. 
After 30 minutes of exposure, worms uncoiled and remained shorter and thicker than 
the controls. These results are in agreement with the observations described by (Pax et 
al., 1978), (Xiao et al., 1985) and (Pica-Mattoccia and Cioli, 2004). All PZQ 
concentrations used in this study caused marked surface damage in the form of 
extensive surface blebbing. The damage was widely spread in male worms compared to 
a localised patchy damage in female worms. These results accord with previous findings 
that adult S. mansoni worms exposed to PZQ showed surface damage and vesicle 
formation which is more extensive in male worms (Becker et al., 1980; Mehlhorn et al., 
1981; Staudt el al., 1992). Similar surface damage was observed in adult S mansoni 
worms recovered from mice treated with PZQ. The worms showed surface damage that 
was more extensive in male worms than that in female worms (Shaw and Erasmus, 
1983; Shaw and Erasmus, 1987; Shaw, 1990). However, Gonnert and Andrews reported 
that both male and female worms of S. mansoni are equally susceptible to the effects of 
pZQ (Gonnert and Andrews, 1977). Unexpectedly, in the present study, after 72h of 
exposure of adult S. mansoni worms to both MZD (at a concentration of 200pg ml") 
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and PZQ (at a concentration of S[Lg ml-1) at the same time, the damage was less than 
when the parasites were exposed to either drug individually. However, the effect of 
PZQ prevailed. This may indicate that the drugs can interfere with each other either 
chemically or physiologically. 
When considering membrane fluidity as an indirect indication of membrane functions, 
both MZD and PZQ caused significant reduction of the mobile fraction of the lipid 
molecules and of the lateral diffusion coefficient of both male and female worms and 
schistosomula of S. mansoni. These results are in agreement with the results of Lima 
and colleagues. They have shown that while both (PZQ-) and (PZQ+) caused reduction 
in the velocity of the lipid molecules, only (PZQ-) caused a reduction in the mobile lipid 
fraction. They suggested that PZQ inserts itself in the membrane and thus acts as a 
barrier for membrane fluidity and this insertion change the organisation of the tegument 
and this may be one of the ways PZQ exerts its action. 'Me altered lipid organisation 
could lead to conformational changes in calcium pumps allowing an enhanced entrance 
of calcium ions (Lima et al., 1994). In other biological systems, membrane fluidity is 
important in regulating enzyme activity (Rimon et al., 1978) as well as the rate of 
second messenger production (Atlas et aL, 1980). PZQ and MZD, by reducing the 
membrane fluidity of the parasites, may interfere with some mechanisms important for 
their survival. 
After exposure to PZQ at concentrations of 200pg ml-1 and 20Pg ml'I, adult worms of S. 
mansoni showed ultra-structural damage in the form of sub-tegumental vacuolisation 
and disruption of the musculature and parenchyma of both male and female worms. The 
damage was more evident in male worms than in the female worms. These results 
corresponded with the previously reported ultra-structural damage of adult S. mansoni 
worms exposed to PZQ (Becker et aL, 1980; Mehlbom et al., 1981). Similar changes 
were reported in worms recovered from mice treated with PZQ (Mehihom et aL, 1981; 
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Shaw and Erasmus, 1983; Shaw and Erasmus, 1987). On the other hand, MZD at high 
concentrations (200[igml-') caused sub-tegumental vacuolisation of both male and 
female worms. Tle damage was evident after 4h of exposure and progressed with time. 
There was no evidence of parenchymal or muscular damage even after 24h of exposure 
of adult worms to the high concentration of MZD. This provides evidence that while 
PZQ may act directly on the tegument and on the muscle and parenchyma as a 
consequence of increased calcium influx, MZD may act only locally on the tegument. 
However, these ultrastructural changes of the tegument of schistosomes are not an 
exclusive feature of PZQ or MZD as they have been reported with other anti- 
schistosomal agents including Astiban (Otubanio, 1981), hycanthone (Hillman et al., 
1977), oxamniquine (Popiel and Erasmus, 1984; Fallon et al., 1996) and artemisinin 
derivatives (Xiao et al., 2000; Yjao et al., 2001; Shuhua et al., 2002). 
Although the mode of action of PZQ is not yet exactly determined, there is good 
evidence that PZQ, at least in part, exerts its action by increasing calcium influx. The 
increase in intra-parasite calcium may in turn be responsible for the increased muscular 
contraction and the tegumental damage (Pax et al., 1978; Day el al., 1992). Similarly, 
increased calcium uptake has been reported in the liver fluke Opisthorchis viverrini in 
response to praziquantel treatment (Ruenwongsa et al., 1983). In this context, voltage- 
gated calcium channels (formed of an alpha chain and a beta chain) have been described 
in schistosomes. The beta subunits of schistosome voltage-gated calcium channels have 
been shown to confer PZQ sensitivity to an otherwise PZQ-insensitive mammalian 
calcium channel, indicating that a possible target for PZQ action is the interaction 
between beta subunits and pore-forming alpha I subunits in schistosomes (Kohn et al., 
2001 a; Kohn et aL, 2003). 
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In the present study, the amount of intra-parasite calcium was indicated by the quantity 
of fluorescence after labelling of calcium with fluo-3. It has been shown that the 
intensity of fluo-3-related fluorescence depends on the Ca2' concentration and that this 
fluorescence can be used as a cytoplasmic or cytosolic C2+ indicator (Kao et al., 1989). 
In S. mansoni, it was shown that compounds which increase intra-parasite calcium 
concentration increase fluo-3/Ca2+ fluorescence and compounds that chelate calcium 
decrease the fluorescence (Sato et al., 2004). In the present study, both PZQ and MZD 
caused a significant increase in the intra-parasite calciurn of both adult male and female 
worms of S. mansoni. The increase in calcium was greater and was evident earlier with 
exposure to PZQ than with exposure to MZD. This corresponds with the previous in 
vitro experiments indicating that PZQ is more effective than MZD against adult worms 
of S. mansoni. However when adult worms were exposed to either drug, washed and 
then labelled with fluo-3, the fluorescent labelling of the intra-parasite calcium was 
significantly higher in worms exposed to MZD than PZQ. This can be explained by the 
finding that the binding of PZQ to the tissues of schistosomes can be easily reversed 
after incubation in drug-free medium (Andrews, 1981) to the extent that 45% and 93% 
of the 14 C-PZQ radioactivity was lost fi-om. schistosomes after 5min and 30min, 
respectively, after transfer. to a drug-free medium (Andrews et aL, 1983). Similarly, the 
effects of praziquantel have been shown to be reversed, at least in part, when the 
parasites were moved to a drug-free medium (Andrews, 1981; Xiao et al., 1985; Pica- 
Mattoccia and Cioli, 2004). On the other hand, the binding of MZD to schistosome 
tissues could be stronger and last longer promoting long lasting effects on the parasite 
calcium distribution. 
Exposure of schistosomula of S mansoni to MZD caused an increase in the labelling of 
intra-parasite calcium. PZQ, on the other hand, caused no significant change in the 
labelling of intra-parasite calciwn. This indicates that the effect of MZD on both adult 
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and schistosomula stages of S. mansoni could be through changes in the calcium 
distribution in the parasite while with PZQ different mechanisms could be responsible 
for its actions. In support of the idea that MZD may act by increasing intra-parasite 
calcium, when adult worms were incubated with ImM EDTA and 5mM EDTA for 
20min before exposure to MZD, there was a significant reduction of intra-parasite 
calcium compared to the worms exposed to MZD without prior exposure to EDTA 
(P<0.01). 
When S. mansoni-infected mice were treated, 6 weeks after infection, with MZD (at a 
dose of 400mg kg-1), there was no significant difference in the number of worms 
recovered after perfusion compared to the infected un-treated mice. The recovered 
worms were mostly paired and did not show any gross morphological changes. There 
was no significant difference in the number of eggs per grain of liver tissue or in the 
total number of eggs deposited in the tissues of infected mice compared to the infected 
un-treated animals. At the dose used in the present study, MZD was safe and there were 
no deaths or signs of toxicity in the treated mice. These results provide no evidence that 
MZD had in vivo anti-schistosomal effects against adult worms of S. mansoni. 
These results agree with the results of Botros and colleagues. They tried several doses 
of MZD and myrrh (180 to 10000mg kg") against different strains of S. mansoni 
(Egyptian, Puerto Rican and Brazilian) in different hosts (mice and hamsters). The 
greatest observed reductions in the number of worms recovered were observed in mice 
infected with the Puerto Rican strain (36% reduction), mice infected with the Egyptian 
strain and treated with myrrh (26% reduction) and mice infected with the Egyptian 
strain and treated with MZD (19% reduction). There was no reduction in the number of 
recovered worms in hamsters infected with the Puerto Rican strain or in mice infected 
with the Brazilian strain and treated with myrrh. There was no significant reduction in 
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the number of eggs in the livers and guts of mice infected with the Egyptian strain after 
treatment with either MZD or myrrh (Botros et al., 2004). 
However, the results of the present study are in contrast with those of Badria and 
colleagues. They reported a 76% reduction of the number of worms recovered from 
mice infected with the Egyptian strain of & mansoni after treatment with either myrrh or 
MZD. They also reported an increase in the percentage of mature stages of eggs 
deposited in the tissues of infected mice compared to immature stages as a result of 
cessation of new egg production (Badria et al., 2001). One possible explanation for this 
distinction is the difference in the schistosome strain or the strain of mice used in both 
experiments. While Badria and colleagues used the Egyptian stain of S. mansoni to 
infect male albino mice, in the present study, the Puerto Rican strain was employed to 
infect female TO mice. However, Botros and colleagues reported a little effect on any 
of the strains of S. mansoni they used. 
One other possibility is the composition of MZD. MZD is an extract of myrrh that can 
be obtained from different species of the plant Commiphora. It has been shown that 
myrrh is a very complex mixture of compounds and that myrrh derived from one 
species of Commiphora is different from that obtained from another species (El Ashry 
et aL, 2003). Myrrh from C molmol contains 23-40% resin (myrrhin), 2-8% volatile 
oils (myrrhol) and 40-60% bitter principle (Al-Awadi et al., 1991). The complex 
composition of myrrh may be difficult to ensure consistency of contents from batch to 
batch. However, the batch of MZD used in this study was different from that used by 
Botros and colleagues who, themselves, used several batches of MZD in their 
multicentre studies but they all confirmed the inefficacy of MZD against S. mansoni. 
Another possible explanation for difference between the results of the present study and 
those reported by Badria and colleagues is the methodology for counting adult worms. 
Whereas in the studies reported herein and those of Botros and colleagues used the 
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standard perftision method and counting of recovered worms, Badria and colleagues, on 
the other hand, used a different method for counting the worms in portal and mesenteric 
veins. They used a 3x lens to count worms in situ (Botros et al., 2004), and this is likely 
to be less accurate. 
PZQ on the other hand, at a single dose of 400mg kg-1, caused a significant reduction in 
the number of recovered worms. The recovered worms were smaller in size compared 
to worms recovered from other groups. There was a significant reduction in the number 
of eggs deposited in the liver and guts of infected and treated animals. These results are 
in agreement with the well documented effects of PZQ accumulated through enormous 
number of studies carried out on different schistosome species and using different 
experimental animals (Pellegrino et al., 1977; Tanaka et aL, 1989; Ghandour et aL, 
1990; Khalil et al., 1995; Botros et al., 2004). 
The apparent discrepancy between the in vitro and in vivo results of the present study 
may be attributed to the pharmacokinetics of MZD. The pharmacokinetics of the drug is 
not known. It is possible that MZD is not readily absorbed from the gut of mice, it is 
rapidly metabolised into inactive compounds, or it is rapidly cleared from the 
circulation after being absorbed. In either case, the active compound of MZD will not 
be available in the circulation and will not have access to the parasite or it will be 
available only for a short duration. Another explanation is that the mode of action of 
MZD is through direct contact with the parasite and a prolonged contact with high doses 
of MZD is required which can be easily obtained and controlled in vitro. However, it 
might be very difficult to reach the same dose for prolonged duration to obtain the same 
results that were obtained in vitro as it was shown that increasing the dose of MZD was 
lethal to mice (Botros et aL, 2004). 
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In support of this idea, when MZD was given with foetal calf serum intra-peritoneally at 
a dose of 300mg kg-1 for two doses to mice infected with S manson! it caused a non 
significant reduction in the number of recoverd worms, a significant decrease in the egg 
burden per gram of liver tissue (P<0.043) and a non significant reduction in the 
diameters of liver granulomas and in the number of eosinophils in the granulomas (data 
not shown). However, this sort of prolonged slow release of the drug which promoted 
prolonged contact with the liver of mice and with the parasites caused liver changes 
which were manifested as gross swelling, dark colouration and roundness of the edges 
of the liver. On the microscopic level there was increased deposition of collagen fibres 
causing thickness of the liver capsule. 
Furthermore, SEM and TEM revealed that while PZQ affects the surface as well as the 
musculature and parenchyma of the schistosome parasites, MZD only affects the 
tegument, without any obvious deeper effects. This pattern of lesions caused by in vitro 
exposure to MZD may support the idea that MZD acts locally through direct contact 
with the tegument of the parasite. In this context, it was reported that some detergents 
such as Triton X- 100 caused disruption of the tegument of S mansoni that never extend 
deeper to the basement membrane. There was a disturbed distribution of some ions 
including calcium which was accumulated into the parasite tissues to levels double 
those of control parasites (Depenbusch et aL, 1983). ne later effects on calcium 
distribution are similar to those reported in parasites after in vitro exposure to MZD in 
the current study. The last possible explanation of this discrepancy is that in the in vivo 
study the effect of MZD was assessed against the adult stage, and not the immature 
stages, of S. mansoni. It was shown from the in vitro study that adult worms are less 
affected by MZD than the immature larval stage. In this context, other drugs particularly 
artemcther was shown to have significant effects against immature developing 
III 
schistosome but modest effects against adult worms both in vivo and in vitro (Yiao and 
Catto, 1989; Lescano et al., 2004). 
One of the most striking reported advantages of treatment of human schistosomiasis 
with MZD is the improvement of symptoms shortly after treatment (Sheir et aL, 2001; 
Abo-Madyan et al., 2004). The main pathological features of schistosome infections are 
attributed to development of inflammatory granulomas around the deposited eggs in 
different tissues of the hosts and the resulting fibroses (Boros, 1989; Auriault et aL, 
1996; Fallon, 2000). The possibility that MZD can act by modulating the 
immunopathology of schistosomiasis and hence improving the symptoms of the disease 
was also investigated in this study. The mean diameter of liver granulomas and the 
structure of granulomas were investigated as parameters of the immunopathology. 
There was no significant difference in the diameter of liver granulomas of infected mice 
of different groups. The mean size of granulomas in the liver of mice treated with PZQ 
was slightly higher than that in the non-treated and in the MZD-treated mice. Similar 
observations were reported by Mehlhom and colleagues. They reported that the mean 
diameters of liver granulomas of mice infected with S manson! and treated with PZQ 
were 350pm one hour after treatment, increased to 380prn 2 weeks after treatment and 
decreased to 140gm 12 weeks after treatment. In infected non-treated mice the mean 
diameter ranged between 350-36OpLm during the same period (Mehlhorn el al., 1982). 
The reason for the slight increase in the diameter of liver granulomas of mice treated 
with PZQ may be explained by the possibility that most of the granulomas found in this 
group of mice were fully developed (mature) with'scanty early developing (immature) 
granulomas as the drug caused decreased formation and deposition of new eggs. In the 
mice of the other groups, there were mature and immature granulomas resulting from 
the continued deposition of new eggs in the livers. 
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There was no significant difference in the number of eosinophils of liver granulomas 
from mice of different groups. However, the fibrous tissues of some granulomas of the 
livers from mice treated with MZD tended to be less than that found in the PZQ-treated 
and in the un-treated mice and the arrangement of collagen fibres tended to be less 
organised. In these mice, the decrease of granuloma diameter, cosinophils and collagen 
fibres was associated with decreased levels of IL-4, IL-13, and IL-10 in supernatants 
from spleen cells and LNs in response to stimulation with either SEA or SWAP. These 
results indicate that MZD may have a suppressor effects on the immune responses to 
schistosome antigens especially the Th2 associated immune responses. Similar anti- 
inflammatory effects were reported for myrrh (Kimura et aL, 2001). It is not clear in 
this study whether this change in the fibrous tissue in the liver granulomas is beneficial 
or harmful for the infected and treated animals. It has been shown that the formation of 
granulomas around the eggs helps to segregate them and thus protect the liver cells from 
exposure to their toxins (Doenhoff et al., 1986). On the other hand, over-development 
of the granulomas and fibrosis leads to the main pathological consequences of the 
disease (Strickland and Ramirez, 2000). However, it is worth mentioning that in a 
previous experiment, infected mice treated with intraperitoneal MZD showed a similar 
pattern of granuloma structure and there was a high mortality rate in this group of mice 
(4 out of 7 mice were dead). 
The exact mechanism of granuloma formation and fibrosis is not fully elucidated. 
Several cytokines have been shown to play a role in this immunopathological process. 
For instance, IL-4 has been shown to increase granuloma formation (Yamashita and 
Boros, 1992; Jankovic et al., 1999a) and to increase the survival of infected hosts by 
preventing Thl skewed immune responses (Brunet et al., 1997; Fallon et al., 2000a; La 
Flamme et al., 2001; Patton et al., 2001). IL-13 has been shown to increase granuloma 
formation and more importantly to be the main cytokine involved in fibrogenic 
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processes (Chiaramonte et al., 1999; Fallon et al., 2000a; Wynn, 2003; Mentink-Kane et 
al., 2004; Kaviratne et al., 2004). On the other hand, IL-10 has been shown to play an 
important role in the modulation of granulomas, reducing fibrosis and prevention of 
over expression of either Th I or Th2 immune responses (Flores-Villanueva et al., 1996; 
Boros and Whitfield, 1998; Zouain et al., 2000; Sadler et al., 2003; Hesse et al., 2004; 
Booth et al., 2004). Although IFN-y may play a role in the early development of 
granulomas (Pearce et al., 199 1; Lukacs and Boros, 1992), it has been shown that IFN-y 
plays a role in the reduction of granuloma size and fibrosis (Henri et al., 2002; Booth et 
al., 2004). 
In PZQ treated mice, there was a decreased production of IL4, IL-13 and IFN-y from 
spleen cells and LNs in response to stimulation with either SWAP or SEA. The greatest 
reduction was that of IFN-y. The levels of IL-10 in the supernatant from lymphocytes 
from mesenteric lymph nodes tend to be higher in PZQ-treated mice in response to 
stimulation with SEA and SWAP. When the levels of IL-10 produced by LNs after 
stimulation with SEA or SWAP were compared to the levels obtained in the absence of 
stimulation, there showed 12 and 7 fold increase, respectively. On the other hand, LNs 
from mice treated with MZD showed 4 and 1.5 fold increase and LNs from untreated 
mice showed 2.5 and 1.5 fold increase after stimulation with SEA or SWAP 
respectively. Furthermore, LNs from mice treated with PZQ produced II and 6 fold 
increase of IL-13 levels after stimulation with either SEA or SWAP compared to the 
levels produced in the absence of stimulation. LNs from mice treated with MZD or 
untreated mice showed only 1.5-2 fold increase in the level of IL-13 after stimulation 
with either SEA or SWAP. These results may indicate that PZQ treatment favours the 
stimulation of Th2 associated immune responses and this response is balanced by virtue 
of increased IL-10 levels. This pattern may explain the slight increase in the diameter 
and eosinophils of liver granulomas in mice treated with PZQ. 
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The preferential M associated immune responses after treatment of schistosomiasis 
with PZQ were reported in the literature. In human schistosomiasis mansoni, the mean 
levels of tegument-specific IL-5 and IL- 10 increased about 10- 15 fold, and mean levels 
of IL-13 increased about 5 fold. Levels of SEA, SWA, and tegument-induced 
interferon- gamma, were not significantly changed by treatment, and, with the exception 
of IL-10, which increased slightly, responses to SEA also remained largely unchanged 
(Joseph et al., 2004). On the other hand, Fitzsimmons and colleagues investigated the 
early changes in immune reactions after praziquantel therapy in S. mansoni infected 
individuals. One day after PZQ treatment, a marked transient increase in plasma IL-5 
levels was observed in 75% of the subjects. Blood cultures from the 16 subjects with the 
greatest increase in plasma IL-5 level displayed reduced IL-5, IL-13, and IL-10 
responses to SWAP. They reported that there was a heterogeneity in early immune 
reactions to treatment, identifying subgroups who have different patterns of reaction and 
who may have different capacities to mount different immune responses (Fitzsimmons 
et al., 2004). In human schistosomiasis haematobium, repeated treatment of infected 
school children led to high specific levels of interleukin (IL)-5 and low interferon-y 
production but did not protect against reinfection (van den Biggelaar et aL, 2002). 
In conclusion the work presented in this chapter has demonstrated that 
1. Both MZD and PZQ showed in vitro anti-schistosome activities against S. 
mansoni. 
2. MZD was more effective against schistosomula than PZQ in vitro but its 
efficacy was less against adult worms. 
3. Lengthy exposures to high concentrations were necessary for the effects of 
MZD to be evident. 
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4. Although there were similarities in the effects of MZD and PZQ after in vitro 
exposure, the extent of the damage was distinct for each drug. 
5. Both MZD and PZQ caused an increase in the intra-parasite calcium levels. 
6. MZD had no anti-schistosome activity in infected mice. On the other hand PZQ 
caused a significant reduction in wonn burden and liver and gut egg loads. 
7. There were no significant differences in the diameter or the structure of liver 
granulomas in treated mice compared to untreated mice. 
116 
Chapter Three 
Effects of in vitro exposure to Mirazido and 
praziquantel on the soluble proteome of adult 
Schistosoma mansoni 
3.1 Introduction 
3.1.1 Two-dimensional gel electrophoresis and mass spectrometry 
The term 'proteome' describes the total protein complement expressed by a genome 
(Wilkins et al., 1996). The separation and characterisation of the protein content of 
complex mixtures has been made possible with the invention of the two-dimensional gel 
electrophoresis (O'Farrell, 1975). As is clear from the name, the two-dimensional gel 
electrophoresis (2-D electrophoresis) comprises two dimensions that separate proteins 
according to two different properties. 
In the first dimension, isoelectric focusing (IEF), proteins are separated according to 
their isoelectric points (pI) which is determined by the relative contents of acidic 
(negatively charged) and basic (positively charged) residues of each protein. The 
isoelectric point (pl) is the specific pH at which the net charge of the protein is zero 
(Berg et aL, 2002b). The presence of a pH gradient is critical to the IEF technique. In a 
pH gradient, under the influence of an electric field, a protein will move to the position 
in the gradient where its net charge is zero. For instance, a protein with a positive net 
charge will migrate toward the cathode, becoming progressively less positively charged 
as it moves through the pH gradient until it reaches its pl. On the other hand, a protein 
with a negative net charge will migrate toward the anode, becoming less negatively 
charged until it also reaches zero net charge. If a protein should diffuse away from its 
pl, it immediately gains charge and migrates back. This is the 'focusing' effect of IEF, 
which concentrates proteins at their pIs and allows proteins to be separated on the basis 
of very small charge differences (Berkelman and Stenstedt, 1998). The introduction of 
the immobilised pH gradient for isoelectric focusing has made the 2-D electrophoresis 
separations highly reproducible and has allowed greater amounts of protein to be loaded 
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(Bjellqvist et al., 1982). After proteins have been separated by IEF, they are subjected 
to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as a second 
dimension. 
In the second dimension, proteins are separated largely on the basis of their molecular 
masses. The mixture of proteins is first dissolved in a solution of sodium dodecyl sulfate 
(SDS), an anionic detergent that disrupts nearly all noncovalent interactions in native 
proteins. Anions of SDS more importantly bind to peptide chains at a fixed ratio of one 
SDS anion for every two amino acid residues. The complex mixture of SDS and the 
denatured protein has a large net negative charge that masks the initial charge of the 
protein. When such a mixture is subjected to electrophoresis, small proteins move 
rapidly through the gel whereas large proteins stay near the point of application of the 
mixture. The mobility of most polypeptide chains under these conditions is linearly 
proportional to the logarithm of their mass (Berg et aL, 2002b). As an initial step for 
protein identification and comparison, they are stained with a specific dye. In theory, 
the analysis of up to 15000 proteins should be possible in one gel, however, in practice 
5000 detected protein spots indicates a very good separation (Berkelman and Stenstedt, 
1998). 
Several methods have been used for protein identification. Ile methods of choice are 
now based on mass spectrometry (MS). They are applicable to all proteins, combining 
the advantages of greater sensitivity and high throughput without the expensive running 
costs of the earlier technologies. MS is a means of accurately determining molecular 
mass. The molecules are ionized in the gas phase, accelerated by an electric field in a 
vacuum and enter a mass analyser, which allows the measurement of their mass to 
charge ratio (Ashton et aL, 2001). After gel mapping, spots are excised and subjected to 
proteolytic digestion e. g. by trypsin that cuts peptide bonds C-terminal to lysine or 
arginine residues to create a diagnostic peptide mixture (Wilson et al., 2004). 
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Until recently, the very low volatility of proteins and probably other macomolecules, 
made MS of no value for the investigation of these molecules. This difficulty has been 
circumvented by the introduction of techniques for effectively dispersing proteins and 
other macromolecules into the gas phase. These methods are called matrix-assisted laser 
desorption ionisation (MALDI) and electrospray spectrometry. With the MALDI 
technique, the protein sample embedded in an appropriate matrix is ionised by the 
application of a laser beam. The ions generated are then accelerated, using an electrical 
field, through the flight tube toward the detector with the smallest molecules traveling 
fastest and arriving first. Thus the time of flight (ToF) in the electric field is a measure 
of mass/charge ratio (Berg et al., 2002b). For protein spots that have been excised from 
2-D gels, the usual approach is to generate a peptide mass fingerprint (PMF). In theory, 
this should be diagnostic of a particular protein and searching a database of full-length 
protein sequences for the organism under investigation will lead to identification if the 
sequence for that protein is present in the database (Wilson et al., 2004). 
In the electrospray mass spectrometry (ESMS), liquid containing the analyte is pumped 
at low microliter-per-minute flow rates through a hypodermic needle at high voltage, to 
electrostatically disperse, or electrospray, small, micrometer-sized droplets, that rapidly 
evaporate and which impart their charge onto the analyte molecules. The molecules are 
transferred into the mass spectrometer with high efficiency for analysis. A wide range 
of compounds can be analyzed by ESMS; the only requirement is that the molecule be 
sufficiently polar to allow attachment of a charge. This includes proteins, 
oligonucleotides, sugars, and polar lipids. For a given compound, the signal strcngth 
(peak height in the spectrum) increases linearly with the analyte concentration over a 
wide range until saturation occurs (Mann et aL, 2001). 
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3.1.2 SchistoS'Ome proteome 
The characterisation of parasite proteomes is a major task in biological research. The 
powerful combination of two-dimensional electrophorcsis and mass spectrometry can 
identify selected parasite proteins rapidly and cheaply, providing a direct route to the 
cDNA and hence recombinant protein, and requiring as little as 500finol of the original 
protein (Ashton et al., 2001). However, such a combination has been available, for 
schistosomes, only in the last few years partly because of the recent advances in the 
sequencing of the schistosorne genorne. For instance, before 1994, there were only 220 
sequences in the database for all schistosome species. With the use of the expressed 
sequence tag (EST) strategy for schistosomes now there are over 139064 public S. 
mansoni ESTs, representing 92% of the S. mansoni gene complement (EI-sayed et al., 
2004). 
Using the combination of two-dimensional electrophoresis and peptide mass 
fingerprinting Curwen and colleagues (2004) compared the proteome profiles of the 
soluble antigen preparations from different stages in the life cycle of S mansoni, 
namely, cercariae (SCAP), lung-stage schistosomula (SLAP), adult worms (SWAP) and 
eggs (SEA). The pattern of protein spots from preparations of different stages showed 
great similarity especially between adjacent life-cycle stages reflecting in part the slow 
transition that occurs in schistosome 'stages' within the mammalian host. The MALDI- 
ToF mass spectrometric analyses of the top 40 spots from each gel revealed thirty-two 
individual protein species, 70% of which were identified in all the life cycle stages. 
However, there were some proteins that were unique for each stage. Amongst the 
twenty-four proteins identified by blotting the gels with sera from hosts with patent 
infections or hosts vaccinated with radiation attenuated cercariae or parasite extracts, 
several of the WHO priority vaccine candidates, including glutathione-S-tmnsferases, 
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fatty acid binding proteins and paramyosin, were strongly recognized in all the life 
cycle stages (Wilson et al., 2004; Curwen et al., 2004). 
As an extension of the study of the effects of MZD and PZQ on S. mansoni, the effect 
of MZD and PZQ on the soluble proteome of adult wonns of S. mansoni was studied. 
3.2 Materials and methods 
3.2.1 Reagents and Equipment 
Unless otherwise stated, all the reagents and equipment used were purchased from 
Amershain Biosciences UK limited, Buckinghamshire, UK. 
3.2.2 Exposure of adult S. mansoni to MZD or PZQ 
Adult worms were recovered from mice infected with the Puerto Rican strain of S. 
mansoni. Adult worms (10 worm pairs/ml-1 of complete RPMI-1640) were exposed for 
24h to either PZQ or MZD at a concentration of 200pg ml-1. Control worms were 
exposed to 1% DMSO (the drug solvent). The worms of each group were then pooled 
and washed three times with 40mM Tris solution. 
3.2.3 Sample preparation 
Washed worms were homogenised using a glass tissue homogeniser immersed in ice. 
The whole worm homogenate was transferred into a universal tube and sonicated on ice 
using a Soniprep 150 sonicator for 4 cycles of I minute each with aI minute interval 
between pulses to prevent over heating of the antigens. The supernatant was centrifuged 
for 20 minutes at 700OOg at 4'C. The supernatant was collected in a universal tube to 
which a protease inhibitor was added. The protein was then concentrated with acetone 
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precipitation method. Briefly, three volumes of ice-cold acetone was added to one 
volume of the sample and incubated at -20"C for 2h. The protein was pelleted by 
centrifugation for 20 minutes at 700OOg at 4'C. The supernatant acetone was gently 
removed and the remaining acetone was air-dried. Ile pellet was resuspended in DIGE 
lysis buffer and stored at -700C. 
3.2.4 Preparation fo r the 2-D fluorescence difference gel 
electrophoresis (2-D DIGE) 
Determination of the protein content of the samples 
The protein assay was carried out using the 2-D Quant Kit. Aliquots of different 
quantities (0,10,20,30,40 and 50pg) of bovine serum albumin (BSA) standard 
solution were prepared. Two microlitres of each sample were placed in an ependorff 
tube (run in duplicate). A 500pl of the precipitant reagent was added to each tube 
(including the standard curve tubes). They were mixed briefly by vortexing and 
incubated for 2-3 min at room temperature. A 500pl co-precipitant reagent was added 
to each tube and mixed briefly by vortexing. The tubes were centrifuged at I 00OOg for 
5 min. The supernatant was decanted gently and the process of precipitation and 
centrifugation was repeated. The tubes were immediately removed from the centrifuge 
and the supernatants were carefully decanted. AI OOPI of copper solution and 400pI of 
distilled de-ionized water were added to each tube. Tile precipitated protein was 
dissolved by brief vortexing. A Iml volume of working color reagent (100 parts of 
colour reagent A to I part of colour reagent B) was added to each tube and mixed 
thoroughly. The tubes were incubated at room temperature for 15-20min. The 
absorbance of each sample and standard was read using a spectrophotomcter at a 
wavelength of 480nm using water as the reference. A standard curve was generated by 
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plotting the absorbance of the standards against the quantity of protein. Using this 
standard curve the protein concentration of the samples was determined. 
Fluorescent labeling of the samples with the CyDye 
With the use of the different CyDye TM fluoros dyes, it is possible to compare between 
more than one protein sample in the same gel. The protein concentration of the samples 
was adjusted to a 5mg ml-1 concentration. Aliquots of 50ýtg proteins in 101A DIGE lysis 
buffer were prepared. The pH was adjusted to between pl-18 and pH9. On ice, 40pmol of 
either CyDye 3 or CyDye 5 was added to each aliquot and mixed immediately. The 
aliquots were then incubated on ice for 30min in the dark. The reaction was stopped by 
addition of I[tl of lOmM lysine and incubation for 10min on ice in the dark. The 
labelled samples were stored at -70'C. 
3.2.5 Isoelectric focusing of the labelled samples 
Control samples (stained blue with CYDye5) were compared with either sample from 
MZD-treated or PZQ-treated wonns. A 150pg of unlabelled. proteins was added to each 
of the 50ýtg labelled proteins aliquot and mixed well. For comparison, 200ýtg of the 
sample from MZD-treated or PZQ-treated worms (stained red) was mixed with 200pg 
of the control sample (stained blue) resulting in a loading amount of 400pg for each 
immobilised pH gradient (IPG) strip. This amount of proteins was loaded in 450111 of 
sample rehydration buffer (see appendix). The rehydration buffer with the proteins was 
placed in the Ettan IPGphor strip holder to which a 24cm-IPG strip, with a p1l gradient 
pH3-10, was gently positioned, covered with few drops of oily solution, to prevent 
evaporation of samples, and then covered with the strip holder cover. The isoclectric 
focusing was carried out using an Ettan IPGphor isoelectric focusing system. The 
isoelectric focusing conditions were as follows: phase I as a rehydration phase and was 
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run under low voltage of 30V for 10h, phase 2 at 300V for lh, phase 3 at 600V for lh, 
phase 4 at IOOOV for lh, phase 5 as a gradient phase was run at 8000V for 3h and 
30min and phase 6 at 8000V for 8h. 
3.2.6 Equilibration of the sample 
After completion of the isoýlectric focusing, the IPG strips were carefully removed and 
equilibrated over two steps using two different equilibration buffers. The equilibration 
step saturates the IPG strip with the SDS buffer system required for the second- 
dimension separation. The equilibration solution contains buffer, urea, glycerol, 
reductant, SDS, and dye. Each strip was placed in the tube containing the first 
equilibration buffer. The tubes were shaken for 15min. 'Me IPG strips were then moved 
into other tubes containing the second equilibration buffer and shaken for 15min. The 
IPG strips were then subjected to the SDS-PAGE. 
3.2.7 SDS-PAGE 
After separation of the protein mixture of the samples on the basis of their pis using. 
isoelectric focusing, the proteins were then separated according to their mass/charge 
using the SDS-PAGE. Twenty-four centimetre PAGE gels with 12.5% acrylamide were 
prepared (see appendix). The IPG strip was dipped in SDS electrophoresis buffer and 
then carefully placed onto the top of the PAGE, avoiding air bubbles between the IPG 
strip and the gel. The IPG strip was sealed in place with agarose sealing solution (see 
appendix). The gel cassettes were placed in the Ettan DALT separation unit containing 
SDS electrophoresis buffer (see appendix). More buffer was added until the fill line was 
reached. The clectrophoresis was carried out at a current of SW/gel for 30min followed 
by 17W/gel for 4h and 3 Omin. 
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3.2.8 Scanning of the gels and image analysis 
Each gel was scanned at 100pm resolution on a TyphoonTm 9400 Variable Mode 
Imager using 580BP30 (Cy3) and 670BP30 (Cy5) emission filters. The gels were 
stained with SYPROTM orange (Bio-Rad) (1/10000 solution in 7.5% acetic acid) to 
ensure uniform staining of protein spots. The gels were destained in 7.5% acetic acid 
and scanned using a 555BP20 filter. Images were analyzed using DeCyder differential 
analysis software, v5.0 in both the differential in gel analysis (DIA) and the biological 
variation analysis (BVA) modules. Individual images were created for the different Cy3 
and Cy5 labeled gels and matched together using DeCyder software. Automatic 
detection was followed by minimal manual, and therefore subjective, intervention, but 
in some regions on each gel spots were split and/or redrawn. Parameters for minimum 
spot volume and contrast were adjusted and the so called 'spiky spots' were also 
removed. Two preparative gels were added to the experimental study and parallel pick 
lists that included all spots of interest (i. e. those differcntially regulated following 
treatment with the candidate drug) were created. The pick list was matched to the 
SYPRO gel images and the spot map was exported for subsequent spot handling prior to 
mass spectrometry. 
3.2.9 Automated spot handling 
Selected proteins were subjected to fully automated spot handling in Ettan Spot 
Handling Workstation. A method that included spot picking, digestion, and spotting on 
Ettan MALDI target slides was selected in the software, and the whole procedure was 
run automatically overnight without any manual intervention either within or between 
steps. In this automated procedure, gel plugs were cut by a 2-mm picking head and 
washed twice in 50% methanol and 50mM ammonium bicarbonate and once in 75% 
acetonitrile before drying. For digestion, 10111 trypsin solution (0.2pg Trypsin, 
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Sequencing Grade) was added before incubation at 370C for 2h. Extraction was 
performed in two steps by addition of 50% acetonitrile and 0.1% trifluoroacetic acid. 
The pooled extract was finally dried prior to the two-step spotting procedure, where the 
matrix solution of 5mg/ml solution of recrystallized a-cyano4-hydroxycinnarnic acid in 
extraction liquid was deposited on the target. In the final step before MALDI-ToF, a 
tenth of the dissolved sample was mixed with the matrix layer on the target, leaving the 
rest for the electrospray. 
3.2.10 Identification of proteins 
Mass spectrometry peaks were obtained from an Ettan MALDI-ToF biospectrometry 
workstation followed by protein identification by peptide-mass fingerprinting (PMF) 
(Voyager DETm Pro, Applied Biosystems, Framingham, MA, USA). Ile MALDI target, 
obtained from spot handling workstation, was loaded into the mass spectrometer. 
Spectra were acquired in reflector mode using the Voyager 5.1 software; all instrument 
settings were optimized for sensitivity. Raw spectrum files were opened in data explorer 
software (Applied Biosytems) and calibrated on two internal peaks resulting from 
autolysis of trypsin (mlz = 842.510 and 2211.104). Peak lists were then prepared from 
each spectnun following application of the process for PMF macro (modified from an 
original macro by Melanie Lin, Applied Biosystems). '17his corrects the baseline, 
removes noise (S. D. = 0.7), de-isotopes the peak list so that only the monoisotopic 
peaks remain and outputs a list of the remaining peaks as a text file, which represents 
the peptide mass fingerprint (PMF) for the original spot. The National Centre for 
Biotechnology Information non-redundant protein (NCBlnr) database, was searched 
with each PMF using Mascot Daemon (Matrixscience, London, UK) with the peptidc 
mass tolerance set to ± 50ppm. 
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When the MALDI-ToF method was unable to identify proteins, electrospray tandem 
mass spectrometry (ESTMS) was used. The tryptic peptides, resulting from the spot 
handling workstation, were solubilized in 0.5 % formic acid and fractionated by 
nanoflow high performance liquid chromatography (HPLQ on a C18 reverse phase 
column, eluting with a continuous linear gradient to 40% acetonitrile over 20 minutes. 
Eluate was analysed by online electrospray tandem mass spectrometry using a Qstar 
Pulsar (Applied Biosystems). A3 second survey scan preceded each MS/MS data 
collection cycle of 4x3 second product ion scans, giving a total duty cycle of 15 
seconds. Data was submitted to an MS/MS ions search via the Mascot search engine 
(Matrix Science), searching both locay established databases for S manson! DNA 
sequence and the current non-redundant NCBI database. 
3.3 Results 
3.3.1 2-D electrophoresis gel 
As a preliminary step, different samples were run at pH3-7 gradient in the isoelectric 
focusing and the immobilised strip was subjected to a 4-12% gradient mini gel. The 
majority of spots were similar in control parasites and the drug treated parasites. Few 
spots showed different intensities between different samples. The experiment was 
expanded by using a wider pH range in the isoelectric focusing and the immobilised 
strip was subjected to electrophoresis using 12.5% 24cm gels. After 2-D clectrophoresis 
and image analysis, DeCyder software matched about 3000 spots in each gel. After 
exclusion of the spiky spots the number of spots were reduced to about 2700. The 
intensity of protein spots tended to be less in drug treated samples especially with MZD. 
This presumably is due to lower protein contents of samples from MZD treated worms. 
However, there were eight spots in MZD treated samples showing more than a 2-fold 
128 
difference in their expression compared to control worms. Nine spots were differentially 
expressed in PZQ treated worrns by at least a 2-fold difference compared to the control 
parasites. The different spots were picked and processed for protein identification. 
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Figure 3.1 2-D electrophoresis gel of MZD-treated samples compared to control samples.. 
2-D PAGE of MZD-treated worms (B) stained with CyDye 3 and control parasItes (A) 
stained with Cydye 5. Only spots that were at least 2-fold up-regulated (T) or down- 
regulated (1) are marked. 
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Figure 3.2 2-D electrophoresis gel of PZQ-treated samples compared to control samples. 
2-D PAGE of PZQ-treated wonns (B) stained with CyDye 3 and control parasites (A) 
stained with Cydye 5. Only spots that were at least 2-fold up-regulated (T) or down- 
regulated (1) are marked. 
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3.3.2 Protein identification using MALDI-ToF 
The PMF of each picked protein spot, obtained from MALDI ToF was searched in the 
database. However, out of the 17 picked spots, only three proteins were identified. In 
some cases, the same protein was identified in two or more adjacent protein spots. 
Although some protein spots were up to 13-fold more expressed in drug treated worms, 
protein identification of these spots using either MALDI-ToF or ESTMS failed to reveal 
any significant matches. In MZD-exposed worms, paramyosin (theoretical M, I OOkDa, 
pI 5.3 1) was 4-fold more expressed and actin (theoretical M, 42kDa, pl 5.46) was Mold 
less expressed compared to control parasites. In PZQ-exposed worms, fructose 1,6 
bisphosphate aldolase (theoretical M, 40kDa, pI 7.63) was 2-fold more expressed 
compared to control parasites. 
3.4 Discussion 
Although PZQ has been the drug of choice for treatment of schistosome infection for 
about thirty years, its mode of action is still not fully understood. With the major 
advances of the 2-D electrophoresis and mass spectrometry techniques, it is now 
possible to separate a mixture of proteins in a sample with very high resolution and by 
accessing protein databases to identify the proteins of interest (Berg et aL, 2002b). This 
powerful combination of techniques was used in the present study to investigate the 
effects of in vitro exposure of adult S. mansoni worms to either PZQ or MZD. Another 
powerful technique, DIGE was used for the comparison between samples from worms 
exposed to either drugs with samples from control worms in one gel as a reference 
(Berkelman and Stenstedt, 1998). 
Protein separation using the 2-D PAGE revealed more than 3000 protein spots in both 
drug-treated and control parasites. The protein spots tended to be less intense in drug 
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treated parasites especially MZD-treated parasites. This is perhaps attributed to the 
amount of protein loaded in the samples. In order to avoid this possibility, only proteins 
that showed more than 2 fold differences were picked. Of the 17 spots, only 3 proteins 
were matched using the PMF obtained from MALDI ToF. Protein identification was 
retried using ESTMS but no additional proteins were identified. 'I'his may be explained 
by the possibility that these spots might have small amounts of proteins. It is estimated 
that about 500finol of the original protein is essential to allow protein identification 
(Ashton et al., 2001). The decreased number of identified proteins may be attributed to 
the incomplete status of the genome of S. mansoni. Against this, Curwen and colleagues 
compared the soluble proteomes of different life cycle stages of S mansoni and they 
were able to identify many proteins (Curwen et aL, 2004). However, in their study they 
set the peptide mass tolerance to ±2 dalton while in the present study it was set to ± 50 
parts per million which, as expected, limits the range of proteins likely to be identified 
by the search tools. Though it would increase the degree of confidence that the matches 
are significant. 
In the sample from worms exposed to MZD, two closely related spots were 4-fold more 
expressed compared to samples from control worms. The database search for the PMF 
from these spots revealed homology with S. mansoni paramyosin. 
Paramyosin is a myofibrillar protein and is usually organised into the core structure of 
the thick filaments of the invertebrate muscle where it interacts with myosin molecules. 
The immunolocalisation studies of paramyosin were controversial. Although it was 
often localized in the muscle of the parasite, it was also localized in the tegument of 
adults and schistosomula and in the post-acetabular glands of the ccrcariae (Kojima, 
2004). However, paramyosin may be multifunctional, playing a role not only as 
structural components but also serving several functions in the host-parasite interaction 
including interference with the complement cascade, impairing augmentation of the host 
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inflammatory response and binding of host immunoglobulins, thus making the parasite 
insusceptible to the immune system (Kalinna and McManus, 1997). 
In this context, a surface protein of 94kDa designated schistosome complement 
inhibitory protein-I (SCIP-1) exhibits antigenic and functional similarities with the 
human complement inhibitor protein CD59. Soluble SCIP-1, partially purified from 
schistosome tegument extracts using anti-CD59 antiscra, was shown to bind to purified 
human C8 and C9 and inhibit lysis of sheep and rabbit RBCs by human complement 
(Parizade et al., 1994). Subsequent sequence analysis of the purified SCIP-1 revealed it 
to be paramyosin. Furthermore, native and recombinant paramyosin was shown to bind 
to human C8 and C9 and to inhibit C9 polymerization on RBCs (Deng et aL, 2003). 
Like CD59, SCIP-1 (paramyosin) is viewed as 'mopping-up' any activated complement 
at the terminus of the pathway that may have escaped the multiple earlier inhibitors 
(Skelly, 2004). 
If the increased expression of paramyosin observed in the present study occurs in vivo, 
in response to drug treatment, one would speculate that this could be a compensatory 
mechanism of the parasites in an effort to avoid both innate and acquired immune 
responses that exploit the complement system. Such immune responses might potentiate 
the damage caused by the drug. 
Whatever the mechanism of increased expression of paramyosin in adult worms in 
response to in vitro exposure to MZD, this observation might support the hypothesis 
that some anti-schistosome drugs might have a temporary immunising cffect promoting 
the stimulation of protective immune responses. 
Paramyosin is a well-recognized vaccine candidate and is one of the vaccine candidate 
recommended by the WHO. Pararnyosin, both the native and the recombinant molecules 
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from S. mansoni, administered intradermally with BCG at total doses of 440lig per 
mouse were found to confer significant resistance (26-33%) against challenge infection. 
In addition, paramyosin was shown to stimulate T lymphocytes from vaccinated mice to 
produce lymphokines especially IFN-y that activate macrophages to kill schistosomula 
(Pearce et aL, 1988). In mice, subcutaneous immunization with S. japonicum 
paramyosin with BCG or alum produced 20-60% worm reduction in challenge infection 
(Kojima, 2004). 
Interestingly, the reported preferential Thi immune responses stimulation by 
immunization with paramyosin may fit with the observed preferential reduction of Tb2- 
related cytokine production by LNs and spleen cells from mice treated with MZD 
(shown in chapter 2). This reduction in Th2 responses may be a consequence of the 
related boosting of the Thl immune responses by the increased expression of 
paramyosin. 
Another protein spot was expressed 3-fold less in samples from worms exposed to MZD 
compared to control worms. Identification of this spot revealed a protein that showed 
sequence homology to actin. 
Actins constitute a highly conserved family of proteins found in all eukaryotes. These 
proteins are found predominantly in the cytoplasm of cells where monomers polymcrisc 
to form microfilamcnts. Microfilaments of actin participate in various cell functions 
such as muscle contraction, cell cytoskelcton and motility (Shcterlinc and Sparrow, 
1994). In S. mansoni, indirect immunofluorescence studies localized actin 
predominantly in surface spines and tubercles of adult schistosomes (Abbas and Cain, 
1987). Furthermore, using immunoelectron microscopy, the surface spines were shown 
to be composed of paracrystalline arrays of actin filaments. Actin was also present in 
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areas recovering ftom damage, implying an important role for this structural protein in 
tegumental repair (Matsumoto et al., 1988). 
The mechanism of decreased expression of actin in worms exposed to MZD in the 
present study is unknown. However, after treatment of S mansoni with the anti- 
schistosome drug Ro 15-5458, the total RNA content of parasites recovered from mice 
12,72 and 96h after dosing was reduced by 14,30 and 41%, respectively. Quantitative 
filter hybridization of blots of RNA extracted from treated and control parasites with 
specific probes indicated a decline in actin and superoxide dismutase mRNA as well as 
rRNA of treated parasites. The decline was observed 12h after dosing, 48h before 
parasites showed drug-induced changes in other vital biological processes (Eshete and 
Bennett, 199 1). A similar mechanism may be involved after exposure to MZD. 
In samples from worms exposed to PZQ, there was one protein spot that was 2-fold 
more highly expressed that control worms. Protein identification revealed a sequence 
homology with fructose 1,6 bisphosphate aldolase. Fructose 1,6 bisphosphate a1dolasc is 
a key enzyme in the glycolytic pathways and in energy metabolism. It catalyses the 
reversible aldol cleavage of the fructose 1,6 bisphosphatc into two trioscs, 
dihydroxyacetone phosphate and glycemldehydc-3-phosphatc (Berg el al., 2002a). 
Schistosomes have a high rate of metabolism and energy consumption necessary for 
several vital functions including egg laying, muscular activity and transport of nutrients 
through the tegument. Although schistosomes live intravascularly with an unlimited 
supply of oxygen, most of their metabolic pathways including glycolysis arc essentially 
anaerobic (Coles, 1984). Immunocytochernical studies localized fructose 1,6 
bisphosphate aldolase in all tissues of adult schistosomes. In malc worms it was mostly 
localised in the tubercles and in the subtegumental region (El Dabaa et aL, 1998). 
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The increased expression of fructose 1,6 bisphosphate aldolase in worms exposed to 
PZQ might indicate an increase in glycolysis and increased energy production. This 
could be attributed to the increased energy demands for repair mechanisms. However, 
this increased protein expression might result in priming of the immune response and 
thus favour the hypothesis of an immunising role for PZQ. 
In conclusion, the present study indicated that in vitro exposure to either PZQ or MZD 
caused changes in the expression of some proteins in schistosomes. However, the 
results of the present study are preliminary and further studies are recommended, 
especially now that the genome sequence of S. manson! is nearing completion. When 
the genome has been completed, it will facilitate the identification of more proteins 
using mass spectrometry. In any case it is possible to investigate the differential 
expression on the genomic level with the recent advanced techniques including 
Microarrays. These studies will undoubtedly reveal invaluable information that will 
revolutionise our understanding of the actions of PZQ, MZD and other drugs. 
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Chapter Four 
Antibody isotype recognition of antigens of 
Schistosoma haematobium by sera from infected 
individuals before treatment, after treatment 
and after reinfection 
4.1 Introduction 
4.1.1 Humoral immunity to schistosomiasis 
All stages in the life cycle of the schistosome may be rccognised by antibodies in the 
serum of infected humans (Butterworth et al., 1985; Hagan et al., 1987). Such 
antibodies can be detected in the serum of various experimental animals and humans 
within days of infection. It is clear that not all of these antibodies are relevant to 
protective immunity and there is a powerful evidence that some may prevent the 
expression of immunity (Hagan, 1987). 
In humans with schistosomiasis a number of immuno-epidemiology studies have 
demonstrated that different antibodies are correlated with resistance to infection or to 
intensity of reinfection. For instance, adult worin and/or schistosomula specific IgE 
antibodies (Rihet et al., 1991; Hagan et al., 1991; Dunne et al., 1992; Demeure et al., 
1993; Caldas et al., 2000), IgA antibody (Ndhlovu et al., 1996; Khalil et al., 1999), 
IgGI antibody (Satti et al., 1996) and IgM antibodies against a 68kDa antigen (King et 
al., 1989) have been associated with immunity to reinfection. On the other hand, a 
number of studies have reported that parasite specific IgM (Butterworth et al., 1987; 
Ndhlovu et al., 1996), IgG4 (Hagan et al., 1991; Demeure et al., 1993; Ndhlovu el al., 
1996) and IgG2 (Demeure et al., 1993; Satti et al., 1996) antibodies have been 
correlated with susceptibility to re-infection. Tle finding of such associations has 
stimulated attempts to determine which schistosome antigens arc rccogniscd by 
antibodies that may result in protection. 'Me identification of the putative 'protective 
antigens' would be of significance in attempts to develop a vaccine that could be used to 
artificially stimulate protection through vaccination. 
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The pattern of recognition of schistosome antigens by antibodies has been described on 
a number of occasions. In some studies antigen recognition has been correlated with 
resistance to re-infection (Roberts et al., 1987; Dessein et al., 1988; King et al., 1989; 
Grzych et al., 1989; Dunne et al., 1992; Webster et aL, 1996; Ndhlovu el al., 1996). 
Roberts and colleagues (1987) used western blotting analyses to examine the different 
recognition patterns of S. mansoni surface antigens using sera from Kenyan children 
previously infected with S mansoni and who were classified as resistant or susceptible 
to re-infection after treatment. The antibody response to three antigens of molecular 
mass 100,50 and 27kDa were detected more frequently in the resistant than in the 
susceptible group. However, Roberts and colleagues concluded that the differences in 
total antibody levels to the tegumental membrane preparation were insufficient to 
account for the resistance or susceptible status of the children (Roberts et al., 1987). 
in a similar study, Dunne and colleagues (1992) reported on the different recognition 
patterns of S. mansoni antigens. Using western blotting analyses with serum from 
individuals classified as resistant or susceptible to reinfection with S. mansonl, they 
were able to demonstrate that the recognition of a 22kDa. S. mansoni antigen by IgE 
antibodies was correlated with lower intensities of reinfection after treatment (Dunne el 
aL, 1992). Critically, the recognition of the rSm22 (rSm22.6) by human JgG3, Ig4 and 
IgA was found to be increased in the resistant group, but only the IgE response was 
significantly correlated with resistance to reinfection after treatment (Webstcr et al., 
1996; Webster et al., 1998). 
In another treatment and reinfection study, Dessein and colleagues (1988) showed that 
IgG antibodies from sera of individuals classiried as resistant to reinfection with S. 
mansoni recognised larval surface antigens of 202,165,90 to 92,85,72 and 37kDa. 
Ile reactivity of IgG against the 37kDa antigen showed an association with potential 
resistance to reinfection (Dessein et al., 1988). In S. haematobium infections both IgE 
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and IgG4 recognised different soluble schistosomula antigens but no difference was 
reported in the pattern of antigen recognition between the older 'putatively resistant' (,, t 
20years) and the younger 'putatively susceptible' (< 20 years) individuals except for the 
37kDa antigen. IgE antibody recognition of the 37kDa antigen was higher in the older 
(putatively resistant) group (Ndhlovu, et aL, 1996). 
King and colleagues (1989) studied the recognition pattern to S. mansoni surface 
antigen (SmW68) using sera from Egyptian individuals chronically infected with S. 
mansoni. They reported a negative correlation between the IgM response to SmW68 
and the intensity of infection (King et al., 1989). Similarly, IgA recognition of S. 
mansoni glutathione-S-transferase (Sm28) has been correlated with resistance to human 
schistosomiasis mansoni infection (Grzych et al., 1989). 
interestingly, the antibody recognition pattern can be a marker for detection of early 
schistosomiasis infection. In a study of previously non-exposed individuals, the 
recognition of S. mansoni antigens of 32-35kDa with IgG I and IgG3 antibody isotypcs 
has been reported to be a potential marker for early schistosome infection (Evengard et 
aL, 1990). Similarly, Shaheen and colleagues (1996) reported that the IgGI and IgG3 
antibody recognition of 30-4OkDa adult worm antigens of S. mansoni was prominent 
during the acute pre-patent phase of schistosomiasis. As the disease progressed to 
chronicity the IgGI and IgG3 recognition shifted to the higher molecular weight 
antigens (ý: 80kDa) (Shaheen et aL, 1996). 
4.1.2 Effects of chemotherapy on antibody immune responses against 
schistosomes 
In schistosome infection there is usually a delay of the development of the protective 
immune response. The delay in the development of protective immunity may be 
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attributed to many factors. Some groups favour the idea that blocking antibodies (IgM, 
IgG2 and IgG4) which appear early in infection might prevent or delay the onset of 
protective response (Hagan et aL, 1991; Derneure et aL, 1993). Others have suggested 
that children are not able to mount a protective response simply because their immune 
responses are not fully developed (the immunocompetence hypothesis). Only when their 
immune responses mature are they able to mount a protective response. The modulation 
and evasion of the immune system by schistosomes can be itself an explanation for the 
delay in development of protective immune responses (Barsourn el al., 1982). One final 
explanation is the lack of availability to the host's immune system of schistosome 
antigens. Only when parasites die are such antigens released to the immune system. 
During natural infection antigens are released in small amounts over a prolonged time 
period. Only when the host has had sufficient experience of these antigens, a process 
that may take years, is the immune response effectively armed to deal with new 
infection. However, none of these hypotheses can on their own completely explain the 
delayed onset of immunity to schistosomiasis and it is likely that several factors are 
involved (Hagan and Sharaf, 2003). Praziquantel, and probably other drugs, damage or 
kill worms perhaps exposing antigens that were previously concealed, or accelerate 
antigen release (Harnett and Kusel, 1986; Woolhouse and Hagan, 1999) that could 
stimulate protective immunity. In this context, treatment of schistosome infections at the 
skin schistosomula stage by Rol 1-3128 resulted in immunity to reinfection. Scra from 
mice immunized by infection plus Rol 1-3128 treatment on days I or 2, co-prccipitatcd 
essentially the same pattern of 
125 I-labclled surface antigens as did serum from mice 
vaccinated with 20 krad irradiated cercariae, viz. M, 38,32,23and 15kDa (Bicklc et aL, 
1990). 
In an early attempt to study the effect of praziquantel treatment on the responses of S. 
haematobium infected Gambians, Hagan and colleagues (1987) studied the differences 
141 
in antibody recognition of S. haematobium whole worm homogenate (WWH) and 
soluble egg antigens (SEA) before treatment, 3 months after treatment and after 
reinfection. They reported that antibodies against WWH increased after treatment and 
fell after reinfection while antibodies against SEA fell after treatment and increased 
after reinfection (Hagan et aL, 1987). However, they reached no conclusion as to 
whether or not particular antigen recognition patterns were associated with protection 
against infection. 
in a study of the effects of praziquantel treatment on the immune responses in S. 
mansoni infection in occupationally hyper-exposed canal cleaners in the Sudan, Satti 
and colleagues (1996) reported that individuals resistant to re-infection showed no 
significant difference in the levels of IgG4 to WWH after treatment. In contrast there 
was a significant increase in the levels of IgG4 to WWH in the susceptible group. 
Levels of specific IgG4 to SEA showed a highly significant decrease after treatment in 
the resistant group. The same antibody subclass increased after treatment in the 
susceptible group. However, none of the groups studied after treatment showed a 
significant change in their specific IgE to WWH (Satti et al., 1996). 
Further support for the effect of chemotherapy on the immune response comes from the 
work of Mutapi and colleagues (1998). They reported that treatment of S. haematobium. 
infected Zimbabwean children, 5-16 years old, with praziquantel induced a switch from 
a predominantly IgA-specific antibody response to a predominantly IgGI response, 
similar to that of adults naturally exposed to infection over many years and supposed to 
be resistant to re-infection. The switch of the immune response which occurs naturally 
after several years of exposure in this community occurred in the children within 12 
weeks of treatment with praziquantel (Mutapi et al., 1998). The same authors studied 
the effect of praziquantel and oxamniquine on the humoral immune responses directed 
against S mansoni soluble egg antigens (SEA) in Zimbabwean children. The proportion 
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of treated children producing IgE and IgG3 increased six weeks post-treatmcnt. There 
was also an increase in the mean levels of IgE, IgM and IgG3 in these children. At 18 
weeks post-treatment, the proportion of treated children producing IgA, IgE, and IgG3 
increased while the proportion producing IgGI and IgG4 decreased. Mean levels of 
IgA, IgE, and IgG3 were higher than pre-treatment levels while levels of IgGI, IgG4 
and IgM were lower. Statistical analyses showed that the magnitude of change in levels 
of IgE, IgM and IgG3 at 6 weeks post-treatment and of IgE, IgG3 and IgG4 at 18 weeks 
post-treatment were significantly greater in treated compared to untreated children. 
There were no significant differences in immune responses between children treated 
with praziquantel and those treated with oxamniquine (Mutapi et al., 2003). 
Furthermore, Grogan and colleagues (1997) studied specific IgG4 and IgE responses 
against S. haematobium adult worm antigens and SEA in S haemaloblum infected 
individuals before and after chemotherapy. In this study there was a substantial drop in 
the IgG4 response to SEA after chemotherapy in both adults and children. However, 
IgG4 and IgE antibodies to adult worm antigen (AWA) and IgE antibodies to SEA 
increased in children but remained unchanged in adults (Grogan el aL, 1996). Similarly, 
in a study of the antibody responses against S. mansoni AWA and SEA in Brazilian 
individuals chronically infected with S. manson! before and after treatment with 
oxamniquine, there was a decrease in the schistosome-spccific IgG level observed 6 
months after treatment. Although there was significant decrease of anti-SEA IgG1 and 
IgG3 levels, the decrease of anti-SEA IgG4 level was much more evident (Vcndramc et 
al, 2001). 
These studies together indicate that treatment of schistosomiasis with praziquantel 
induces some changes of the immune response in the form of an incrcasc of IgE levels, 
an antibody isotype which has been correlated with rcsistancc, and decrease of IgG4 
levels, an antibody isotype which has been correlated with susceptibility to reinfection. 
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To further investigate the possibility that schistosome antigen recognition is associated 
with susceptibility or resistance to reinfection, a unique serum bank containing samples 
obtained in the reinfection study reported by (Wilkins et al., 1987) was provided 
together with access to the parasitological database. Using this material it was possible 
to compare the isotype specific recognition patterns of S haematobium soluble adult 
worm antigens. Serum samples from a resistant group (showing no or few eggs in their 
urine after exposure to re-infection) and a susceptible group (showing high numbers of 
eggs in their urine after re-infection) before treatment, after treatment with praziquantel 
and after re-infection were exploited. 
4.2 Materials and Methods 
4.2.1 Serum samples 
Background information on the serum samples 
The serum samples were collected from two villages (Madina Samaco and Njarinjufa) 
in Upper River Division of The Gambia (Hagan et al., 1987). The communities were 
mainly dependent on subsistence agriculture. The transmission of S haemalobium in 
these villages was seasonal. Pools forms in the rainy season between June and 
November. No transmission of schistosomiasis occurred from December to June/July. A 
cohort of 40% of the population of the villages was included in this study. In February 
and March 1983, urine samples were collected for egg count studies with intensities of 
infection being assessed. After blood samples were collected (prc-trcatmcnt sera), the 
participants were treated with a single dose of 40mg kg" of praziquantcl. 71rce months 
after the treatment, further urine and blood samples were collected (post-trcatmcnt sera). 
During the transmission season, careful observation of water contact by trained 
observers allowed an index of cumulative exposure to infection throughout the 
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transmission season to be calculated for each individual. In April 1984,5 months after 
the end of the transmission season, a third urine sample was collected and the intensity 
of re-infection was calculated. Blood samples were also collected at this time 
(reinfection sera). 
This study showed that among groups of subjects with an apparently similar intensity of 
exposure to infection, reinfection tended to be much heavier in children under 10 years 
of age than in 10 to 14-year-olds, while only light infections were found in the few 
adults who became reinfected. This trend for re-infection to decrease with increasing 
age, after an allowance for variation in exposure, was highly significant (P<0.001) 
(Wilkins et al., 1987). Levels of parasite specific IgE were positively correlated with 
resistance to reinfection while levels of JgG4 showed a positive correlation with 
susceptibility to reinfection (Hagan et al., 199 1). 
Grouping of patients' sera 
Individuals who became re-infected with S. haemalobium aftcr treatment with 
praziquantel were considered to be susceptible. On the other hand, individuals with no 
eggs detected in their urine after exposure to reinfection, were considered to be 
resistant. Sera from five control non-infected individuals living in a non-endcmic area 
were included in this antigen recognition study. 
Comparisons were carried out between resistant and susceptible groups at cach time 
point and between the different time points within the same group. 
4.2.2 Antigens 
Freeze-dried adult S. haemalobium wonns were kindly provided by Professor Frcd 
Lewis (Biomedical Research Institute, Rockville, Maryland, USA). They were rc- 
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suspended in PBS (pH 7.4) and homogenised, using a tissue homogeniser immersed in 
ice to prevent overheating. Ile whole worm homogenate was transferred into a 
universal tube and sonicated on ice using a sonicator (Soniprep 150) for 4 cycles of I 
minute each with a minute interval between pulses to prevent over heating of the 
antigens. The supernatant was centrifuged for 20 minutes at 700OOg at 4'C. 'me 
supernatant was collected in a universal tube to which a protease inhibitor was added. 
The protein content of the soluble adult worm antigens preparation (SWAP) was then 
quantified. 
4.23 Determination of protein concentration of SWAP 
Five microlitres of PBS (as blank), 5pLI of each of the standard's concentrations (1500, 
1000,500,200,100,50 and 20pg ml-1) and 5pl of the sample were pipetted in each well 
of a microwell plate. Standards and samples were run in triplicate. A 250pl of 
Coomassie-brilliant blue reagent was added to each well and their protein 
concentrations were measured, immediately after an initial shaking for 30 seconds at a 
wavelength of 595nm using a Dynex ELISA plate reader. The protein concentration of 
the homogenate was adjusted to I mg ml" and it was then stored at -800C. 
4.2.4 Sodium-Dodecyl-Sulphate Polyacrylamide, Gel Electrophoresis 
(SDS-PAGE) 
The method used in this study was a modification of that described by Lacmmli (1970). 
The conditions of electrophoresis and immunoblotting were adjusted after several 
preliminary experiments. All reagents used for SDS-PAGE were purchased from 
Invitrogen (Paisley, UK). Schistosoma haematobium SWAP was treated with sample 
buffer (NuPAGEO LDS Sample Buffer) 4: 1 volume to volume, respectively, and then 
boiled for 5 minutes. 4-12% gradient precast gels (NuPAGE-0 Novcx Bis-Tris Gels) 
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were used. Each gel is Imm thick and has one well for the molecular weight markers 
(MWM) and a 7cm trough for the sample. Five hundred microlitres (containing 500pg) 
of the SWAP was loaded in the trough on each gel and run in parallel with 7pl of a 
prestained wide range molecular weight markers (SeeBlueo Pre-Staincd Standard) in 
the single well. The running buffer was prepared by diluting the running buffer 
(NuPAGEO MES Running Buffer) 20 times with deionised distilled water and 500ml 
was put into the electrophoresis cell. The gel was run at 80mV for the stacking gel and 
then at 140mV until the bromophenol blue dye was approximately 0.5 cm from the 
bottom of the gel. The power was then switched off, the cast removed and the gel 
carefully extracted. 
4.2.5 Staining of proteins 
After running the proteins on SDS-PAGE, the proteins were stained to confirm that they 
were adequately resolved. Gels were stained with Coomassie blue stain for 2h with 
shaking at room temperature. The gels were removed from the stain and were dcstained 
with Coomassie destain for 4h with shaking at room temperature (until the background 
became clear). The gels were then removed from the destain solution and the molecular 
weights of the protein bands were measured using UV gel documentary systcm and 
using a software program (LabworksTm analysis software). 
4.2.6 Western blotting 
After protein resolution onto the SDS-PAGE gel, a sheet of nitrocellulose membrane 
was placed against the surface of the gel and a current was allowed to pass across the 
gel. This current caused the proteins to move from the gel onto the nitoccliulosc 
membrane. Once there, they are bound firmly by non-covalcnt forces (Hudson and Hay, 
1989). Three Whatman filter papers, soaked in the cathode buffer (see appendix), were 
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placed onto the flat surface of the inimunoblot apparatus. The gel was placed over the 
cathode papers. A piece of nitrocellulose membrane, 0.45um (Amersham) was cut 
slightly bigger than the size of the gel and was placed facing the gel, taking care to 
exclude air bubbles. One filter paper soaked in anode 2 (see appendix) was placed over 
the nitrocellulose membrane. Two filter papers soaked in anode I (see appendix) were 
then put over the anode 2 paper. The inimunoblot plate was then covered and the 
current passed. The conditions of the protein transfer were adjusted after several 
experiments. A current of 200mA for 35minutes gave the best results with these 
samples. The nitrocellulose membrane was then removed and stained with Ponceau S (a 
red dye) to confirm that the proteins were properly transferred. The membrane was 
washed with distilled water to remove the dye and the membrane allowed to dry. 
For proper alignment and comparison of the protein bands, a line was drawn near the 
bottom of the membrane, outside the protein migration area. Each membrane was cut 
into 18, numbered, longitudinal strips (enough for blotting the six antibody isotypes 
with three serum samples). IMe nitrocellulose strips were blocked with 0.3% PBS- 
Tween solution for 30minutes at room temperature, with shaking. The strips were 
removed from the blocking buffer and washed with 0.05% PBS-Tween wash buffer 3 
times of 10 minutes each. In the mean time, serum samples were diluted 1: 100 with 
0.05% PBS-Tween solution. Ile diluted serum samples were put in universal tubes and 
6 strips (one strip for each antibody isotype; IgG, IgM, IgGI, IgG2, IgG3 and IgG4) 
were incubated with the serum in each universal tube. Ile tubes containing the serum 
samples and the strips were then shaken over night at 4"C. The strips were rcmovcd 
from the sera and washed with washing buffer 3 times for 10 minutes each. One strip 
from each serum sample was put into a universal tube containing a 1: 750 dilution of the 
secondary antibodies [anti-human IgG, IgM, IgGl, IgG2, IgG3 or IgG4 labelled with 
horse radish peroxidase (HRP) enzyme]. The strips were incubated with the secondary 
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antibodies over night at 4'C. The strips were removed from the secondary antibodies 
and washed with the washing buffer 3 times for 10 minutes each. The Strips were 
incubated with the substrate solution (see appendix) until the bands became visible. Tle 
reaction was stopped by washing the strips with distilled water, 3 times, for 10 minutes 
each. The strips were then rearranged in their original sequence, the protein bands were 
visualised using a UV gel documentary system and the molecular weight of the bands 
was determined. The recognition was expressed as the percentage of senun samples of 
each group recognising a particular protein band. 
The same procedure was employed for IgE with increasing the concentration of serum 
samples to up to 1: 10 and of the anti-human IgE antibodies to 1: 50. Despite repeated 
attempts, no recognition of parasite antigens by IgE was detected even afler pooling the 
serum samples from each group. 
4.2.7 Comparison between groups 
After probing, identification of each antigen by each serum sample of those within the 
susceptible or resistant groups recognising a particular antigen was assessed. 
Recognition of each antigen was then expressed as a percentage of those within each 
group. For comparison between resistant and susceptible groups, the percentage 
recognition of the susceptible group of each band was subtracted from the value of the 
resistant group. The resultant value is the net difference between both groups. The same 
method was employed when assessing the impact of chemotherapy and reinfection on 
the antibody isotypes in each group. 
149 
4.3 Results 
4.3.1 SDS-PAGE gel 
A wide range of glycoproteins/proteins was separated on the SDS-PAGF gel. In total 
thirty distinct bands were recognised and their molecular masses ranged from 5 to 
280kDa. An initial scan to identify which proteins were recognised by sera from 
patients included in this study showed that sera reacted to manv of the scparatcd 
proteins (see figure 4.1 ). 
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4.3.2 Antigen recognition by IgM antibodies 
Most of parasite antigens were recognised by at least some of the sennn samples from 
the resistant and susceptible groups. Sera from control individuals did not rccognisc any 
parasite antigens. 
Differences in antigen recognition between resistant and susceptible groups 
Before treatment, sera from resistant individuals showed more frequent recognition of 
antigens at 170 (13%), 150 (270/o), 133 (27%), 123 (275/o), 95 (175/6), 84 (27%), 78 
(14%), 74 (18%), 65 (14%), 52-54 (29%), 45-47 (46%), 42 (12%) and 37kDa (27%) 
than the recognition by the susceptible group. Sera from susceptible individuals showed 
more frequent recognition of antigens at 23 (12%) and 16-18kDa (39%) than the 
resistant group. 
Three months after treatment with PZQ, sera from resistant individuals showed more 
frequent recognition of antigens at 123 (13%), 95 (25vo), 84 (381/6), 78 (30%), 74 
(26%), 4547 (42%), 42 (IM), 37 (26%) and 34kDa (13%) and less frequent 
recognition of antigens at 150 (80/o), 26 (20%), 23 (13%), 16-18 (26%) and 13kDa 
(18%) than the recognition by the susceptible group. 
After exposure to re-infection, sera from resistant individuals showed more frequent 
recognition of antigens at 186 (14%), 170 (14%), 95 (17%), 84 (30'/o), 65 (29%), 52-54 
(47%) and 13kDa (6%) and less frequent recognition of antigens at 34 (10%), 28-30 
(29%) and 23kDa (12%) than the recognition by the susccptiblc group. 
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Table 4.1 Percentage recognition of antigen bands in resistant and susceptible groups at different 
time points. 
The percentage recognition of different S. haernatobiurn antigens by sera from resistant 
(R) and susceptible individuals (S) prior to treatment (Pre-ttt), three months aftcr 
treatment with PZQ (Post-ttt) and after exposure to reinfection (Rcino. (Note that the 
table is continued over the next page). 
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Impact of treatment and re-infection on antigen recognition 
After treatment with PZQ, sera from resistant individuals showed increased frequency 
in the recognition of antigens at 34 (14%) and 28-3OkDa (21%) and less frequent 
recognition of antigens at 170 (21%), 150 (36%), 133 (21%), 123 (14%), 84 (14%), 52- 
54 (21%) and l3kDa (14%) than the recognition patterns prior to treatment. Sera from 
susceptible individuals showed more frequent recognition of antigens at 65 (17vo), 52- 
54 (17%), 45-47 (17%), 28-3 0 (16%) and 26kDa (25%) and less frequent recognition of 
antigens at 84kDa (25%) than the recognition patterns of the same individuals prior to 
treatment (see figure 4.3). 
After exposure to re-infection, sera from resistant individuals showed more frequent 
recognition of antigens at 186 (14%), 170 (14%) and 52-54 (41%) and less frequent 
recognition of antigens at 133 (14%), 123 (14Vo), 45-47 (2lVo), 42 (14%), 37 (21%), 34 
(14%) and 28-3OkDa (28%) than the recognition patterns of the same individuals three 
months after treatment. Sera from susceptible individuals showed more frequent 
recognition of antigens at 78 (17%), 74 (25%), 45-47 (18%), 34 (8%) and 34kDa (8%) 
and less frequent recognition of antigens at 65 (17%), 52-54 (33%), 26 (25%), 16-18 
(24%) and l3kDa (17%) than the recognition patterns three months after treatment. 
When comparing the recognition pattern after exposure to re-infection with the pre- 
treatment recognition, sera, from resistant individuals showed more frequent recognition 
of antigens at 186 (140/o), 65 (14%) and 52-54kDA (21%) and less frequent recognition 
of antigens at 170 (70/o), 150 (36%), 133 (36%), 123 (29%), 84 (14%), 45-47 (22%) and 
37kDa (14%) than the recognition patterns of the same individuals prior to treatment. 
Sera from susceptible individuals showed more frequent recognition of antigens at 74 
(17%), 4547 (330/o), 37 (17%) and 28-3OkDa (17%) and less frequent recognition of 
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antigens at 186 (80/o), 84 (17%), 52-54 (17%), 16-18 (24%) and l3kDa, (17%) than the 
recognition prior to treatment (see figure 4.2). 
These results showed that the effect of treatment with PZQ on the pattern of recognition 
of parasite antigens in both resistant and susceptible individuals (and groups) was 
heterogeneous. However, sera from resistant individuals showed less frequent 
recognition of antigens of high molecular weights (123 to 170kDa) after treatment with 
PZQ. After exposure to re-infection, while sera from susceptible group showed more 
frequent recognition of antigens at 45-47 (33%) and 37kDa (17%) compared to the 
recognition before treatment, sera from resistant individuals showed less frequent 
recognition of the same antigens (22% and 14%, respectively) as well as of antigens at 
molecular masses between 123 and 150kDa. On the other hand, while sera from 
resistant individuals showed more frequent recognition of antigens at 186 and 52- 
54kDa, sera from susceptible individuals showed less frequent recognition of the same 
antigens compared to the recognition before treatment. 
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Figure 4.2 Differences in the IgM recognition pattern after exposure to reinfection compared to the 
recognition pattern prior to praziquantel treatment. 
The percentage recognition prior to treatment was extracted from the percentage 
recognition after exposure to infection in both resistant and susceptible groups and the 
differences plotted. 
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Figure 4.3 Differences in the IgM recognition pattern three months after praziquantel treatment 
compared to the recognition pattern prior to treatment. 
The percentage recognition prior to treatment was extracted from the percentage 
recognition after treatment in both resistant and susceptible groups and the differences 
plotted. 
4.3.3 Antigen recognition by total IgG antibodies 
Most of parasite antigens were recognised by at least some of the serum samples from 
the resistant and susceptible groups. Sera from control individuals did not recognise any 
parasite antigens. 
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Differences in antigen recognition between resistant and susceptible groups 
Before treatment, there was a general trend of more frequent recognition of parasite 
antigens by sera from the resistant group than from the susceptible group. The marked 
differences were in the recognition of antigens at 95 (101/6), 78 (15%), 74 (19%), 65 
(42Vo), 52-54 (29%), 45-47 (39%), 42 (19%), 37 (271/o), 28-30 (30%) and l3kDa (10%). 
However, sera from susceptible individuals showed more frequent recognition of 
antigens at 34 (19%) and 26kDa (35%) compared to the recognition patterns of the 
resistant group. 
After treatment with PZQ, the pattern of recognition was altered. Sera from susceptible 
individuals showed more frequent recognition of antigens at 186 (17'/o), 150 (10%), 133 
(121/6), 123 (20%), 95 (14%), 84 (11%), 42 (14%), 34 (11%), 28-30 (13%), 26 (20%), 
23 (15%), 20 (15%) and 16-18kDa (45%) than the recognition by the resistant group. 
Sera from resistant individuals showed more frequent recognition of antigens at 65 
(I I O/o) and 45-47kDa (17%) than the susceptible group. 
After exposure to re-infection, sera from susceptible individuals showed more frequent 
recognition of antigens at 123 (IOVo), 95 (21%), 84 (33Vo), 78 (26%), 74 (21%), 45-47 
(20%), 34 (10%) and 26kDa (26%) than the recognition patterns of the resistant group. 
Sera from resistant individuals showed more frequent recognition of antigens at 65 
(120/6), 52-54 (10%) 23 (11%) and 20kDa (14%) than the susceptible group. 
Impact of treatment and re-infection on antigen recognition 
After treatment with PZQ, sera from resistant individuals showed more frequent 
recognition of antigens at 78 (14%) and 26kDa (14%) and less frequent recognition of 
antigens at 186 (7%), 170 (7%), 95 (7%), 65 (14%), 28-30 (44%), 23 (7%), 20 (21%), 
16-18 (7%) and 13kDa (7%) than sera taken from the same individuals prior to 
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treatment. Sera from susceptible individuals showed an increased frequency in the 
recognition of antigens after treatment compared with pre-treatment. Differences were 
greatest for the recognition of antigens at 186 (17%), 133 (17%), 123 (17%), 95 (17%), 
78 (33%), 74 (25%), 65 (170/o), 52-54 (30%), 45-47 (17vo), 42 (33%), 37 (25%), 23 
(17%) and 16-18kDa (32%) (see figure 4.5). 
After exposure to re-infection, resistant individuals showed a general pattern of 
decreased recognition of parasite antigens. They showed less frequent recognition of 
antigens at 133 (141/o), 123 (14%), 84 (140/6), 78 (141/o), 74 (7%), 4547 (24%), 42 
(14%) and 26kDa (14%) and more frequent recognition of the antigen at 20kDa (14%) 
compared to the recognition patterns of the same individuals three months after 
treatment. Sera from susceptible individuals, also, showed a general pattern of 
decreased recognition of antigens than post-treatment. They showed less frequent 
recognition of antigens at 186 (17%), 150 (17%), 133 (25%), 123 (25%), 52-54 (17vo), 
42 (25%), 23 (33%), 20 (17%) and 16-18kDa (39%) and more frequent recognition of 
antigens at 84 (8%), 78 (80/6), 74 (8%) and 45-47kDa (10%) than the recognition 
patterns of the same individuals three months after treatment. 
When comparing the recognition pattern after exposure to re-infection with the pre- 
treatment recognition, sera from resistant individuals showed a decreased recognition of 
most antigens after exposure to re-infection. T'hey showed less frequent recognition of 
antigens at 123 (14%), 95 (14%6), 84 (14%), 74 (7%), 65 (21%), 4547 (340/0), 42 (14VO), 
37 (7%), 28-30 (42%) and 23kDa (14%) compared to the recognition patterns of the 
same individuals prior to treatment. Sera from re-infected susceptible individuals 
showed increased frequency in the recognition of antigens at 95 (17%), 84 (170/6), 78 
(42%), 74 (33%), 65 (8%), 52-54 (IM), 45-47 (25%) and 37kDa (17%) and less 
frequent recognition of antigens at 34 (IM), 23 (17%) and 20kDa (17%) compared to 
the recognition prior to treatment (see figure 4.4). 
159 
These results showed that after treatment with PZQ, while sera from resistant 
individuals showed a general pattern of decreased frequency of recognition, sera from 
susceptible individuals showed increased frequency in the recognition of most antigens 
after treatment compared to the recognition prior to treatment. Furthermore, while sera 
from re-infected susceptible individuals showed increased frequency in the recognition 
of antigens at molecular masses between 37 and 95kDa (especially the 78,74 and 45- 
47kDa) sera from resistant individuals exposed to re-infection during the same period 
showed less frequent recognition of the same antigens compared to the recognition prior 
to treatment. 
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Figure 4.4 Differences in the IgG recognition pattern after exposure to reinfection compared to the 
recognition pattern prior to praziquantel treatment. 
The percentage recognition prior to treatment was extracted from the perccntage 
recognition after exposure to infection in both resistant and susceptible groups and the 
differences plotted. 
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Figure 4.5 Differences in the IgG recognition pattern three months after praziquantel treatment 
compared to the recognition pattern prior to treatment. 
The percentage recognition prior to treatment was extracted from the percentage 
recognition after treatment in both resistant and susceptible groups and the differences 
plotted. 
4.3.4 Antigen recognition by IgGl antibodies 
Most of parasite antigens were recognised by at least some of the serum samples from 
the resistant and susceptible groups. Sera from control individuals did not recognise any 
parasite antigen. 
Differences in antigen recognition between resistant and susceptible groups 
Before treatment, sera from resistant individuals showed more frequent recognition of 
antigens at 95 (17%), 78 (10%), 74 (37%), 65 (21%), 52-54 (21%), 45-47 (23%) and 
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37kDa (13%) and less frequent recognition of antigens at 42 (12%), 34 (25%), 28-30 
37Vo), 26 (26%) and 23kDa, (14%) compared to the susceptible group. 
After treatment with PZQ, sera from susceptible individuals showed a generally 
increased frequency in the recognition of most antigens compared to the resistant group. 
The main differences were in the recognition of antigens at 78 (15%), 74 (200/6), 52-54 
(17%), 45-47 (45%), 42 (56%), 37 (1 Mo), 34 (25%), 26 (36%), 23 (24%), 16-18 (15%) 
and l3kDa (20%). 
After exposure to reinfection, sera from susceptible individuals showed more frequent 
recognition of antigens at 150 (17%), 133 (17%), 123 (181/6), 74 (11%), 45-47 (20%), 
42 (320/o), 34 (17%), 26 (26) and 16-18kDa (14%) compared to the resistant group. 
However, sera from resistant individuals showed more frequent recognition of antigens 
at 186 (14%), 170 (14%) and 95 (25%). 
Impact of treatment and reinfection on antigen recognition 
After treatment with PZQ, sera from resistant individuals showed more frequent 
recognition of antigens at 150 (14%), 133 (14%), 123 (14%) and 28-3OkDa (21%) and 
less frequent recognition of antigens at 52-54 (21%), 4547 (42%) and 42kDa (36%) 
compared to the recognition patterns of the same individuals prior to treatment. Sera 
from susceptible individuals showed increased recognition particularly of antigens at 
133 (250/6), 123 (25%), 78 (25%), 74(50%), 52-54 (170/6), 45-47 (25%), 37 (17%), 26 
(17%), 23 (17%), 20 (17Vo), 16-18 (25%) and l3kDa (25%) after treatment than prior to 
treatment (see figure 4.7). 
After exposure to re-infection, sera from resistant individuals showed more frequent 
recognition of antigens at 186 (14%), 170 (14%), 78 (14%) and 42kDa (7%) and less 
frequent recognition of antigens at 150 (14%), 133 (21%), 123 (14%), 65 (14%), 37 
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(14%), 28-30 (36%) and 16-18kDa (14%) compared to the recognition patterns of the 
same individuals after treatment. Sera from susceptible individuals showed decreased 
recognition after treatment especially of antigens at 133 (17%), 74 (17%), 52-54 (17%), 
45-47 (25%), 42 (17%), 37 (250/o), 28-30 (250/o), 26 (17%), 23 (17%), 20 (17%), 16-18 
(I 6Vo) and 13kDa (25%). 
When comparing the recognition pattern after exposure to reinfection with the pre- 
treatment recognition, sera from resistant individuals showed more frequent recognition 
of antigens at 78kDa (14%) and less frequent recognition of antigens at 74 (14%), 65 
(14%), 52-54 (22%), 4547 (24%), 42 (290/6), 37 (2 1 %) and 28-3 OkDa (14%) compared 
to samples taken from the same individuals prior to treatment. On the other hand, sera 
from susceptible individuals showed more frequent recognition of antigens at 123 
(I 7Vo), 78 (17%) and 74kDa (33%) and less frequent recognition of antigens at 42 (8%), 
37 (8%), 34 (8%) and 28-3OkDa (45%) compared to the recognition patterns prior to 
treatment (see figure 4-6). 
These results showed that while the effect of treatment with PZQ on the recognition 
pattern of the resistant individuals was heterogeneous, sera from susceptible individuals 
showed a general pattern of increased recognition of most antigens especially antigens 
of molecular masses between 34 and 74kDa as a direct result of treatment with 
praziquantel. After exposure to re-infection, scra from susceptible individuals showed 
more frequent recognition of antigens at 74 (33%), 65 (8%) and 4547kDa (81yo) 
compared to the recognition patterns prior to treatment. Sera from resistant individuals 
showed less frequent recognition of the same antigens (14,14 and 24%, respectively) 
than the recognition prior to treatment. 
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Figure 4.6 Differences in the IgGI recognition pattern after exposure to reinfection compared to 
the recognition pattern prior to praziquantel treatment. 
The percentage recognition prior to treatment was extracted from the percentage 
recognition after exposure to infection in both resistant and susceptible groups and the 
differences plotted. 
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Figure 4.7 Differences in the IgGI recognition pattern three months after praziquantel treatment 
compared to the recognition pattern prior to treatment. 
The percentage recognition prior to treatment was extracted from the percentage 
recognition after treatment in both resistant and susceptible groups and the differences 
plotted. 
4.3.5 Antigen recognition by IgG2 antibodies 
Few proteins from the parasite were recognised by IgG2 in the serum samples from the 
resistant and susceptible groups. IgG2 antibodies in sera from control indIvIduals did 
not recognise any parasite antigen. 
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Differences in antigen recognition between resistant and susceptible groups 
Before treatment with PZQ, sera from resistant individuals showed more frequent 
recognition of antigens a 133 (7Vo), 123 (7%), 74 (14%), 45-47kDa (7%) compared to 
the recognition pattern in the susceptible individuals. 
After treatment with PZQ, sera from susceptible individuals showed more frequent 
recognition of antigens at 150 (8%), 133 (8%), 123 (8/o), 45-47 (17? /o), 42 (17%o), 28-30 
(17%) and 23 (8%) and less frequent recognition of antigens at 52-54 (7%) compared to 
the recognition pattern in the resistant individuals. 
After exposure to reinfection, sera from susceptible individuals showed more frequent 
recognition of antigens at 84 (11%), 28-30 (8%) and 26 (8%) compared to the 
recognition pattern in the resistant individuals. 
Impact of treatment and reinfection on antigen recognition 
After treatment with PZQ, sera from susceptible individuals showed more frequent 
recognition of most antigens particularly of antigens at 78 (17%), 74 (17%), 45-47 
(17%), 42 (17%) and 28-3OkDa (17%) compared to the recognition patterns of the same 
individuals prior to treatment. Sera from resistant individuals showed more frequent 
recognition of antigens at 78 (14%) and 52-54kDa (7%) and less frequent recognition of 
antigens at 133 (71/o) and 123 (7%) compared to the recognition patterns of the same 
individuals prior to treatment (see figure 4.9). 
After exposure to reinfection, sera from resistant individuals showed less frequent 
recognition of antigens at 78 (70/o), 74 (7%), 52-54 (7%), and 4547kDa (7%) and more 
frequent recognition of the antigen at 42kDa (7%) compared to the recognition pattern 
of the same individuals after treatment. Sem from susceptible individuals showed less 
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frequent recognition of most antigens especially of antigen at 45-47 (17%) and more 
frequent recognition of antigens at 84 (8%) and 26kDa (8%) compared to the 
recognition pattern after treatment. 
When comparing the recognition pattern after exposure to reinfection with the pre- 
treatment recognition, sera from susceptible individuals showed more frequent 
recognition of antigens at 84 (8%), 78 (8*/o), 74 (8%), 42 (M), 28-30 (8%) and 26kDa 
(8%) compared to samples taken from the same individuals prior to treatment. Sera 
from resistant individuals showed more frequent recognition of antigens at 78 (8%) and 
42kDa (8%) and less frequent recognition of antigens at 133 (8%), 123 (8%), 74 (M) 
and 45-47kDa (8%) compared to the recognition patterns prior to treatment (see figure 
4.8). 
These results showed that while the effect of treatment with PZQ on the recognition 
pattern of the resistant individuals was heterogeneous, there was a general pattern of 
increased IgG2 recognition of parasite antigens in the susceptible individuals as a direct 
result of treatment with praziquantel. After exposure to re-infection, sera from 
susceptible individuals showed more fi-equent recognition of antigens at 74kDa 
compared to the recognition patterns prior to treatment. Sera from resistant individuals 
showed less frequent recognition of the same antigen. 
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Figure 4.8 Differences in the IgG2 recognition pattern after exposure to reinfection compared to 
the recognition pattern prior to praziquantel treatment. 
The percentage recognition prior to treatment was extracted from the percentage 
recognition after exposure to infection in both resistant and susceptible groups and the 
differences plotted. 
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Figure 4.9 Differences in the IgG2 recognition pattern three months after praziquantel treatment 
compared to the recognition pattern prior to treatment. 
The percentage recognition prior to treatment was extracted from the percentage 
recognition after treatment in both resistant and susceptible groups and the differences 
plotted. 
4.3.6 Antigen recognition by IgG3 antibodies 
Most of the proteins from the parasite were recognised by IgG3 in at least some of the 
serum samples from the resistant and susceptible groups. IgG3 antibodies in sera from 
control individuals did not recognise any parasite antigen. 
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Differences in antigen recognition between resistant and susceptible groups 
Before treatment with PZQ, sera from resistant individuals showed more frequent 
recognition of proteins at 123 (5%), 78 (6%), 65 (20%), 52-54 (28%), 45-47 (30%), 42 
(12%) and 37kDa (18%) compared to sera from the susceptible individuals. The 
susceptible individuals, on the other hand, showed more frequent recognition of 
antigens at 186 (17%), 150 (12%), 95 (7%), 84 (27%), 74 (5%), 28-30 (43%), 26 (12%), 
23 (18%), 16-18 (29%) and II kDa (8%) compared to the resistant group. 
Three months after treatment with PZQ, sera from resistant individuals showed more 
frequent recognition of antigens at 170 (21%) and 65kDa. (27%) compared to the 
susceptible group. Sera from susceptible individuals showed more frequent recognition 
of antigens at 74 (180/6), 52-54 (14%), 45-47 (11%), 42 (19%), 26 (13%), 23 (20%), 16- 
18 (17%) and l3kDa (20%) compared to the resistant group. 
After exposure to infection, sera from susceptible individuals showed more frequent 
recognition of antigens at 95 (20%) and 74kDa (20%) compared to the resistant group. 
Sera from resistant individuals showed more frequent recognition of antigens at 186 
(7%), 170 (70/o), 84 (13%), 78 (14%), 65 (14%), 52-54 (3 1 O/o), 45-47 (11 O/o) and 23kDa 
(19%) compared to the susceptible group. 
Impact of treatment and reinfection on antigen recognition 
IgG3 recognition of S haematobium adult wonn antigens was altered in both resistant 
and susceptible groups after treatment with praziquantel. Three months after the 
treatment, sera from resistant individuals showed more frequent recognition of antigens 
at 186 (14%), 170 (14%), 28-30 (43%) and 23kDa (14%) and less frequent recognition 
of antigens at 95 (14%), 78 (14%), 74 (21%), 52-54 (42%), 45-47 (27%), 42 (14%) and 
37kDa (14%) compared to the frequency of recognition patterns of the same individuals 
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prior to treatment. Sera from susceptible individuals showed more frequent recognition 
of antigens at 45-47 (8/o), 42 (17%), 23 (17%) and l3kDa (17%) and less frequent 
recognition of antigens at 186 (80/o), 150 (170/6), 95 (17%), 84 (33%) and 28-3OkDa 
(M) compared to the recognition patterns observed with sera taken before treatment 
(see figure 4.11). 
After exposure to re-infection, sera from resistant individuals showed more frequent 
recognition of antigens at 78 (14%), 74 (14%), 52-54 (28%), 4547 (21%), 37 (14%), 23 
(14%) and 16-18kDa (14%) and less frequent recognition of antigens at 170 (14%), 150 
(14%), 133 (21%), 123 (21%) and 65kDa (21%) compared to the recognition patterns of 
the same individuals after treatment. Sera from susceptible individuals showed more 
frequent recognition of antigens at 74 (17%) and 37kDa (17%) and less frequent 
recognition of antigens at 133 (17Vo), 123 (17%), 52-54 (16%), 42 (17%), 26 (17%), 23 
(25%) and l3kDa (17%) compared to the recognition observed after treatment. 
When comparing the recognition after exposure to re-infection with the pre-treatment 
values, sera taken from resistant individuals after exposure to re-infection showed more 
frequent recognition of antigens at 186 (70/o), 84 (7%), 28-30 (35%) and 23kDa (29%) 
and less frequent recognition of antigens at 150 (141yo), 133 (14%), 123 (140/o), 95 
(2 10/6), 74 (7%), 65 (14%) and 4547kDa (14%) compared to the recognition patterns of 
the same individuals prior to treatment. Sera taken from susceptible re-infected 
individuals showed more frequent recognition of antigens at 74 (8%) and 37kDa (17%) 
and less frequent recognition of antigens at 186 (17%), 150 (25%), 133 (17%), 84 
(33%), 52-54 (17%), 28-30 (M), 23 (8%) and 16-18kDa (17%) compared to the 
recognition patterns prior to treatment (see figure 4.10). 
These results illustrate that the effect of praziquantel treatment on the humoral immune 
response to schistosome antigens is heterogeneous with much variation among 
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individuals. However, sera from resistant individuals showed a trend of decreased 
recognition against antigens of medium molecular masses (37 to 123kDa) while sera 
from susceptible individuals showed a trend of decreased recognition against antigens 
of higher molecular masses (74 to 186kDa). After 12 months of exposure to re- 
infection, sera from resistant individuals showed increased recognition of antigens at 
28-30 (35%) and 23kDa (29%) compared to the recognition prior to treatment. Sera 
from susceptible individuals showed less frequent recognition of the same antigens after 
the same period of exposure. 
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Figure 4.10 Differences in the IgG3 recognition pattern after exposure to reinfection compared to 
the recognition pattern prior to praziquantel treatment. 
The percentage recognition prior to treatment was extracted from the percentage 
recognition after exposure to infection in both resistant and susceptible groups and the 
differences plotted. 
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Figure 4.11 Differences in the IgG3 recognition pattern three months after praziquantel treatment 
compared to the recognition pattern prior to treatment. 
The percentage recognition prior to treatment was extracted from the percentage 
recognition after treatment in both resistant and susceptible groups and the differences 
plotted. 
4.3.7 Antigen recognition by IgG4 antibodies 
After western blotting and probing, the percentage of serum samples of each group 
recognising each antigen band was calculated. Sera from control individuals did not 
recognise any parasite antigen. 
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Differences in antigen recognition between resistant and susceptible groups 
Most of the proteins from the parasite were recognised by at least some of the serum 
samples from the resistant and susceptible groups. Before treatment, the percentages of 
recognition of different antigens were generally higher in the susceptible group than in 
the resistance group with antigens of molecular masses of 52-54 (31%), 4547 (52%), 
34 (35%), 28-30 (30%), 26 (27%) and 16-18kDa (33%) being the most frequently 
recognised. Only antigens of 170 (6%) and 65kDa (14%) were recognised more 
frequently by resistant group than by the susceptible group. 
Three months after treatment with PZQ, sera from susceptible individuals showed a 
general pattern of more frequent recognition of most antigens than the resistant group 
particularly of antigens at 74 (18'Yo), 45-47 (20'/o), 37 (26%), 34 (331yo), 26 (37%), 20 
(19%), 13 (38%) and IlkDa (26%). Sera from resistant individuals showed more 
frequent recognition of antigens at 170 (21%) and 150kDa (19%) compared to the 
susceptible group. 
After exposure to reinfection, sera from the susceptible group still showed more 
frequent IgG4 antibody recognition of a wide range of antigens than the resistant group. 
However the greatest differences were in the recognition of antigens at 74 (33%), 4547 
(40%) and 42 (33'Yo), 28-30 (25Vo), 16-18 (30%), 13 (54%) and II kDa (33%). 
Impact of treatment and reinfection on antigen recognition 
After treatment with PZQ, sera from resistant individuals showed an increased 
frequency of recognition of antigens at 170 (71/o), 150 (21%), 133 (14%), 123 (7vo), 95 
(14%), 45-47 (70/o), 42 (14%), 26 (7%) and 16-18kDa (22%) and a decreased frequency 
of recognition of antigens at 84 (7%), 74 (14%), 34 (7%) and 13kDa (14%) compared to 
the frequency of recognition of antigens by sera from the same patients prior to 
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treatment. Sem from susceptible patients showed more frequent recognition of antigens 
at 133 (17), 123 (80/6), 65 (8), 42 (17Vo), 37 (259/6), 26 (170/6), 23 (80/6), 20 (80/o), 13 
(8%) and II kDa (17%) compared to the recognition pattern of the resistant group (see 
figure 4.13). 
After exposure to infection after PZQ treatment, sera from resistant individuals showed 
a decreased frequency of recognition of most antigens except antigens at 84 (7'Yo) and 
26kDa (7%) which were recognised more frequently after exposure to infection 
compared to the recognition pattern after treatment. The greatest reductions were in the 
recognition of antigens at 150 (36%), 133 (29%), 123 (21%), 45-47 (37%), 42 (21%), 
28-30 (29%) and 16-18kDa (37%). Sera from susceptible patients showed decreased 
frequency in the recognition of antigens at 133 (25%), 123 (17%), 37 (25vo), 34 (17%), 
26 (33%) and 23kDa (25%) and increased recognition of antigens at 170 (8%), 84 
(17%), 74 (8%), 42 (8%) and l3kDa (80/6). 
When comparing the recognition of antigens by sera of infected individuals before 
treatment and after exposure to re-infection, sera from resistant individuals maintained a 
reduced frequency of recognition of most antigens after exposure to re-infection except 
the antigens at 95 (7%) and 26kDa (141/o) which showed an increase in the percentage 
recognition. On the other hand, sera from susceptible individuals showed reduction in 
the percentage recognition of all protein bands except those of 84 (8%), 42 (25'Yo), 13 
(17%) and II kDa (17%) (see figure 4.12). 
These results showed that after treatment of S haemalobium infection with praziquantcl 
there was heterogeneity in the effect of treatment on IgG4 isotypc reactivity. AfIcr 
treatment, some antigen bands were rccognised more frequently and others less 
frequently than by sera taken prior to treatment. After exposure to rc-infcction, 
individuals who were not re-infected were considered resistant and their serum samples 
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showed a decreased percentage recognition of antigens at 42,13 and II kDa and 
increased percentage recognition of the 26kDa (14%) antigens compared to sera from 
susceptible individuals who were reinfected during the same transmission period. 
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Figure 4.12 Differences in the IgG4 recognition pattern after exposure to reinfection compared to 
the recognition pattern prior to praziquantel treatment. 
The percentage recognition prior to treatment was extracted from the percentage 
recognition after exposure to infection in both resistant and susceptible groups and the 
differences plotted. 
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Figure 4.13 Differences in the IgG4 recognition pattern three months after praziquantel treatment 
compared to the recognition pattern prior to treatment. 
The percentage recognition prior to treatment was extracted from the percentage 
recognition after treatment in both resistant and susceptible groups and the differences 
plotted. 
4.4 Discussion: 
While several control measures have been exploited to control schistosome infection 
chemotherapy now underpins virtually all major control programmes. Concern for the 
relatively limited use of anthelminthics in areas that are endemic for the major parasitic 
worrns has led the World Health Assembly to adopt resolution 54.19 to encourage 
WHO member states to seek to achieve 75% deworining of schoolchildren by 2010. In 
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response to the resolution, a number of countries in sub-Saharan Africa have 
implemented chemotherapy-based control activities. However, the occurrence, though 
limited, of schistosome strains with lower susceptibility to chemotherapy and the 
occurrence of reinfection after chemotherapy are major concerns for the long-term 
sustainability of chemotherapy as the sole tool for control (Hagan and Sharaf, 2003). 
Although the most important impact of chemotherapy is the removal of worms, eggs or 
larval stages that are responsible for the induction of pathology, recent studies have 
indicated that anti-schistosomal drugs particularly praziquantel, may alter the immune 
responses to infection. For example children, considered to be potentially susceptible to 
reinfection had their immune responses profiles modified after treatment with 
praziquantel in such a way that they were similar to those of adults considered to be 
resistant to reinfection (Mutapi et al., 1998; Mduluza et al., 2001). In addition there is 
strong evidence supporting the view that in communities treated with PZQ there was a 
decrease in the prevalence and intensity of infection which has obvious benefits for the 
population (Gryseels and Nkulikyinka, 1989; Talaat and Miller, 1998; Abu-Elyazeed el 
al., 1998; Campagne et al., 200 1). 
It is generally accepted that in order to achieve satisfactory, long-term and sustainable 
control of schistosome infection, several control measures will have to be employed. 
Vaccination has been used as a very powerful tool for the control of many bacterial and 
viral diseases. Over the last two decades, several attempts have been made to develop 
and test an efficacious anti-schistosome vaccine. The complex life cycle and the 
antigenic complexity of each life stage as well as the complex network of immune 
responses elicited by schistosome infection are major obstacles to the development of 
such a vaccine. Nevertheless, a number of promising vaccine antigens have been 
identified. Some have been tested in animal models, and at least one has reached phase 
Il clinical trials for safety and immunogcnicity in humans. Vaccine candidate antigens 
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have been identified in a number of ways, by screening DNA libraries with serum from 
infected animals or animals that had been immunised against infection with irradiated 
parasites. Serum from such animals, or from humans naturally exposed to infection (and 
considered to be resistant to infection), has also been used to screen for parasite antigen 
recognition by immunoprecipitation using protein A or protein 0 Sepharose or that have 
been separated by SDS-PAGE, in one or two dimensions and blotted to nitrocellulose. 
The identification of vaccine candidate antigens using human serum has been facilitated 
by attempts to determine immunological correlates of resistance to reinfection in 
immunoepidemiological studies in humans (Butterworth et al., 1996). Serum samples 
from studies that have demonstrated a degree of resistance to infection in naturally 
exposed individuals has obvious value for screening schistosome antigens. 
The serum samples exploited in the present study were obtained from an 
immunoepidemiological study by Hagan and his colleagues (1991) that gave the first 
clear immune correlation between the parasite specific IgE and IgG4 and the resistance 
or susceptibility to reinfection with S. haematobium. They reported that parasite specific 
IgE correlated with resistance to reinfection while IgG4 correlated with susceptibility to 
reinfection (Hagan et al., 1991). The present study was designed to investigate the 
differences in antigen recognition between potentially resistant individuals and 
potentially susceptible individuals after exposure to reinfection with S. haemaloblum. 
The effect of treatment with praziquantel on the immune responses of resistant and 
susceptible individuals was also investigated. 
Before discussing the results of the present study, it is important to note that the 
molecular weights of the proteins reported herein may vary slightly from the reported 
molecular weights obtained in other studies. 17his is due to the limitations of the SDS- 
PAGE technique in making precise determinations of molccular weights of proteins. 
Even with the two dimensional SDS-PAGE and mass spectrometry, which is a far 
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superior technique in terms of accuracy of molecular weight determinations there is an 
error factor of up to 2% of the molecular weight of the identified protein (Berg et al., 
2002b). It is worth mentioning that schistosomes share most of their antigens as 
evidenced by their cross reactivity. Several studies confirmed the reactivity of sera or 
lymphocytes obtained from hosts infected with one schistosome species with antigenic 
preparations from the other schistosome species (Abdel-Hafez et aL, 1983; Barral-Netto 
et al., 1983; Amanor et al., 1996). Using immunoprecipitation techniques, it was 
reported that the immune responses of patients infected with S. mansoni or S. 
haematobium were so similar that differentiation could not be established easily 
(Norden and Strand, 1984). However, some species-specific antigens were identified for 
each schistosome species (Kelly et al., 1987; Amanor et al., 1996). 
The effect of treatment with PZQ on the recognition pattern of & haemajobium SWAP 
by IgM antibodies was heterogeneous in both resistant and susceptible individuals with 
some antigens being recogriised more frequently and others less frequently, three 
months after treatment, compared to the recognition pattern prior to treatment. However 
when the same individuals were exposed to reinfection, sera from infected individuals 
maintained more frequent recognition of antigens at 4547,42,37,34 and 28-3OkDa. 
Sera from resistant individuals recognised these antigens less frequently compared to 
the recognition three months after treatment or prior to treatment. One possible 
interpretation of these data is that the reduction in IgM recognition may be a 
contributory factor in rendering these individuals resistant to reinfection. In the 
susceptible individuals, the enhanced recognition of these antigens by IgM may 
compete with potentially-protective antibodies rendering these individuals susceptible 
to reinfection. These results and this interpretation arc consistent with the reported role 
of IgM as a blocking antibody (Butterworth et al., 1987; Ndhlovu el al., 1996). 
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Three months after treatment with PZQ, sera from susceptible individuals showed more 
recognition of almost all antigens except the 28-3OkDa antigen by IgGI antibody 
isotype compared to the recognition prior to treatment. When the same individuals were 
reinfected. they failed to maintain the higher levels of recognition and showed a further 
reduction in the recognition of the antigen of 28-3OkDa. The effect of treatment on the 
recognition pattern of sera from resistant individuals was heterogeneous. The greatest 
increase in the recognition was the recognition of the antigen at 28-3OkDa. However, 
the resistant individuals failed to maintain this increased recognition after exposure to 
reinfection. The boost in recognition of the 28-3OkDa antigens after treatment may have 
contributed to the observed protection. While the treatment boosted the responses it 
seems that it was insufficient to stimulate a long-term increase in antibodies against this 
antigen. Others have speculated that in order to acquire sufficient levels of protective 
antibody isotypes, several episodes of schistosome infection (Li el al., 2002) or repeated 
chemotherapy (Mduluza et al., 2001) may be required. 
After treatment with PZQ, the recognition of S. haematobium SWAP by IgG3 in sera 
from resistant and susceptible individuals showed heterogeneous changes. The most 
striking effects of treatment on the recognition pattern were increased frequency of 
recognition of antigens of 23 and 28-3OkDa of both resistant and susceptible 
individuals. However, while sera from resistant individuals maintain the increased 
recognition after exposure to reinfection, sera from susceptible individuals failed to 
maintain such response. These observations favour the possibility that PZQ may have, 
albeit temporarily, an immunising effect (Mutapi et al., 1998; Woolhousc and I lagan, 
1999; Mutapi et al., 2003). However, although the present study provided an evidence 
for this hypothesis, other factors may be involved in the difference in the immune 
responses between resistant and susceptible individuals. The resistant individuals (mean 
age 35±13.5 years) of the present study are significantly older than the susceptible 
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individuals (mean age 8.2±3 years). Ile protective response of the resistant individuals 
observed in the present study may result from prolonged experience of the immune 
system of those individuals with parasite antigens released from naturally dying 
parasites and repeated infection rather than the release of these antigens in response to 
enhanced parasite death by the chemotherapy (Hagan et al., 1985; Butterworth et al., 
1985; Woolhouse et al., 199 1; Fulford et al., 1992) or it may be attributed to age per se 
(van dam et al., 1996; Ouma et al., 1998). 
In the present study, the majority of antigens were less frequently recognised at all time 
points by IgG4 antibody isotype of sera from resistant individuals compared to sera 
from susceptible individuals. Although sera from both resistant and susceptible 
individuals showed heterogeneous changes in the recognition pattern in response to 
treatment with PZQ, the recognition of most antigens became less frequent after 
exposure to reinfection in sera from resistant individuals compared to susceptible 
individuals. These results agree with the proposed role of IgG4 as a blocking antibody 
during schistosome infections (Hagan et al., 1991; Demeure el al., 1993; Ndh1ovu et al., 
1996). Similar effects of treatment with PZQ on the recognition of S. mansoni SWAP 
by IgG4 antibody isotye were reported by Satti and colleagues. They reported that the 
resistant group maintained the same level of IgG4 to SWAP after treatment compared to 
a significant increase in the susceptible group (Satti el al., 1996). Furthermore, Mduluza 
and colleagues treated children aged under six years of age and living in a S. 
haematobium endemic area with praziquantel every eight weeks for two years. 
Chemotherapy reduced infection prevalence and mean intensity of infection. no 
immunoglobulin levels changed during the course of treatment with a shift towards 
'protective' mechanisms. The significant changes noted in some individuals were the 
drop in 'blocking' IgG2 and IgG4 whereas the 'protecting! IgA and IgGl levels 
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increased. However, the antibody profiles in the rest of the children remained generally 
unchanged throughout the study (Mduluza et aL, 2001). 
The recognition of the majority of antigens by total IgG antibodies were more frequent, 
prior to treatment with PZQ, in sera from resistant individuals compared to sera from 
susceptible individuals. Three months after treatment, the recognition pattern changed 
with most antigens being more frequently recognised by sera from susceptible 
individuals than resistant individuals. Because of the preponderance of IgG4 antibodies 
in the serum of infected individuals, the pattern of recognition obtained from the blots 
when assessing the total IgG antibody responses will be dominated by the antigens that 
are recognised by IgG4. In practice therefore the patterns of antigen recognition 
obtained for total IgG and IgG4 were virtually similar. 
Interestingly, some of the known vaccine candidates were highly immunogenic and 
frequently recognised by different antibody isotypes from the serum samples employed 
in the present study. The recognition of these vaccine candidates was different between 
resistant and susceptible individuals with some antigen specific antibody isotypcs being 
associated with resistance and others associated with susceptibility to reinfection. After 
exposure to reinfection, sera from resistant individuals showed a higher frequency of 
recognition of the antigen of 28-3OkDa by IgG3 antibody isotype compared to the 
susceptible individuals. The 28-3OkDa antigen band recognised in this study may 
correspond to glutathione-S-transferase (GSI) which has been idcntificd in all 
schistosome species as a major enzyme acting as an antioxidant and involved in 
detoxification of xenobiotics. GST is one of the leading vaccine candidate antigens. 
GST was tested in independent trials in animals that were coordinated by WHO. Like 
the other vaccine candidate antigens it failed to give greater than the 40% level of 
protection that had been set as the cut-off for success. Nonetheless in infected human 
populations, schistosome anti-fecundity immunity has been associated with JgA and 
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IgG3 responses (Riveau et al., 1998; Remoue et al., 2000) directed against GST. In 
phase I clinical trials it was found that following 3 injections of Mpg of S. 
haematobium GST in alum hydroxide as adjuvant (Bilhvax), a strong IgG inunune 
response was elicited in immunised individuals. Analysis of isotypic profile revealed 
high levels of IgGl, IgG3 and low levels of IgG2 and IgA (Capron et aL, 2002). 
On the other hand, after exposure to reinfection, sera from susceptible individuals 
showed higher recognition of the 28-3OkDa antigen by the IgM, IgG2 and IgG4 
antibody isotypes compared to the resistant individuals. These results are in agreement 
of those of Al-Shcrbiny and colleagues (2003). They investigated the cellular and 
humoral immune responses of peripheral blood lymphocytes from individuals resistant 
or susceptible to reinfection with S. manson! in response to in vitro stimulation with 
SM28-GST. They reported that increased levels of antigen specific IgA and IgE were 
associated with resistance while IgG2 and IgM antibodies were associated with 
susceptibility to infection (Al Sherbiny el aL, 2003). The increased IgG4 recognition in 
the susceptible group may interfere with the neutralising effects of the protective 
isotypes rendering them more susceptible to reinfection. It has been demonstrated that 
IgG4 antibodies may compete with the protective antibodies for the recognition of the 
same antigens and thus act as blocking antibodies (Butterworth el al., 1987; 1 lagan el 
al., 1991; Demeure et aL, 1993). 
In the present study, sera from resistant individuals exposed to reinfection showed more 
frequent recognition of antigens at 23kDa by IgG3 antibody compared to scra from 
susceptible individuals. These results appear to parallel those of Webster and collcagucs 
(1996). They reported that the recognition of the rSm22 (rSm22.6) by human IgG3, 
IgG4, IgE and IgA was increased in a group of naturally exposed individuals considercd 
to be resistant to reinfection. However, only the IgE antibody response against this 
antigen was significantly correlated with resistance to reinfection aftcr treatment 
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(Webster et al., 1996). In vitro stimulation of lymphocytes from the peripheral blood of 
individuals resistant to infection with S. mansoni showed preferential production of 
IgG3 in response to stimulation with multiple antigenic pepticles (MAP3) from the 
integral membrane antigen Sm23 (Al Sherbiny et aL, 2003). 
in the present study, IgM, IgG3 and IgGI antibodies of scra from resistant individuals 
showed more frequent recognition of the antigen of 84kDa compared to the susceptible 
individuals. The 84kDa antigen could be the S. haematobium equivalent of the calcium 
binding protein (Calpain Sm-p80) which was reported by Hota-Michell and colleagues 
(1997). They reported that recombinant Sm-p80 provided a 29-39% reduction in worm 
burden when they immunised mice and challenged them with S mansoni. The 
recombinant Sm-p80 was recognised by IgA, 19M, IgGl, and IgG3 isotype antibodies 
found in S. mansoni-infected humans (Hota-Mitchell et al, 1997). DNA immunisation 
using Sm-p80 with or without plasmids encoding granulocyte-macrophage colony- 
stimulating factor (GM-CSF) and interleukin-4 (IL-4) were tried in mice. 'Fhe protection 
achieved with administration of GM-CSF DNA with Sm-p80 DNA was associated with 
distinct increases in total IgG and IgGI titers, whereas the coadministration of IL-4 
DNA with Sm-p80 DNA resulted in a slight elevation of IgG I and IgG3 titers (Siddiqui 
et al., 2003). 
After exposure to reinfection, sera from resistant individuals showed more frequent 
recognition of the antigen of 65kDa by IgM and IgG3 compared to sera from 
susceptible individuals. It is possible to speculate that this antigen band may correspond 
to the 68kDa antigen from S. mansoni (SmW68) reported by King and colleagues. Tlicy 
found a negative correlation between intensity of infection and the recognition of tile 
SmW68 antigen by IgM antibodies in chronically infected individuals (King et al., 
1989). 
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One of the most frequently recognised antigen bands in the present study was that of 
95kDa which is most likely the S. haematobium equivalent of paramyosin (97kDa). 
Paramyosin is a myofibrillar protein found exclusively in invertebrates and has been 
identified in all schistosome species (McManus, 1999). The 95kDa antigen was highly 
recognised by all antibody isotypes of sera from both susceptible and resistant 
individuals. However, sera form resistant individuals showed more frequent recognition 
of the 95kDa band by IgG1 and IgM and less frequent recognition by total IgG and 
IgG3 compared to the susceptible individuals, after exposure to reinfection. In a small 
community infected with S. japonicum there was a higher recognition of paramyosin by 
IgA antibodies in older putatively resistant individuals (Hernandez et aL, 1999). 
Futhermore, oral immunisation of mice with recombinant S. japonicum paramyosin 
elicited significantly increased levels of antigen specific IgGI, IgG2a, IgG2b and IgM 
(Kalinna and McManus, 1997). In vitro stimulation of peripheral blood lymphocytes 
from infected individuals with Sm97-paramyosin revealed association bctwccn antigen 
specific IgE and resistance and between total IgG, IgG I, IgG2, IgG3, IgG4 and IgA and 
susceptibility to reinfection (Al Sherbiny et al., 2003). 
Ile antigen band of 52-54kDa was represented as a strong band on the SDS-PAGE. 
After exposure to reinfection, sera from resistant individuals showed more frcqucnt 
recognition of the 52-54kDa band by IgG3 and IgM antibodics compared to the 
susceptible individuals. This antigen band may correspond to the PR52-filamin. In mice 
vaccinated with DNA of the partial coding sequence of the structural protein, filamin 
lead to 50% protection. The protection offered was associated with clcvatcd IcvcIs of 
total IgG and IgG2a antibodies (Cook et al., 2004). 
The 37kDa band in the present study which May correspond to glyccraldchydc-3- 
phosphate dehydrogenase (G3PDH) was more frequently recogniscd by IgM and JgG4 
antibody isotypes of sera from susceptible individuals than resistant individuals. After 
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exposure to reinfection, while sera from the susceptible individuals showed more 
frequent recognition of the 37kDa antigen by total IgG, IgGl and IgG3 isotypes 
compared to the recognition prior to treatment, sera from the resistant individuals 
showed less recognition. However when the percentage recognition of both resistant 
and susceptible individuals was directly compared, there was a tendency of more 
frequent recognition of this antigen by IgGl and IgG3 isotypes for sera taken from the 
resistant individuals. I'liese results are correspondent to those of EI-Ridi and colleagues. 
They investigated the recognition patterns of the recombinant G3PDII as well as 
different peptides from this molecule. They used sera from adolescent individuals 
resistant or susceptible to reinfection with schistosome infection. The antigen was 
recognised more frequently by IgG4 and IgM antibody isotypes of sera from susceptible 
individuals while there was more recognition by IgG, IgGl and IgG3 isotypes of sera 
from resistant individuals (El Ridi et aL, 2001a; El Ridi el al., 2001b). Similarly, IgGl 
antibodies from sera of resistant individuals recogniscd one of the B cell dcten-ninants 
of S. mansoni G3PDH (Sm 37-5) more than sera from susceptible individuals (Argiro et 
al., 2000). 
There were some other antigens that were recogniscd with patterns that might be 
expected of antigens that were contributing to protection. For instance, the antigen of 
16-18kDa was more frequently recogniscd by the IgG3 isotypc of scra from resistant 
individuals after exposure to reinfection compared to the susceptible group. Scra from 
the susceptible group showed more frequent recognition of the same antigen by JgG4 
and IgM antibodies after exposure to reinfection. Ibis antigen may correspond to PN 18- 
cyclophillin. Al Sherbiny and others investigated the in vitro response of peripheral 
blood lymphocytes from resistant and susceptible individuals after stimulation with 
pNI8-cyclophillin. Resistance to reinfection was correlated with increased levels of 
antigen specific IgGlantibody isotye (Al Sherbiny et al., 2003). 
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Furthermore, sera from susceptible individuals showed more recognition of antigen of 
45-47kDa by total IgG, IgGl, IgG3 and IgM antibodies after exposure to reinfection 
compared to sera from resistant individuals. This antigen may correspond to PIAS- 
phosphoglycerate kinase. After in vitro stimulation of peripheral blood lymphocytes 
from resistant and susceptible individuals by PL45-phosphoglyccrate kinase revealed 
correlation of IgE with resistance and IgGI with susceptibility to reinfection (Al 
Sherbiny et al., 2003). 
It should also be mentioned that there is a consensus that IgE antibody is one of the 
most important antibody involved in the resistant to schistosome infection in humans 
and it has been correlated with resistance to human reinfection with schistosome 
infection in many immunoepiderniological studies including the study from which the 
sera of the present study were obtained (Hagan et aL, 1991). The procedure applied for 
investigating the recognition patterns of S. haemalobium SWAP by IgM and different 
IgG isotypes were used for the IgE antibody. Despite the use of higher concentrations of 
serum samples and secondary antibodies, no recognition by IgE antibody was achieved 
in the present study. The recognition patterns by IgA antibody were not investigated in 
the present study essentially because of the limited quantities of the serum samples. 
In conclusion the work presented in this chapter has demonstrated that: 
1. The treatment with PZQ can cause alteration of the immune rcsponscs from 
responses characteristic of susceptible individuals to protective responses. 
2. Most of the identified vaccine candidates were recognised by sera from putativcly 
resistant individuals by inunune responses characteristic of protcction. 
3. The 28-3OkDa antigen (ShGST) was rccognised more frequently by IgG3 of sera 
from resistant individuals and by IgM, IgG2 and IgG4 in susceptible individuals. 
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4. The 23kDa. antigen was recognised more frequently by IgG3 of scra from resistant 
individuals. 
5. The 95kDa (paramyosin) was recognised more frequently by IgM and IgG I of scra 
from resistant individuals. 
6. The 84kDa (Calpain) was recognised more frequently by IgM, IgG I and IgG3 of sera 
from resistant individuals. 
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Chapter Five 
General Discussion 
Human schistosomiasis is one of the most important parasitic diseases and it constitutes 
a major health problem in many areas in the world especially in sub-Saharan Aftica. 
Although several measures have been used to control the infection, chemotherapy is still 
the cornerstone for the most successfid control programs around the world. Praziquantel 
is now the drug of choice for treatment of all schistosome species infecting humans and 
has been used in mass chemotherapy scale in control programmes in many areas 
(Magnussen, 2003; Hagan et aL, 2004). Ile exact mode of action of PZQ is not fully 
understood. However, the most important effects of PZQ, the tegumental damage and 
muscular contraction, have been attributed to its effects on calcium influx and 
redistribution. Other effects including its effects on the metabolic pathways of the 
parasite have been proposed (Cioli et aL, 1995). 
However, because of the limited efficacy of praziquantel on the immature stages of 
schistosomes (Sabah et al., 1986) there is a high probability of missing some of the 
infected population thus ensuring the continued transmission of the disease. Although 
repeated doses of praziquantel and combination chemotherapy regimens can help 
reduce this Problem, this appears to be impractical for control programs in the endemic 
areas. Furthermore, the appearance of schistosome strains with decreased susceptibility 
to the effects of praziquantel (Ismail et al., 1996) has cmphasised the necessity for 
investigation and discovery of new drugs for treatment of schistosomiasis (Cioli, 2000). 
In the last few years, Mirazie, an extract of myrrh, has been devclopcd and liccnsed for 
use for the treatment of human schistosomiasis. Since then, thcrc has bccn a lot of 
debate in the scientific communities about the real potential for its cfficacy against 
schistosome infections. In the present study, the effects of MZD against S. mansoni 
were investigated both in vitro and in vivo, comparcd to the standard drug PZQ. I'lic 
effects of both drugs on the hosts' immune responses to schistOsOme infection wcre also 
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investigated. Finally, the effects of in vitro exposure to both drugs on the protein 
expression of the parasite were investigated. 
The in vitro effects of both drugs on the viability of schistosomula of S manson! were 
investigated using the toluidine blue dye exclusion test and the Hoechst test. The 
principle of these tests is that intact parasite membrane is impermeable to these dyes 
and hence only damaged or dead parasites will be stained (Modha et al., 1997). The 
effects on the fluidity of the outer membrane of the parasite, which is important for 
many biochemical processes, were also investigated using the fluorescent recovery after 
photobleaching technique. The effects of both drugs were confirmed by virtue of 
scanning electron microscopy. As shown in chapter 2, the in vitro studies revealed that 
MZD, albeit at high doses, is more effective against the schistosomula of S. mansoni 
than PZQ. These results are not unique since other drugs such as artcmisinin derivatives 
were reported to have more effects against immature stages of schistosome than PZQ 
(Xiao and Catto, 1989). The possibility of treating schistosomiasis with drugs that affect 
different life-cycle stages of the parasite has renewed the focus of attention on the 
potential benefits of combination chemotherapy. This combination of PZQ, against 
adult worms, and artemether, against immature stages, was tried in mice and hamsters 
infected with either S japonicum or S. mansoni and having different developmental 
stages present in the animals at the time treatment was administered. The worm 
reductions obtained with the combination therapy were greater than those obtained with 
pZQ alone (Utzinger et al., 2001a). If these effects can be repeated in vivo one would 
expect that NED might be used effectively in combination with PZQ. One important 
aspect that was not investigated in the present study and needs further investigation is 
the effect of MZD on the immature stages. However that is because the present study 
was designed essentially to answer a simple question, that is "Is Mirazid'o cffcctivc 
against S mansoni? " 
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The in vitro studies revealed that PZQ was more effective than MZD against the adult 
worms of S. mansoni. A prolonged exposure to high concentrations of MZD was 
necessary to cause damage to the surface of the parasite. The most striking and earliest 
cffect of MZD was the separation of worm pairs. The unpairing CffCct started within 
15min after exposure. The exact mechanism of worm separation is not clear, however, 
SEM revealed surface damage and blebs on the interior surface of the gynaecophoric 
canal of male parasite that extraordinarily occurred after relatively short pcriods of 
exposure to lower concentrations of MZD. This preferential surface damage might give 
a clue to the cause of the observed worm separation. In murine schistosomiasis it was 
reported that MZD caused unpairing of worm pairs and shifting of separated worms to 
the livers (Badria et al., 2001). However, the hepatic shift per se is not a criterion for 
drug efficacy since some drugs and even anaesthetics can cause a temporary hepatic 
shift of schistosomcs. Once the effect of the drug is lost they resume their position in 
their normal habitat (Aboul-Atta et al., 1989). Another interesting observation after 
exposure of adult worms to MZD was a temporary increase in worm motility. With 
time, the motility returned to normal and then diminished. Several antischistosome 
drugs have been shown to increase worm motility including oxamniquine and PZQ at 
sub-lethal doses (Chavassc et al., 1979). In the case of hycanthone and oxamniquine, 
the increased worm motility was attributed to the blockage of the acetylcholine 
receptors, thus removing the inhibitory effects of acetylcholine (Hillman and Senft, 
1975). 
As one would expect, PZQ caused very early contractions of the parasite musculature 
followed later by surface damage with the characteristic surface blcbbings. TEM 
revealed that while PZQ caused disruption of the parasite tegument, musculature and 
parenchyma, MZD apparently caused physical damage only to the surface of the 
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parasite. Both drugs caused a significant reduction in the fluidity of the parasites' 
surface membrane. 
The present study attempted to shed light on the mode(s) of action of MZD. Its effect on 
calcium distribution was investigated using the NO dye. Both MZD and PZQ caused a 
significant increase in the levels of intra-parasite calcium. Taking these results together 
with the parasite surface damage caused by both drugs, it is possible to speculate that 
both MZD and PZQ share some of their modes of action. However, the extent of 
damage caused by MZD might point to a possibility of a more localised action of this 
drug. In this context, Triton X-100 was shown to cause surface damage of adult 
schistosome and to increase calcium accumulation inside the parasites (Dcpcnbusch et 
al., 1983). 
The in vivo effects of MZD and PZQ were investigated using the murine model. 
Although PZQ was very effective in causing worm reductions, and reductions of liver 
and tissue egg burden, MZD did not show any of these effects. 11c apparent 
discrepancy between the in vitro and the in vivo results of the present experiments are 
not fully understood. The pharmacokinetics of MZD may be one explanation for this 
discrepancy. It is possible that MZD is poorly absorbed, rapidly mctaboliscd or cleared 
from the circulation. In any case, the level of MZD in the blood may not be enough to 
exert the actions that were obtained in vitro. In order to get these effects one would 
predict that very large doses are needed, doses that proved to be toxic to mice (Botros et 
al., 2004). However, earlier studies in mice reported the efficacy of MZD in reducing 
worm and egg burdens (Badria et al., 2001). Another possibility is that one or more of 
the many compounds that are constituents of MZD might be responsible for the anti- 
schistosome effects while others might have no effects and may even have deleterious 
effects on the hosts. If these active components could be idcntiried one would predict 
that efficacy of NED can be greatly increased. Preliminary attempts to fractionate MZD 
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by column chromatography and using different concentrations of dichloromcthanc in 
hexanc, revealed 10 fractions. The potential anti-schistosome effects of these fractions 
was assessed and revealed that only two of these fractions had anti-schistosomal effects 
(data not shown). Further fractionation experiments are in progress. 
The results of the in vivo studies do not agree with the reported efficacy of MZD in 
human studies. In human studies, MZD was used to treat both S. haemalobium and S. 
mansoni infected Egyptians with cure rates of more than 90% being reported (Sheir el 
al., 2001; El Baz et aL, 2003). 'Ibis might be attributed to differences in the drug 
metabolic pathways in humans and mice. However, other human studies failed to 
demonstrate any significant anti-schistosomal effects of MZD (Fenwick el aL, 2003). 
Sheir and colleagues and El Baz and colleagues reported that MZD caused an apparent 
improvement of the symptoms of infected individuals. The possibility that MZD instead 
of affecting the worm burden might have anti-pathology effects was investigated in the 
present study. Although there are some differences between the immunopathology of 
schistosome in humans and mice, there is enough similarity to allow murine infections 
to be used to investigate the likely effects on pathology in humans (Chcever el aL, 
2002). There was no significant difference in the diameter of liver granulomas or their 
eosinophil contents in MZD-treated, PZQ-treated and un-treated mice. However, in 
MZD treated mice, the slight decrease in the diameter of liver granulomas and fibrosis 
was accompanied with a preferential decrease of Th2 type immune response cytokincs. 
Spleen cells and LNs from mice treated with MZD produced lower amounts of IL-10, 
IL-4 and IL-13 in response to stimulation with either SEA or SWAP compared to the 
un-treated mice. This might indicate an anti-inflammatory cffect of MZD or one or 
more of its components (Kimura et al., 200 1). 
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The in vitro effects of both MZD and PZQ on the soluble proteome of adult worrns of S. 
mansoni were investigated. The use of the powerful DIGE technique allowed the 
comparison between two samples in one gel with the advantage of them being run under 
identical conditions. Although several protein spots were expressed differently in both 
drug treated and control parasites, only three proteins were identified using the MALDI 
ToF and electrospray tandem mass spectrometry. This is partly because the genome 
sequence of S. mansoni has yet to be completed (LoVerde et aL, 2004). Some proteins 
such as actin had reduced expression in MZD-treated worms. Interestingly other 
proteins were more highly expressed in drug treated parasites. For instance, paramyosin, 
which is a leading vaccine candidate, showed a 4-fold increased expression in worms 
exposed to MZD compared to control parasites. In worms exposed to PZQ, there was a 
2-fold increase in the expression of fructose 1,6 bisphosphate a1dolase compared to 
control parasites. Whatever the mechanism of this differential expression of such 
proteins in drug-exposed worms, the increased expression of some proteins might shcd 
some light on the changes of the immune responses that occur after the use of some 
anti-schistosome drugs. 
in addition to its chemotherapeutic effects against schistosomcs, PZQ has been 
proposed to have the capacity to enhance immune protection against reinfection. As 
reported by others, treatment of infected children can change their immune responses 
from 'putatively susceptible to reinfection' to immune responses similar to adults that is 
'putatively resistant to reinfection' (Mutapi et al., 1998; Mduluza et al., 2001). Thc 
hypothesis behind the immune priming effect of PZQ is that, by damaging or killing 
worms, PZQ might expose previously concealed parasite antigens or simply initiate the 
release of a considerable amount of parasite antigens that normally would have been 
released only after a long duration of infection in conditions of normal exposure 
(Hamett and Kusel, 1986; Woolhouse and Hagan, 1999). 
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In the present study, the differences in the recognition patterns of SWAP S. 
haematobium prior to PZQ treatment, after treatment and after exposure to reinfection 
were addressed with an emphasis on the differences between resistant and susceptible 
individuals and the impact of chemotherapy on the humoral immune responses against 
different parasite antigens. Not surprisingly, most of the identified vaccine candidates 
were highly recognised by sera from both resistant and susceptible individuals. 
However, resistant individuals more frequently recognised some of these antigens by 
antibody isotypes that have been characterised as those that might be associated with 
protective immune responses. For instance, an antigen band of 28-3OkDa (Sh28GST) 
was recognised more frequently by the IgG3 antibody isotype and less frequently by 
IgM, IgG2 and IgG4 antibody isotypes of sera from resistant compared to susceptible 
individuals. 
ARer treatment with PZQ, many antigens including some of the potential vaccine 
candidate antigens were recognised by antibody isotypes that favoured protective 
immune responses compared to their recognition prior to treatment. However, 
sometimes such immune responses were not maintained when the individuals wcrc 
exposed to reinfection and thus rendered susceptible to reinfection. It seems reasonable 
that repeated treatments might be necessary to maintain such protective immune 
responses (Mduluza et aL, 200 1). 
Conclusion 
Although MZD was effective against the schistosomula and adult stages of S. mansoni, 
in vitro, the results of the in vivo experiments in the murine model do not support the 
use of MZD for the treatment of schistosomiasis. Further independent investigations of 
its efficacy in human studies may need to be done. Until this happens, all measures must 
be taken to ensure that MZD is withheld in order that it is not substituted for the more 
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effective drug, PZQ, in communities where both drugs are available. Otherwise, there 
will be a risk of an increase in the prevalence of human schistosomiasis which is now 
partly under control, in many parts of the world by virtue of the efficacy of PZQ. 
Another major factor against the use of MZD on a community basis is its cost (double 
that of PZQ) and the inconvenience of the way of its administration. 
The present study supports the efficacy of PZQ for treatment of schistosome infections. 
it also supports the hypothesis that PZQ, albeit after repeated cycles of treatment, can 
help the development of protective immune responses by infected individuals. Ibis is 
perhaps a consequence of an increase in antigen production and expression by the 
parasites. 
In conclusion the work presented in the present thesis has demonstrated that 
1. Both MZD and PZQ showed in vitro anti-schistosome activities against S. 
mansoni. 
2. MZD was more effective against schistosomula than PZQ in vitro but its cfflcacy 
was less against adult wonns. 
3. Lengthy exposures to high concentrations were necessary for the Cffects of MZD 
to be evident. 
4. Although there were similarities in the effects of MZD and PZQ after in vitro 
exposure, the extent of the damage was distinct for each drug. 
5. Both MZD and PZQ caused an increase in the intra-parasite calcium lcvcls. 
6. MZD had no anti-schistosome activity in infected mice. On the other hand PZQ 
caused a significant reduction in wonn burden and liver and gut egg loads. 
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7. There were no significant differences in the diameter or cell content of liver 
granulomas from treated mice. 
8. The treatment with PZQ can cause alteration of the immune responses from 
responses characteristic of susceptible individuals to protective responses. 
9. Most of the identified vaccine candidates were recognised by sera from putatively 
resistant individuals by immune responses characteristic of protection. 
10. The 28-3OkDa antigen (ShGST) was recognised more frequently by IgG3 of sera 
from resistant individuals and by IgM, IgG2 and IgG4 in susceptible individuals. 
11. The 23kDa antigen was recognised more frequently by IgG3 of sera from 
resistant individuals. 
12. The 95kDa (paramyosin) was recognised more frequently by IgM and IgG I of 
sera from resistant individuals. 
13. The 84kDa (Calpain) was recognised more frequently by IgM, IgG I and IgG3 of 
sera from resistant individuals. 
14. In vitro exposure of adult wonns to PZQ caused increased expression of fructose 
1,6 bisphosphate aldolase supporting the immunising hypothesis of some anti- 
schistosome drugs. 
15. In vitro exposure of adult worms to MZD caused increased expression of 
paramyosin and decreased expression of actin. 
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Suggestions for future work 
The efficacy of MZD against early schistosome, infection should be investigated. 
From the results of the present in vitro experiments, one would expect that if 
MZD has any anti-schistosome effects it is more likely to be against the 
immature stages of the parasite. 
2. The true potential of MZD in treatment of human schistosomiasis should be 
independently investigated. 
3. Based on the results of the preliminary studies on the effects of MZD on the 
immunopathology of schistosome infection, the possibility that MZD can affect 
the immunopathology of human disease needs further investigation. 
4. Fractionation of MZD and identification of the potential anti-schistosome 
components is strongly recommended. One would expect if there is a potential 
anti-schistosome effect of this mixture of compounds, identification of the active 
ingredient would greatly improve this efficacy. 
S. Further studies on the effects of PZQ and other drugs on the soluble schistosomc 
proteome, would greatly increase our understanding of the mode of actions of 
these drugs. This is possible with the use of the rapidly developing 2-D PAGE 
and mass spectrometry techniques. It is expected that these techniques would be 
applicable with more efficiency in the near future especially when the gcnome 
of schistosome is completed. 
Making use of the 2-D PAGE and mass spectrometry techniques it is now 
possible to study the differences in the recognition patterns of parasite antigcns 
in resistant and susceptible individuals. The impact of chcmothcrapy on the 
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recognition patterns of such parasite antigens can be also investigated. The 
antigens associated with protective responses in resistant individuals can then be 
identified and investigated as potential vaccine candidates. 
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Appendix 
Reagents used in western blotting 
Phospate buffered saline (pH 7.2) 
Amount 
Na2HP04-121120 60. Og 
Na2HP04.2H20 13.6g 
NaCl 8.5g 
De-ionised and distilled water Completed to I litre 
Coomassie Blue Stain 
Amount 
Methanol 250. Oml 
Acetic acid 100.0mi 
Glycerol 10.0ml 
Coomassie Blue Log 
De-ionised and distilled water Completed to I litre 
Coomassie Blue Destain 
Amount 
Methanol 250.0m], 
Acetic acid 100.0ml 
Glycerol 10.0mi 
De-ionised and distilled water Completed to I litre 
Tris Buffered Saline (TBS) 
Amount 
NaCl 9g 
Tris HCI 1.6g 
pH Adjusted to pil 7.6 with I ICI 
De-ionised and distilled water leted to I litre 
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Anode 1 solution 
Amount Final concentration 
Tris- base 36.3g 300mM 
Methanol 200ml 20% 
DdH20 800ml 
The Tris- base was dissolved in 800ml of water and then the methanol was added to 
make a litre. 
Anode 2 solution 
Amount Final concentration 
Tris- base 3. Og 25mM 
Medmol 200ml 20% 
DdH20 800ml 
Cathode solution 
A 40mM of 6-amino-caproic acid was dissolved in I litre of anode 2 solution to obtain 
the cathode solution. 
Substrate solution for development of the western blotting reaction 
Amount 
4-chloro-I -naphthol 90mg 
Medmol 20ml 
TBS I 00ml 
H202 (immediately before development) 200pl 
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Reagents used in ELISA 
Phosphate buffered saline 
Amount 
NaCI 8g 
KCI 0.2g 
Na2HP04 1.15g 
KH2PO4 0.21g 
DdH20 Complete to I litre 
HCI Adjust the pH to 7.2-7.4 
Wash buffer 
To 1 litre of PBS, 0.5ml Tween X20 was added to reach a concentration of 0.05% 
Tween. PH must be 7.2-7.4. 
Block buffer 
Amount 
PBS I litre 
BSA I Og 
Sucrose sog 
I NaN3 I 0.5g 
Reagent diluent 
Ten grams of BSA were dissolved in I litre of PBS to reach a final concentration of I% 
BSA. The solution was sterilised through a 0.2pm filter. 
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Reagents used in the 2D gel electrophoresis 
DIGE lysis buffer 
Final concentration 
Urea 7M 
Thiourea 2M 
CHAPS 
ý 
4% 
Tns base 
1 [- 
25mM 
Sample rehydration stock buffer 
Amount Final concentration 
Urea (FW 60.06) 12g 8M 
CHAPS 0.5g 2% (w/v) 
IPG Buffer 125pl 0.5% (V/V) 
Bromophenol blue 50pl 1% solution 0.002% 
Double distilled H20 Complete to 25ml 
I 
The stock was aliquoted in 2.5ml aliquots and stored at -200C. 7mg of DTT was added 
for each aliquot just prior to use. 
Sample equilibration buffer 
Amount Final concentration 
Tris-HCI, pH 8.8 lO. OmI 50m. M 
Urea (FW 60.06) 72.07g 6M 
Glycerol (87% V/V) 69ml 30% (v/v) 
SDS (FW 288.38) 4.0 g 2% (w/v) 
Bromophenol blue 400pl of 1% solution 0.002% (w/v) 
Double distilled H20 Complete to 200ml 
The stock solution was aliquoted in 10ml aliquots and stored at -200C. Just prior to usc 
100mg of DTT was added to l0ml of the stock to prepare the first equilibration bufficr. 
To prepare the second equilibration buffer, 250mg of iodacetamide was added to 10ml 
of the stock solution. 
I 
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SDS gel electrophoresis buffer 
Amount Final concentration 
Tris-base (FW 12 1.1) 30.3 g 2M 
Glycine (FW 75.07) 144.0 g 192 mM 
SDS (FW 288.38) 10.0 g 0.1% (W/V) I 
Double distilled H20 I Complete to 10 litre 
Store at room temperature 
Preparation of the 12.5% PAGE 
Amount 
Acrylamide/Bis 40% (w/v) 281.25ml 
Tris (1.5M, pH 8-8) 225ml 
10% (w/v) SDS 9.0mi 
10% (w/v) Ammonium Persulfate (APS) 9. OmI 
10% (w/v) TEMED (immediately before use) 1.24ml 
Double distilled H20 Complete to 900ml 
Agarose sealing solution 
Amount Final concentration 
SDS Electrophoresis buffer 
-- 
100 mi 
arose Xg 0.5 g 0.5% 
Bromophenol blue 200 til 0.002% (w/v) 
Add all ingredients into a 500 ml Erlenmeyer flask. Swirl to disperse. Ifeat in a 
microwave oven on low or a heating stirrer until the agarose is completely dissolvcd. 
Do not allow the solution to boil over. Dispense 2 ml aliquots into screw-cap tubes and 
store at room temperature. 
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